false FY 0001465470 0001465470 2024-04-01 2025-03-31 0001465470 2024-11-04 0001465470 2025-11-03 0001465470 2025-03-31 0001465470 2025-03-30 0001465470 us-gaap:NonrelatedPartyMember 2025-03-30 0001465470 us-gaap:RelatedPartyMember 2025-03-30 0001465470 SHMP:SeriesERedeemableConvertiblePreferredStockMember 2025-03-30 0001465470 SHMP:SeriesFRedeemableConvertiblePreferredStockMember 2025-03-30 0001465470 SHMP:SeriesGRedeemableConvertiblePreferredStockMember 2025-03-30 0001465470 SHMP:SeriesEConvertiblePreferredStockMember 2025-03-30 0001465470 SHMP:SeriesEConvertiblePreferredStockMember 2024-03-31 0001465470 SHMP:SeriesFRedeemableConvertiblePreferredStockMember 2024-03-31 0001465470 SHMP:SeriesGRedeemableConvertiblePreferredStockMember 2024-03-31 0001465470 SHMP:SeriesAConvertiblePreferredStockMember 2025-03-30 0001465470 SHMP:SeriesAConvertiblePreferredStockMember 2024-03-31 0001465470 2024-03-31 0001465470 2024-04-01 2025-03-30 0001465470 us-gaap:NonrelatedPartyMember 2024-04-01 2025-03-30 0001465470 us-gaap:RelatedPartyMember 2024-04-01 2025-03-30 0001465470 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-03-31 0001465470 us-gaap:CommonStockMember 2024-03-31 0001465470 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001465470 SHMP:StockToBeIssuedMember 2024-03-31 0001465470 SHMP:SubscriptionReceivableMember 2024-03-31 0001465470 us-gaap:RetainedEarningsMember 2024-03-31 0001465470 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-04-01 2025-03-30 0001465470 us-gaap:CommonStockMember 2024-04-01 2025-03-30 0001465470 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2025-03-30 0001465470 SHMP:StockToBeIssuedMember 2024-04-01 2025-03-30 0001465470 SHMP:SubscriptionReceivableMember 2024-04-01 2025-03-30 0001465470 us-gaap:RetainedEarningsMember 2024-04-01 2025-03-30 0001465470 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-03-30 0001465470 us-gaap:CommonStockMember 2025-03-30 0001465470 us-gaap:AdditionalPaidInCapitalMember 2025-03-30 0001465470 SHMP:StockToBeIssuedMember 2025-03-30 0001465470 SHMP:SubscriptionReceivableMember 2025-03-30 0001465470 us-gaap:RetainedEarningsMember 2025-03-30 0001465470 SHMP:HydrenesisLLCMember 2025-03-31 0001465470 SHMP:StreetervilleMember 2025-02-11 0001465470 SHMP:BucktownCapitalMember 2025-02-11 0001465470 us-gaap:WarrantMember 2024-04-01 2025-03-31 0001465470 SHMP:PromissoryNoteMember 2024-04-01 2025-03-31 0001465470 2025-03-30 2025-03-30 0001465470 2022-11-04 2022-11-04 0001465470 2022-11-04 0001465470 us-gaap:PatentsMember 2025-03-30 0001465470 SHMP:LicenseRightsMember 2025-03-30 0001465470 2018-03-01 2018-03-31 0001465470 SHMP:PatentsPurchaseAgreementMember SHMP:FAndTWaterSolutionsLLCMember 2021-05-19 2021-05-19 0001465470 SHMP:PatentsPurchaseAgreementMember SHMP:FAndTWaterSolutionsLLCMember 2021-05-19 0001465470 SHMP:HydrenesisDeltaSystemsLLCMember 2021-08-25 0001465470 SHMP:HydrenesisDeltaSystemsLLCMember SHMP:TechnologyRightsAgreementMember 2021-08-25 0001465470 SHMP:TechnologyRightsAgreementMember 2024-04-01 2025-03-30 0001465470 us-gaap:BuildingMember 2025-03-30 0001465470 us-gaap:MachineryAndEquipmentMember srt:MinimumMember 2025-03-30 0001465470 us-gaap:MachineryAndEquipmentMember srt:MaximumMember 2025-03-30 0001465470 us-gaap:VehiclesMember 2025-03-30 0001465470 us-gaap:FurnitureAndFixturesMember srt:MinimumMember 2025-03-30 0001465470 us-gaap:FurnitureAndFixturesMember srt:MaximumMember 2025-03-30 0001465470 SHMP:ShrimpSalesMember 2024-04-01 2025-03-30 0001465470 SHMP:TechnologyAndEquipmentServicesMember 2024-04-01 2025-03-30 0001465470 SHMP:StreetervilleAndBuckstownCapitalMember 2025-02-28 0001465470 2025-05-14 2025-05-14 0001465470 SHMP:StreetervilleAndBuckstownCapitalMember 2025-05-14 0001465470 SHMP:CapitalOneBankMember 2025-03-30 0001465470 SHMP:CapitalOneBankMember 2024-04-01 2025-03-30 0001465470 SHMP:CapitalOneBankMember 2024-04-01 2025-03-31 0001465470 SHMP:CapitalOneBankMember 2025-03-31 0001465470 SHMP:ChaseBankMember 2025-03-31 0001465470 SHMP:ChaseBankMember 2024-04-01 2025-03-31 0001465470 SHMP:BucktownCapitalLLCMember 2024-08-01 2024-08-31 0001465470 SHMP:BucktownCapitalLLCMember 2025-03-31 0001465470 SHMP:JanuaryTwoThousandTwentyThreeNoteMember 2023-01-20 0001465470 SHMP:JanuaryTwoThousandTwentyThreeNoteMember 2023-01-19 2023-01-20 0001465470 SHMP:JanuaryTwoThousandTwentyThreeNoteMember 2023-11-17 2023-11-17 0001465470 SHMP:NewPromissoryNoteMember SHMP:JanuaryTwoThousandTwentyThreeNoteMember 2023-11-08 0001465470 SHMP:JanuaryTwoThousandTwentyThreeNoteMember 2023-11-08 0001465470 us-gaap:CommercialPaperMember SHMP:JanuaryTwoThousandTwentyThreeNoteMember us-gaap:CommonStockMember 2023-11-08 2023-11-08 0001465470 us-gaap:CommercialPaperMember SHMP:JanuaryTwoThousandTwentyThreeNoteMember us-gaap:CommonStockMember 2023-11-08 0001465470 SHMP:JanuaryTwoThousandTwentyThreeNoteMember 2023-11-08 2023-11-08 0001465470 SHMP:NewPromissoryNoteMember SHMP:JanuaryTwoThousandTwentyThreeNoteMember 2024-01-17 0001465470 SHMP:JanuaryTwoThousandTwentyThreeNoteMember 2024-01-17 0001465470 us-gaap:CommercialPaperMember SHMP:JanuaryTwoThousandTwentyThreeNoteMember us-gaap:CommonStockMember 2024-01-17 2024-01-17 0001465470 us-gaap:CommercialPaperMember SHMP:JanuaryTwoThousandTwentyThreeNoteMember us-gaap:CommonStockMember 2024-01-17 0001465470 SHMP:JanuaryTwoThousandTwentyThreeNoteMember 2024-01-17 2024-01-17 0001465470 SHMP:NewPromissoryNoteMember SHMP:JanuaryTwoThousandTwentyThreeNoteMember 2024-02-22 0001465470 SHMP:JanuaryTwoThousandTwentyThreeNoteMember 2024-02-22 0001465470 us-gaap:CommercialPaperMember SHMP:JanuaryTwoThousandTwentyThreeNoteMember us-gaap:CommonStockMember 2024-02-22 2024-02-22 0001465470 us-gaap:CommercialPaperMember SHMP:JanuaryTwoThousandTwentyThreeNoteMember us-gaap:CommonStockMember 2024-02-22 0001465470 SHMP:JanuaryTwoThousandTwentyThreeNoteMember 2024-02-22 2024-02-22 0001465470 SHMP:NewPromissoryNoteMember SHMP:JanuaryTwoThousandTwentyThreeNoteMember 2024-04-03 0001465470 SHMP:JanuaryTwoThousandTwentyThreeNoteMember 2024-04-03 0001465470 us-gaap:CommercialPaperMember SHMP:JanuaryTwoThousandTwentyThreeNoteMember us-gaap:CommonStockMember 2024-04-03 2024-04-03 0001465470 us-gaap:CommercialPaperMember SHMP:JanuaryTwoThousandTwentyThreeNoteMember us-gaap:CommonStockMember 2024-04-03 0001465470 SHMP:JanuaryTwoThousandTwentyThreeNoteMember 2024-04-03 2024-04-03 0001465470 us-gaap:CommercialPaperMember SHMP:YottaInvestmentLLCMember 2023-04-21 0001465470 us-gaap:CommercialPaperMember SHMP:YottaInvestmentLLCMember 2023-05-17 0001465470 SHMP:PromissoryNoteMember SHMP:WilliamsMember 2020-07-15 0001465470 SHMP:PromissoryNoteMember SHMP:WilliamsMember 2020-07-15 2020-07-15 0001465470 SHMP:PromissoryNoteMember SHMP:WilliamsMember 2025-03-31 0001465470 SHMP:SecuritiesPurchaseAgreementMember 2022-08-17 0001465470 SHMP:SecuritiesPurchaseAgreementMember 2022-08-17 2022-08-17 0001465470 2024-04-01 2024-12-31 0001465470 srt:MaximumMember 2023-06-30 0001465470 2023-11-18 2023-11-20 0001465470 2022-10-24 2022-10-24 0001465470 SHMP:RestructuredAugustNoteMember 2024-04-01 2025-03-30 0001465470 SHMP:RestructuredAugustNoteMember 2025-03-31 0001465470 SHMP:RestructuredAugustNoteMember 2025-03-30 0001465470 SHMP:RestructuredAugustNoteMember 2024-04-01 2025-03-31 0001465470 SHMP:SecuritiesPurchaseAgreementMember SHMP:DecemberFifteenTwoThousandTwentyOneDebentureMember 2021-12-15 0001465470 SHMP:SecuritiesPurchaseAgreementMember SHMP:DecemberFifteenTwoThousandTwentyOneDebentureMember us-gaap:DebenturesSubjectToMandatoryRedemptionMember 2021-12-15 0001465470 SHMP:SecuritiesPurchaseAgreementMember SHMP:DecemberFifteenTwoThousandTwentyOneDebentureMember 2021-12-15 2021-12-15 0001465470 SHMP:AmendedAndRestatedSecuredPromissoryNoteMember 2022-11-04 2022-11-04 0001465470 SHMP:AmendedAndRestatedSecuredPromissoryNoteMember 2022-11-04 0001465470 SHMP:AmendedAndRestatedSecuredPromissoryNoteMember 2023-06-30 0001465470 SHMP:DecemberFifteenTwoThousandTwentyOneDebentureMember 2024-04-01 2025-03-30 0001465470 SHMP:RestructuredSeniorNoteMember 2025-03-30 0001465470 SHMP:RestructuredSeniorNoteMember 2024-04-01 2025-03-30 0001465470 SHMP:RestructuredSeniorNoteMember 2024-03-30 0001465470 SHMP:RestructuredSeniorNoteMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-03-30 0001465470 SHMP:RestructuredSeniorNoteMember us-gaap:MeasurementInputPriceVolatilityMember 2025-03-30 0001465470 SHMP:RestructuredSeniorNoteMember us-gaap:MeasurementInputSharePriceMember 2025-03-30 0001465470 SHMP:RestructuredSeniorNoteMember 2025-03-31 0001465470 us-gaap:SeriesAPreferredStockMember 2025-03-31 0001465470 us-gaap:SeriesAPreferredStockMember 2024-03-31 0001465470 us-gaap:SeriesBPreferredStockMember 2025-03-31 0001465470 us-gaap:SeriesBPreferredStockMember 2024-03-31 0001465470 us-gaap:SeriesDPreferredStockMember 2025-03-31 0001465470 us-gaap:SeriesDPreferredStockMember 2024-03-31 0001465470 us-gaap:SeriesEPreferredStockMember 2025-03-31 0001465470 us-gaap:SeriesEPreferredStockMember 2024-03-31 0001465470 SHMP:SeriesFRedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2025-03-31 0001465470 SHMP:SeriesFRedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-03-31 0001465470 SHMP:SeriesGRedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2025-03-31 0001465470 SHMP:SeriesGRedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-03-31 0001465470 us-gaap:SeriesEPreferredStockMember 2021-04-14 2021-04-14 0001465470 us-gaap:SeriesEPreferredStockMember 2021-04-14 0001465470 us-gaap:SeriesEPreferredStockMember srt:MinimumMember 2021-04-14 2021-04-14 0001465470 us-gaap:SeriesEPreferredStockMember srt:MaximumMember 2021-04-14 2021-04-14 0001465470 SHMP:SecuritiesPurchaseAgreementMember us-gaap:SeriesEPreferredStockMember 2021-04-14 2021-04-14 0001465470 SHMP:SecuritiesPurchaseAgreementMember us-gaap:SeriesEPreferredStockMember 2021-11-22 0001465470 SHMP:SecuritiesPurchaseAgreementMember us-gaap:SeriesEPreferredStockMember srt:MaximumMember 2021-11-22 0001465470 SHMP:SecuritiesPurchaseAgreementMember us-gaap:SeriesEPreferredStockMember 2021-11-22 2021-11-22 0001465470 SHMP:SecuritiesPurchaseAgreementMember us-gaap:SeriesEPreferredStockMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-11-22 0001465470 SHMP:SecuritiesPurchaseAgreementMember us-gaap:SeriesEPreferredStockMember us-gaap:MeasurementInputPriceVolatilityMember 2021-11-22 0001465470 SHMP:SecuritiesPurchaseAgreementMember us-gaap:SeriesEPreferredStockMember us-gaap:MeasurementInputExpectedDividendRateMember 2021-11-22 0001465470 SHMP:SecuritiesPurchaseAgreementMember us-gaap:SeriesEPreferredStockMember 2022-04-01 2023-03-31 0001465470 SHMP:ShareExchangeAgreementMember us-gaap:SeriesDPreferredStockMember 2021-04-14 2021-04-14 0001465470 SHMP:ShareExchangeAgreementMember us-gaap:SeriesDPreferredStockMember 2021-04-14 0001465470 SHMP:SecuritiesPurchaseAgreementMember us-gaap:SeriesDPreferredStockMember 2021-04-14 2021-04-14 0001465470 us-gaap:SeriesEPreferredStockMember 2022-06-16 0001465470 2022-06-16 2022-06-16 0001465470 2022-03-01 2022-03-01 0001465470 us-gaap:SeriesEPreferredStockMember 2023-03-31 0001465470 us-gaap:SeriesEPreferredStockMember 2022-04-01 2023-03-31 0001465470 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2022-04-01 2023-03-31 0001465470 us-gaap:SeriesEPreferredStockMember 2025-03-30 0001465470 SHMP:GHSPurchaseAgreementMember 2022-11-05 2022-11-05 0001465470 2022-11-05 2022-11-05 0001465470 SHMP:SecuritiesPurchaseAgreementMember us-gaap:SeriesEPreferredStockMember 2023-07-24 2023-07-24 0001465470 SHMP:SecuritiesPurchaseAgreementMember us-gaap:SeriesEPreferredStockMember 2023-07-24 0001465470 us-gaap:SeriesEPreferredStockMember 2024-04-01 2025-03-30 0001465470 us-gaap:SeriesEPreferredStockMember 2023-05-01 2023-05-01 0001465470 SHMP:SeriesGRedeemableConvertiblePreferredStockMember 2023-12-01 0001465470 SHMP:SeriesGRedeemableConvertiblePreferredStockMember 2023-12-01 2023-12-01 0001465470 SHMP:SeriesGRedeemableConvertiblePreferredStockMember 2023-12-14 2023-12-14 0001465470 SHMP:SeriesGRedeemableConvertiblePreferredStockMember 2023-12-14 0001465470 SHMP:SeriesGRedeemableConvertiblePreferredStockMember 2023-12-19 2023-12-19 0001465470 SHMP:SeriesGRedeemableConvertiblePreferredStockMember 2024-01-24 2024-01-24 0001465470 SHMP:SeriesGRedeemableConvertiblePreferredStockMember 2024-01-24 0001465470 SHMP:ConsultingAgreementMember SHMP:SeriesGRedeemableConvertiblePreferredStockMember 2024-02-23 0001465470 SHMP:ConsultingAgreementMember SHMP:SeriesGRedeemableConvertiblePreferredStockMember 2024-02-23 2024-02-23 0001465470 SHMP:SeriesGRedeemableConvertiblePreferredStockMember 2024-02-23 2024-02-23 0001465470 SHMP:SeriesGRedeemableConvertiblePreferredStockMember 2024-02-23 0001465470 SHMP:SeriesGRedeemableConvertiblePreferredStockMember 2024-04-23 2024-04-23 0001465470 SHMP:SeriesGRedeemableConvertiblePreferredStockMember 2024-04-23 0001465470 SHMP:SeriesGRedeemableConvertiblePreferredStockMember 2024-06-12 2024-06-12 0001465470 SHMP:SeriesGRedeemableConvertiblePreferredStockMember 2024-06-12 0001465470 SHMP:SeriesGRedeemableConvertiblePreferredStockMember 2024-07-10 2024-07-10 0001465470 SHMP:SeriesGRedeemableConvertiblePreferredStockMember 2024-07-10 0001465470 SHMP:SeriesGRedeemableConvertiblePreferredStockMember 2024-04-01 2025-03-30 0001465470 2023-09-28 0001465470 SHMP:GHSPurchaseAgreementMember 2022-11-04 2022-11-04 0001465470 SHMP:GHSPurchaseAgreementMember 2022-11-04 0001465470 SHMP:EquityFinancingAgreementMember SHMP:GHSInvestmentLLCMember 2023-04-28 2023-04-28 0001465470 SHMP:EquityFinancingAgreementMember SHMP:GHSInvestmentLLCMember 2023-04-28 0001465470 SHMP:EquityFinancingAgreementMember 2024-04-01 2025-03-30 0001465470 SHMP:EquityFinancingAgreementMember srt:MinimumMember 2025-03-30 0001465470 SHMP:EquityFinancingAgreementMember srt:MaximumMember 2025-03-30 0001465470 SHMP:GHSTwoThousandTwentyThreePurchaseAgreementMember 2023-05-09 2023-05-09 0001465470 SHMP:GHSTwoThousandTwentyThreePurchaseAgreementMember 2023-04-01 2023-06-30 0001465470 SHMP:GHSTwoThousandTwentyThreePurchaseAgreementMember srt:MinimumMember 2023-06-30 0001465470 SHMP:GHSTwoThousandTwentyThreePurchaseAgreementMember srt:MaximumMember 2023-06-30 0001465470 SHMP:ConsultantMember 2023-12-04 2023-12-04 0001465470 SHMP:ConsultantMember 2023-04-01 2023-12-31 0001465470 SHMP:ConsultantMember 2023-12-31 0001465470 SHMP:ConsultantMember 2023-06-19 2023-06-19 0001465470 SHMP:ConsultantMember 2023-06-19 0001465470 SHMP:ConsultantMember SHMP:BusinessAgreementMember 2022-06-22 2022-06-22 0001465470 SHMP:NewEmployeesMember 2024-03-01 2024-03-31 0001465470 SHMP:NewEmployeesMember 2024-02-01 2024-02-29 0001465470 SHMP:NewEmployeesMember srt:MinimumMember 2024-03-31 0001465470 SHMP:NewEmployeesMember srt:MinimumMember 2024-02-29 0001465470 SHMP:NewEmployeesMember srt:MaximumMember 2024-03-31 0001465470 SHMP:NewEmployeesMember srt:MaximumMember 2024-02-29 0001465470 SHMP:NewEmployeeMember 2023-10-10 2023-10-10 0001465470 SHMP:NewEmployeeMember 2023-10-10 0001465470 us-gaap:WarrantMember 2025-03-31 0001465470 us-gaap:WarrantMember 2024-04-01 2025-03-31 0001465470 us-gaap:RelatedPartyMember 2023-07-10 2023-07-17 0001465470 us-gaap:RelatedPartyMember 2023-07-17 0001465470 SHMP:LoanAgreementMember SHMP:PromissoryNotesMember 2022-08-10 2022-08-10 0001465470 SHMP:LoanAgreementMember SHMP:PromissoryNotesMember SHMP:FiveRelatedPartiesMember 2022-08-10 0001465470 SHMP:LoanAgreementMember SHMP:PromissoryNotesMember SHMP:FiveRelatedPartiesMember 2022-08-10 2022-08-10 0001465470 us-gaap:RelatedPartyMember SHMP:PromissoryNotesMember 2024-04-01 2025-03-30 0001465470 srt:ChiefFinancialOfficerMember 2021-05-11 2021-05-11 0001465470 SHMP:PresidentAndChiefTechnicalOfficerMember 2021-08-10 0001465470 SHMP:PresidentAndChiefTechnicalOfficerMember 2024-04-01 2025-03-30 0001465470 SHMP:PresidentAndChiefTechnicalOfficerMember 2023-04-01 2024-03-31 0001465470 2016-01-01 0001465470 SHMP:NotesPayableMember 2024-04-01 2025-03-30 0001465470 SHMP:PresidentsMember us-gaap:RelatedPartyMember 2025-03-31 0001465470 SHMP:ShareholdersOfNSHAndBillWilliamsMember us-gaap:RelatedPartyMember 2024-04-01 2025-03-31 0001465470 SHMP:ShareholdersOfNSHAndBillWilliamsMember us-gaap:RelatedPartyMember 2024-03-31 0001465470 us-gaap:RelatedPartyMember 2025-03-31 0001465470 2021-08-01 2021-08-01 0001465470 2022-10-01 2023-03-31 0001465470 2021-06-02 0001465470 2021-08-01 0001465470 2023-12-20 2023-12-20 0001465470 2023-12-19 0001465470 2024-01-01 0001465470 2024-01-01 2024-01-01 0001465470 2021-09-08 2021-09-08 0001465470 2021-09-08 0001465470 2021-11-15 2021-11-15 0001465470 2021-11-15 0001465470 2022-03-31 0001465470 2021-04-01 2022-03-31 0001465470 us-gaap:CommonStockMember SHMP:GaryShoverMember 2022-04-01 2023-03-31 0001465470 us-gaap:CommonStockMember SHMP:GaryShoverMember 2023-04-01 2024-03-31 0001465470 SHMP:MergerAgreementMember 2023-07-20 0001465470 2023-04-01 2024-03-31 0001465470 us-gaap:CommonStockMember SHMP:MergerAgreementMember 2022-10-24 2022-10-24 0001465470 us-gaap:CommonStockMember SHMP:MergerAgreementMember 2022-10-24 0001465470 SHMP:MergerAgreementMember 2022-10-24 2022-10-24 0001465470 SHMP:SeriesAConvertiblePreferredStockMember 2022-10-24 0001465470 SHMP:SeriesFConvertiblePreferredStockMember 2022-10-24 0001465470 SHMP:SeriesEConvertiblePreferredStockMember 2022-10-24 0001465470 SHMP:StreetervilleAndBuckstownCapitalMember 2025-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure SHMP:Integer utr:sqft

false FY 0001465470 0001465470 2025-04-01 2026-03-31 0001465470 2024-11-04 0001465470 2026-07-05 0001465470 2026-03-31 0001465470 2025-03-31 0001465470 2025-04-01 0001465470 2024-04-01 2025-03-30 0001465470 us-gaap:NonrelatedPartyMember 2024-04-01 2025-03-30 0001465470 us-gaap:RelatedPartyMember 2024-04-01 2025-03-30 0001465470 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-03-31 0001465470 us-gaap:CommonStockMember 2024-03-31 0001465470 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001465470 SHMP:StockToBeIssuedMember 2024-03-31 0001465470 SHMP:SubscriptionReceivableMember 2024-03-31 0001465470 us-gaap:RetainedEarningsMember 2024-03-31 0001465470 2024-03-31 0001465470 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-04-01 2025-03-30 0001465470 us-gaap:CommonStockMember 2024-04-01 2025-03-30 0001465470 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2025-03-30 0001465470 SHMP:StockToBeIssuedMember 2024-04-01 2025-03-30 0001465470 SHMP:SubscriptionReceivableMember 2024-04-01 2025-03-30 0001465470 us-gaap:RetainedEarningsMember 2024-04-01 2025-03-30 0001465470 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-03-30 0001465470 us-gaap:CommonStockMember 2025-03-30 0001465470 us-gaap:AdditionalPaidInCapitalMember 2025-03-30 0001465470 SHMP:StockToBeIssuedMember 2025-03-30 0001465470 SHMP:SubscriptionReceivableMember 2025-03-30 0001465470 us-gaap:RetainedEarningsMember 2025-03-30 0001465470 2025-03-30 0001465470 SHMP:StreetervilleMember 2025-02-11 0001465470 SHMP:BucktownCapitalMember 2025-02-11 0001465470 SHMP:StreetervilleAndBuckstownCapitalMember 2025-02-28 0001465470 us-gaap:RelatedPartyMember 2026-03-31 0001465470 2026-03-17 2026-03-17 0001465470 us-gaap:MeasurementInputSharePriceMember 2026-03-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure SHMP:Integer utr:sqft

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

(Mark One)

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Fiscal Year Ended March 31, ~~2025~~2026

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________________________ to __________________________

Commission file number 000-54030

NATURALSHRIMP INCORPORATED

(Exact name of registrant as specified in its charter)

Nevada		74-3262176
(State or other jurisdiction		(I.R.S. Employer
of incorporation or organization)		Identification No.)

~~13601~~1200 ~~Preston~~N ~~Road~~Federal Highway, Suite ~~E1092~~200, ~~Dallas~~Boca Raton, ~~Texas~~FL, ~~75240~~33432

(Address of principal executive offices) (Zip Code)

(~~888~~561) ~~791~~716-~~9474~~0684

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of exchange on which registered
None		None		None

Securities registered pursuant to section 12(g) of the Act:

Shares of common stock with a par value of $0.0001

(Title of class)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐		Accelerated filer ☐

Non-accelerated filer ☒		Smaller reporting company ☒

		Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐☒ No ☒☐

The aggregate market value of the common equity held by non-affiliates was $6,648,639 computed by reference to the price at which common equity was last sold (which was $0.0054 per share on November 4, 2024). For purposes of the above statement only, all directors, executive officers and 10% shareholders are assumed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for any other purpose.

The number of shares outstanding of the registrant’s common stock as of ~~November~~July 35, ~~2025~~2026 was 1,277,546,746.

TABLE OF CONTENTS

		Page
PART I
ITEM 1. BUSINESS		4
ITEM 1A. RISK FACTORS		10
ITEM 1B. UNRESOLVED STAFF COMMENTS		10
ITEM 1C. CYBERSECURITY		10
ITEM 2. PROPERTIES		11
ITEM 3. LEGAL PROCEEDINGS		11
ITEM 4. MINE SAFETY DISCLOSURES		11
PART II
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES		12
ITEM 6. [RESERVED]		12
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS		12
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK		14
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA		15
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE		15
ITEM 9A. CONTROLS AND PROCEDURES		15
ITEM 9B. OTHER INFORMATION		16
ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS		16
PART III
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE		17
ITEM 11. EXECUTIVE COMPENSATION		20
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS		23
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE		23
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES		25
PART IV
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES		26
ITEM 16. FORM 10-K SUMMARY		26
SIGNATURES		27

	Page
PART I

ITEM 1. BUSINESS	4

ITEM 1A. RISK FACTORS	5

ITEM 1B. UNRESOLVED STAFF COMMENTS	5

ITEM 1C. CYBERSECURITY	5

ITEM 2. PROPERTIES	5

ITEM 3. LEGAL PROCEEDINGS	5

ITEM 4. MINE SAFETY DISCLOSURES	5

PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES	6

ITEM 6. [RESERVED]	6

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	6

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	8

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA	8

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE	8

ITEM 9A. CONTROLS AND PROCEDURES	8

ITEM 9B. OTHER INFORMATION	9

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS	9

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE	10

ITEM 11. EXECUTIVE COMPENSATION	11

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS	13

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE	13

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES	13

PART IV

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES	14

ITEM 16. FORM 10-K SUMMARY	14

SIGNATURES	15

FORWARD-LOOKING STATEMENTS

The information contained in this report should be read in conjunction with the financial statements and related notes contained elsewhere in this Annual Report on Form 10-K. Certain statements made in this report, including those in the sections of this report entitled “Item 1. Business,” ~~“Item 1A. Risk Factors,”~~ and “Item 7. Management’s Discussion and Analysis of Financial Condition and Results Of Operations,” are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements are based upon beliefs of, and information currently available to, us as of the date hereof, as well as estimates and assumptions made by us. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. When used herein, the words “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “future,” “intend,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue” or the negative of these terms and similar expressions identify forward-looking statements. Such statements reflect our current view with respect to future events and are subject to risks, uncertainties, assumptions, and other factors, including the risks relating to our business, industry, and our operations and results of operations. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ materially from those anticipated, believed, estimated, expected, intended, or planned.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Our financial statements are prepared in accordance with accounting principles generally accepted in the United States. These accounting principles require us to make certain estimates, judgments, and assumptions. We believe that the estimates, judgments, and assumptions upon which we rely are reasonable based upon information available to us at the time that these estimates, judgments, and assumptions are made. These estimates, judgments, and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenue and expenses during the periods presented. Our financial statements would be affected to the extent there are material differences between these estimates and actual results. The following discussion should be read in conjunction with our financial statements and notes thereto appearing elsewhere in this report.

These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, or performance. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of these forward-looking statements. Except as required by law, we undertake no obligation to update any forward-looking statements after the date of this report to conform these statements to actual results.

PART I

ITEM 1. BUSINESS

As used in this Annual Report on Form 10-K and unless otherwise indicated, the terms “NaturalShrimp,” “Company,” “we,” “us,” and “our” refer to NaturalShrimp Incorporated and its wholly-owned subsidiaries: NaturalShrimp USA Corporation (“NSC”), NaturalShrimp Global, Inc. (“NS Global”) and Natural Aquatic Systems, Inc. (“NAS”). The Company owns 51% of NaturalShrimp/Hydrenesis LLC, a Texas limited liability company. Unless otherwise specified, all dollar amounts are expressed in United States Dollars.

Corporate History

The Company was incorporated in the State of Nevada on July 3, 2008 under the name “Multiplayer Online Dragon, Inc.” On January 30, 2015, we acquired substantially all of the assets of NaturalShrimp Holdings, Inc. (“NSH”), which had developed ~~the~~ proprietary technology to grow and sell shrimp ~~potentially anywhere in the world that is now the basis of our business~~. Such assets consisted primarily of all of the issued and outstanding shares of capital stock of its subsidiaries NaturalShrimp Corporation, now called NaturalShrimp USA Corporation (“NSC”), and NaturalShrimp Global (“NS Global”), and certain real property located outside of San Antonio, Texas, in exchange for our issuance of 75,520,240 shares of NaturalShrimp common stock to NSH. As a result of the transaction, ~~NSH~~ ~~acquired 88.62% of the issued and outstanding shares of NaturalShrimp common stock, NSC and NS Global became our wholly-owned subsidiaries, and~~ we changed our principal business to a global shrimp farming company. and We changed our name to “NaturalShrimp Incorporated” in 2015.

Receivership

On September 4, 2024, Streeterville Capital, LLC, a Utah limited liability company, and ~~Bucktown~~Buckstown Capital, LLC, a Utah limited liability company (collectively, “Lenders”), filed a Verified Emergency Motion for Appointment of Receiver (the “Motion”) under Civil Case No. 240907138, in the District Court of Salt Lake County, Utah, against NaturalShrimp, Inc. (“NaturalShrimp”).

The Motion ~~alleges~~alleged, among other things, that NaturalShrimp ~~has~~had defaulted under the terms of its loan agreements with the Lenders. The Motion sought the appointment of a Receiver to immediately take control of NaturalShrimp’s assets to preserve the same.

An order was entered ex parte by the Utah State Court in the Receivership Case on September 9, 2024 granting the relief requested by Lenders. The Utah State Court duly appointed Amplēo Turnaround and Restructuring, LLC (the “Receiver”) as the receiver over NaturalShrimp’s assets. The Utah State Court’s order further scheduled a hearing to be held on September 17, 2024, on a preliminary injunction to address issues raised in the Motion.

On November 20, 2024, the Lenders and NaturalShrimp filed a Verified Amended and Stipulated Emergency Motion for Immediate Appointment of a Receiver in the Receivership Case.

On November 22, 2024, the Utah State Court entered an order granting the Stipulated Motion and appointed Receiver as the receiver over the assets of NaturalShrimp. Under the Amended Receivership Order, the Receiver is the receiver over the Receivership Entities’ assets.

On February 11, 2025, the Receiver filed a Motion for Approval to Sell Substantially all of the Receivership Entities’ Assets to Streeterville Captial, LLC and Bucktown Captial, LLC (or Their Designees) or Any Other Party With a Higher and Better Offer Free and Clear of All Liens, Interests, Claims, and Encumbrances (the “Sale Motion”) in the Receivership Case. The Sale Motion ~~seeks~~sought the Utah State Court’s approval for the Receiver to sell substantially all of the Receivership Entities’ assets free and clear of all liens, interests, claims, and encumbrances to Streeterville and Bucktown Capital, through their designated entities, NaturalShrimp Farms, Inc. (“NV Purchaser”), a Nevada corporation, Iowa Shrimp Holdings, LLC (“IA Purchaser”), an Iowa limited liability company, Texas Shrimp Holdings, LLC (“TX Purchaser” or together with NV Purchaser and IA Purchaser, the “Purchasers”), a Texas limited liability company, for a roughly $35,703,789.87 credit bid (based on a secured and administrative claim basis) and $100,000 cash, pursuant to the terms and conditions set forth in that certain Asset Purchase Agreement (“APA”) between Trustee and Purchasers. The order to sell the assets was approved on March 30, 2025 and the title to the assets was transferred to the lenders on May 14, 2025. As part of the sale, the Company transferred its ownership rights to its fixed assets, patents and license agreements in exchange for the extinguishment of its outstanding debt to both Streeterville and Buckstown Capital. As of the date of the ownership transfer, the Company ceased its ~~current~~ business operations.

~~Going~~Perpetual ~~Concern~~License ~~and Liquidation Basis of Accounting~~Agreement

~~Due~~During toMarch ~~the Company’s significant amount~~ of ~~debt~~2026, ~~that~~NaturalShrimp ~~was~~Incorporated inentered ~~default~~into asan ofIntellectual ~~September~~Property ~~30,~~and ~~2024,~~Management ~~Ampleo~~Transition ~~Turnaround~~Agreement ~~and Restructuring, LLC~~ (“the ~~receiver~~“Agreement”) ~~was placed as the receiver over the Company’s assets. Further, the receiver filed a motion to~~ ~~sell~~with ~~substantially all of the Company’s assets to Streeterville and Bucktown Capital for an approximate credit bid of $35.7 million and $100~~Hydrenesis,~~000~~ ~~in cash~~Inc. ~~The motion to sell the assets was approved by the court on March 30~~, ~~2025 and title to the assets was transferred to Streeterville on May 14, 2025. The Company believes that it continued to function as~~ a ~~going~~Florida ~~concern~~corporation until the date that the motion to sell its assets was approved by the court on March 30, 2025 at which point its liquidation became imminent. As such, the Company has presented going concern financial statements as of March 30, 2025 and for the period from April 1, 2024 through March 30, 2025. Furthermore, in accordance with ASC 205-30, Liquidation Basis of Accounting, the Company has presented its financial statements (~~using a convenience date~~“Hydrenesis”) ~~as of March 31~~, ~~2025~~and ~~under the~~David ~~liquidation basis of accounting~~Antelo. AsPursuant ~~such,~~to the financial statements included in the filing also include a Statement of Net Liabilities in liquidation as of March 31, 2025. As there was only a one-day period between the time liquidation became imminent and the end of the reporting period, a Statement of Changes in Net Assets (liabilities) in liquidation has not been presented.agreement:

●

The Company agreed to transition its operations toward the commercialization of aquaculture and water treatment technologies; and

●

Governance and control of the Company transferred in accordance with the Agreement.

●

Hydrenesis will grant the Company a perpetual license to certain intellectual property, technology rights, know-how, and related commercialization rights, subject to the terms and conditions of the agreement

●

The Company’s outstanding obligation to Hydrenesis in the amount of approximately $1,034,112 will be converted into equity;

●

The Company approved and executed Certificates of Designation for Series P, Series P-2, and Series L Preferred Stock, which are expected to be filed with the Nevada Secretary of State and

●

Existing liabilities, obligations, and legacy securities, including Series A Preferred Stock and Series F Preferred Stock, will be restructured, amended, cancelled, or exchanged into Series L Preferred Stock;

While governance and control of the Company transferred as of the date of the initial agreement, the grant of the perpetual license rights and the related preferred share consideration was not consummated until June 25, 2026. Refer to our Form 8-K/A filed on July XX, 2026 for additional information.

Business Overview

We are an aquaculture technology company that has developed proprietary, patented platform technologies to allow for the production of aquatic species in an ecologically-controlled, high-density, low-cost environment, and in fully contained and independent production facilities without the use of antibiotics or toxic chemicals. NaturalShrimp owns and operates indoor recirculating Pacific White shrimp production facilities in Texas and Iowa using these technologies.

On October 5, 2015, together with F&T Water Solutions, LLC (“F&T”), we formed NAS, with NaturalShrimp holding a majority interest. The purpose of NAS was for NaturalShrimp and F&T to jointly develop certain water technologies including, without limitation, the electrocoagulation equipment dealing with enclosed aquatic production systems worldwide.

On December 17, 2020, we acquired for $10,000,000 certain assets from VeroBlue Farms USA, Inc. (“VBF”) and its subsidiaries VBF Transport, Inc. and Iowa’s First, Inc., which included facilities located in Webster City, Iowa, Blairsburg, Iowa, and Radcliffe, Iowa. These facilities were designed for the growth of barramundi fish. We have converted 40% of the Webster City facility and 20% of the Blairsburg facility for producing shrimp using the Company’s propriety technology.

On May 25, 2021, the Company purchased from F&T its ownership interest in the water treatment technology that the Company and F&T had previously jointly developed and patented (the “Patent”) through NAS, which is used or useful in growing aquatic species in re-circulating and enclosed environments, as well as F&T’s 100% interest in a second patent associated with the Patent that was issued to F&T in March 2018 and all other intellectual property rights owned by F&T. In addition, the Company acquired all of the outstanding shares of common stock of NAS owned by F&T (the “Common Shares”), thereby making NAS a wholly-owned subsidiary of the Company. The purchase price for both the Patent and the Common Shares totaled $3,000,000 in cash and 13,861,386 shares of NaturalShrimp common stock valued at $7,000,000 for a total consideration of $10,000,000.

On August 25, 2021, the Company, through its now wholly-owned subsidiary NAS, entered into an Equipment Rights Agreement with Hydrenesis Delta Systems, LLC, and a Technology Rights Agreement with Hydrenesis Aquaculture, LLC, in a sub-license agreement with Hydrenesis Aquaculture LLC. The Equipment Rights Agreements relates to specialized and proprietary equipment used to produce and control, dose, and infuse Hydrogas® and RLS® into both water and other chemical species, while the Technology Rights Agreement provides us with a sublicense to the rights to Hydrogas® and RLS®. These technologies enhance the health of the aquatic species and minimize stress in high ammonia conditions. Each such agreement is for a 10-year term and automatically renew for successive 10-year terms unless terminated in accordance therewith. The agreements give NAS the exclusive rights to purchase or distribute the technology, or buy or rent the equipment, in the Industry Sector, which is the primary business and revenue stream generated from indoor aquaculture farming of any species in the Territory, defined as anywhere in the world except for the countries in the Gulf Corporation Council. The Company paid Hydrenesis Delta Systems, LLC the sum of $2,500,000 (staged over a period of time, with $1,250,000 still due), plus a 12.5% royalty for the Equipment Rights Agreement and for the Technology Rights Agreement. The Company paid Hydrenesis Aquaculture, LLC a total of $10,000,000, comprised of $2,500,000 at closing, $1,000,000 within 60 days and 6,500,000 shares of common stock of the Company. The Technology Rights Agreement also carried the same royalty provision.

Development of our Technology

General Background and Overview

Historically, efforts to raise shrimp in a high-density, closed system at the commercial level have been met with either modest success or outright failure through “BioFloc Technology.” An aquaculture system using “BioFloc Technology” recycles waste nutrients to culture microorganisms to form microbial protein from the toxic waste and other organic matter in the water. Infectious agents such as parasites, bacteria, and viruses potentially present in BioFloc systems are the most damaging and most difficult to control. While bacterial infection can in some cases be combated using antibiotics (although not always), the use of antibiotics is generally considered undesirable and counter to “green” cultivation practices. Viruses can be worse in that they are immune to antibiotics. Once introduced to a shrimp population, viruses can wipe out entire farms and shrimp populations, even with intense probiotic applications.

Our primary solution against infectious agents is our “Vibrio Suppression Technology.” This technology utilizes electrocoagulation (a procedure that uses heat from an electric current to destroy abnormal tissue) to kill potential pathogens and harmful bacteria such aa vibrio. While bacteria and other pathogens can still survive using this technology, Vibrio Suppression Technology helps to significantly reduce and suppress harmful organisms that usually cause “BioFloc” and other enclosed technologies to fail. Based on several peer-reviewed studies as well as management’s experience with this technology, we believe that this system creates higher sustainable densities, consistent production, improved growth and survival rates, and improved food conversion without the use of antibiotics, probiotics, or unhealthy anti-microbial chemicals.

Our technology platforms combine electrocoagulation and Hydrogas. Our patented electrocoagulation system replaces the need for biofilters and instead applies non-biological, electrical processes and uses electronics to remove ammonia and to control the level of pathogens in an aquaculture system. These technologies generate water chemistry with antioxidant properties, as demonstrated by third-party studies and our own trial conducted on North Atlantic Salmon at the RASLab research facility in Norway in 2021. The findings showed an increase in the well-being of aquatic species, including enhanced growth rates.

Hydrogas technology is based on a reducing gas that is produced on demand and infused into an aquaculture water column. The gas lowers the Oxidation Reduction Potential (“ORP”) of water to a negative reading on an ORP meter. Negative ORP refers to the water’s ability to either gain or lose electrons, acting as a measure of its reduction or oxidation capacity. When water has a negative ORP, it is more prone to gaining electrons, indicating a higher reduction potential. The more negative the ORP value of the water column, the stronger the reduction capacity, effects of which have been shown to have benefit within the aquaculture industry. The use of negative ORP water in recirculating aquaculture systems can have several beneficial effects on the animals and their environment such as lowering of the oxidation stress on the animals leading to better food conversion rates.

We have conducted several internal tests over a period of two years with finfish and shrimp, where we observed decreased mortality rates in the test groups utilizing the Hydrogas system.

The use of electrocoagulation in Recirculating Aquaculture Systems (RAS) plays a pivotal role in achieving higher sustainable densities. This technology utilizes an electrical current to coagulate particulates, bacteria, and other pollutants, leading to their precipitation out of the water column. By removing these harmful elements, the water quality is significantly improved, which in turn can support higher densities of animals without compromising their health and well-being. Furthermore, by reducing the bacterial load in the water, such as harmful Vibrio species, the overall health and immunity of the aquaculture species can be boosted, resulting in lower disease incidences and higher sustainable densities.

Maintaining a negative ORP water column using Hydrogas not only aids in consistent production but also improves food conversion rates. A negative ORP signifies a reducing environment, which is beneficial for lowering the oxidative stress on the animals, leading to better food conversion rates. Moreover, the constant removal of harmful substances and bacteria from the water ensures a stable, high-quality environment for the cultured species, leading to consistent growth rates and production. Thus, through the combined benefits of improved water quality, enhanced health, and optimized nutrient utilization, electrocoagulation with a negative ORP water column serves as a valuable tool for sustainable and efficient aquaculture systems.

The principal theories behind the Company’s system are characterized as:

● High-density shrimp production ● Weekly production ● Natural ecology system ● Regional production ● Regional distribution

These principles form the foundation for the Company and our potential distributors so that consumers can be provided with continuous volumes of live and fresh shrimp at competitive prices.

Research and Development; Evolution of Our Technology

In 2001, we began research and development of a high density, natural aquaculture system that is not dependent on ocean water to provide quality, fresh shrimp every week, 52 weeks a year. Our initial system was successful, but we determined that it would not be economically feasible due to high operating costs. Over the next several years, using the knowledge we gained from developing the first system, we developed a shrimp production system that eliminated the high costs associated with the previous system. We have continued to refine this technology, eliminating bacteria and other problems that affect recirculating systems, and now have a successful shrimp-growing process. We have produced thousands of pounds of shrimp over the years in order to develop a design that will consistently produce quality shrimp that grow to a large size at a specific rate of growth. This included experimenting with various types of natural live and synthesized feed supplies before selecting the most appropriate nutritious and reliable combination. It also included utilizing monitoring and control automation equipment to minimize labor costs and to provide the necessary oversight for proper regulation of the shrimp environment.

Our system consists of a nursery tank where the shrimp are acclimated and then moved to a larger grow-out tank for the rest of the growth cycle. During 2016, we engaged in additional engineering projects with third parties to further enhance our indoor production capabilities. The Company, working with F&T, contracted with RGA Labs, Inc. to build and update a prototype of our patented electrocoagulation system for the grow-out and harvesting of fully mature, antibiotic-free Pacific White shrimp. The design provided a viable pathway to begin generating revenue and producing shrimp on a commercially-viable scale. During 2019 the Company decided to begin an approximately $2,000,000 facility renovation, demolishing the interior wood-lined tanks (720,000 gallons). The Company began replacing the previous tanks with 40 new fiberglass tanks (600,000 gallons) at a cost of approximately $400,000, allowing complete production flexibility with smaller tanks.

On March 18, 2020, our research and development plant in La Coste, Texas was destroyed by a fire. The Company believed that it was caused by a natural gas leak, but the fire was so extensive that the cause was never determined. No one was injured as a result of the fire. The majority of the damage was to our pilot production plant, which comprised approximately 35,000 square feet of the total size of the production facilities at the La Coste location, but the fire did not impact the separate greenhouse, reservoirs, or utility buildings. The Company used the proceeds from its subsequent insurance claim to rebuild a 40,000 square foot production building at the La Coste facility and to repurchase the equipment needed to replace what was lost in the fire. The Company further refined the electrocoagulation system for installation in the Texas and later in its Iowa shrimp production facilities. The Company began developing a live shrimp delivery system from the Iowa production facility in November 2021 and from the Texas production facility. In 2023, the Company changed the focus of the Texas facility into a research and development center.

Overview of Industry

Shrimp is a well-known and globally-consumed commodity, constituting one of the most important types of seafood and a staple protein source for much of the world. According to the Food and Agriculture Organization of the United Nations, the 2021 global production of shrimp was 9.9 billion pounds with over 1.9 billion pounds of shrimp consumed in the United States alone. Approximately 65% of the global supply of shrimp is caught by ocean trawlers and the other 35% is produced by open-air shrimp farms, mostly in developing countries.

Shrimp boats catch shrimp through the use of large, boat-towed nets. These nets are quite toxic to the undersea environment as they disturb and destroy ocean-bottom ecosystems; these nets also catch a variety of non-shrimp sea life, which is typically killed and discarded as part of the shrimp harvesting process. Additionally, the world’s oceans can only supply a finite amount of shrimp each year, and in fact, single-boat shrimp yields have fallen by approximately 20% since 2010 and continue to decrease. The shrimping industry’s answer to this problem has been to deploy more (and larger) boats that deploy ever-larger nets, which has in the short-term been successful at maintaining global shrimp yields. This benefit, however, cannot continue forever, as eventually global demand has the potential of outstripping the oceans’ ability to maintain the natural ecosystem’s balance, resulting in a permanent decline in yields. When taken in light of global population growth and the ever-increasing demand for nutrient-rich foods such as shrimp, this method is clearly an unsustainable production paradigm.

Shrimp farming, known in the industry as “aquaculture,” has ostensibly stepped in to fill this demand/supply imbalance. Shrimp farming is typically done in open-air lagoons and man-made shrimp ponds connected to the open ocean. Because these ponds constantly exchange water with the adjacent sea, the farmers are able to maintain the water chemistry that allows the shrimp to prosper. This method of cultivating shrimp, however, also carries severe ecological peril. First of all, most shrimp farming is primarily conducted in developing countries, where poor shrimp farmers have little regard for the global ecosystem. As a result, these farmers use large quantities of antibiotics and other chemicals that maximize each farm’s chance of producing a crop, putting the entire system at risk. For example, a viral infection that crops up in one farm can spread to all nearby farms, quite literally wiping out an entire region’s production. In 1999, the White Spot virus invaded shrimp farms in at least five Latin American countries: Honduras, Nicaragua, Guatemala, Panama, and Ecuador, and in 2013-14 Early Mortality Syndrome wiped out most of the shrimp yields in the Asia Pacific region and Mexico. Secondly, there is also a finite amount of coastline that can be used for shrimp production — eventually shrimp farms that are dependent on the open ocean will have nowhere to expand. Again, this method is also an ecologically damaging and ultimately unsustainable system for producing shrimp.

In both the cases, the current method of shrimp production is unsustainable. As global populations rise and the demand for shrimp continues to grow, the current system is bound to fall short. Shrimp trawling cannot continue to increase production without completely depleting the oceans’ natural shrimp population. Trends in per-boat yield confirm that this industry has already crossed the overfishing threshold, putting the global open-ocean shrimp population in decline. While open-air shrimp aquaculture may seem to address this problem, it is also an unsustainable system that destroys coastal ecological systems and produces shrimp with very high chemical contamination levels. Closed-system shrimp farming is clearly a superior alternative, but its unique challenges have prevented it from becoming a widely-available alternative.

Of the 1.9 billion pounds of shrimp consumed annually in the United States, over 1.5 billion pounds are imported — much of this from developing countries’ shrimp farms. These farms are typically located in developing countries and use high levels of antibiotics and pesticides that are not allowed under USDA regulations. As a result, these shrimp farms produce chemical-laden shrimp in an ecologically unsustainable way.

Unfortunately, most consumers in the United States are not aware of the origin of their store-bought shrimp or the shrimp that they consume in restaurants. This lack of knowledge is due to a USDA rule that states that only bulk-packaged shrimp must state the shrimp’s country of origin; any “prepared” shrimp, which includes arrangements sold in grocery stores and seafood markets, as well as all shrimp served in restaurants, can simply be sold “as is.” Essentially, the foregoing means that most U.S. consumers may be eating shrimp laden with chemicals and antibiotics. Our product is free of pesticide chemicals and antibiotics, a fact that we believe will be highly attractive and beneficial in terms of our eventual marketing success.

Our Products

Product Description

Most of the shrimp consumed in the world today come from shrimp farms that can only produce crops between one and four times per year. Consequently, the shrimp from these farms requires freezing between crops until consumed. Our system is designed to harvest different tanks each week, which provides for fresh shrimp throughout the year. We strive to create a niche market of “Always Fresh, Always Natural” shrimp. As opposed to many of the foreign shrimp farms, we can also claim that our product is 100% free of antibiotics. The ability to grow shrimp locally and year-round allows us to provide this high-end product to upscale restaurant and grocery stores throughout the world. The Company is currently selling live shrimp to grocery stores outlets in Chicago and to stores and restaurants in Texas. We rotate the stocking and harvesting of our tanks each week, which allows for weekly shrimp harvests. Our product is free of pollutants and is fed only the highest-quality feeds.

International

We own 100% of NS Global, which was formed to create international partnerships and licensing for our platform technologies. Each international partnership is expected to use the Company’s proprietary technology to penetrate shrimp markets throughout the world utilizing existing food service distribution channels.

Competition

There are a number of companies conducting research and development projects in their attempt to develop closed-system technologies in the U.S., some with reported production and sales. Most North American shrimp farms are using a BioFloc System to intensify shrimp growth. Since these are privately-held companies, it is not possible to know, with certainty, their state of technological development, production capacity, need for water exchange, location requirements, financial status, and other matters. To the best of our knowledge, none are producing significant quantities of shrimp relative to their local markets, and such fresh shrimp sales are likely confined to an area near their production facility.

Additionally, any new competitor would face significant barriers for entry into the market and would likely need years of research and development to develop the proprietary technology necessary to produce similar shrimp at a commercially viable level. It is possible that additional competitors will arise in the future, but with the size and growth of the worldwide shrimp market, we are confident that many competitors could co-exist and thrive in the fresh shrimp industry.

Intellectual Property

The following table provides information regarding our issued patents:

Patent Document Number (Issued)

Description

Jurisdiction

Type

Date Filed

Date Issued

Expiration Date

Current Ownership

Currently In Active Use

Must Be In Continued Use

Will Be Maintained Until a Third-Party Challenge

US Patent 10,163,199 B2

Recirculating Aquaculture System and Treatment method of Aquatic Species

United States

Utility*

11/28/2016

12/25/2018

11/28/2036

Natural Shrimp Inc

Yes

US Patent 11,297,809 B1

Ammonia Control in a Recirculating Aquaculture System

United States

Utility*

7/7/2021

4/12/2022

7/7/2041

Natural Shrimp Inc

Yes

US Patent 9,908,794 B2

Electrocoagulation Chamber with Atmospheric & Pressurized Flow Regimes

United States

Utility*

5/25/2015

3/6/2018

5/25/2035

Natural Shrimp Inc

Yes

* Utility patents are granted to anyone who invents or discovers any new and useful process, machine, article of manufacture, or compositions of matters, or any new useful improvement thereof.

Patent Document Number (Applied)		Description		Jurisdiction		Date Filed
Application No 17/895,906		Method and Apparatus for removing specific contaminants from water in a recirculating or linear treatment system		United States		8/25/2022

Trademarks

Jurisdiction

Live

First Used in Commerce

Date Filed

Published for Opposition

Registration Date

Word Mark

Currently In Active Use

Must Be In Continued Use

Will Be Maintained Until a Third Party Challenge

6,122,073

United States

Yes

12/31/2004

7/2/2019

5/26/2020

8/11/2022

NATURALSHRIMP

Yes

There are potential additional technical processes for which the Company may be able to file a patent. There are no assurances, however, that such applications, if filed, would be issued and no right of enforcement is granted to a patent application. Therefore, the Company plans to use a variety of other methods, including copyright registrations as appropriate, trade secret protection, and confidentiality and non-compete agreements to protect its intellectual property portfolio.

Source and Availability of Raw Materials

We receive necessary raw materials from established suppliers, generally in a timely manner. Currently, we buy our feed from Zeigler, a leading producer of aquatic feed. Post larvae shrimp are available from Sea Products Development in Texas and Homegrown Shrimp in Florida.

Notwithstanding our current relationship with our suppliers of Post Larvae (PLs) shrimp, we have previously experienced temporary shortages and delays as a result issues arising at their hatcheries. We have favorable contacts and past business dealings with other major shrimp feed producers from which we can purchase required raw materials if our current suppliers are not available. In addition, we have also experienced supply-chain problems that have restricted our access to needed equipment parts and supplies. However, we have been able to mitigate these issues by modifying off-the-shelf readily available parts and equipment to work within our system.

Government Approvals and Regulations

We are subject to government regulation and require certain licenses. The following list includes regulations to which we are subject and/or the permits and licenses we currently hold:

● Annual permit issued by the Texas Commission on Environmental Quality (“TCEQ”). TCEQ regulates facility wastewater discharge. The La Coste facility is rated Level 1 (Recirculation System with No Discharge). The Company’s technologies provide for zero discharge, which makes it much easier to locate production facilities in various locations having strict environmental requirements. ● The Company has applied to register the La Coste facility with the FDA in case the Company decides to process the shrimp in the future at this facility. However, the shrimp are currently delivered heads-on with no processing. ● The Company has applied to register the facility in Webster City, Iowa with the FDA in case the Company decides to process the shrimp in the future at this facility. However, the shrimp are currently delivered heads-on with no processing. ● Annual aquaculture license issued by Iowa Department of Natural Resources in respect of the Webster City, Iowa facility to produce shrimp in Iowa.

We are subject to certain regulations regarding the need for field employees to be certified. We strictly adhere to these regulations. The cost of certification is an accepted part of expenses. Regulations may change and become a cost burden, but compliance and safety are our main concern.

Corporate and Available Information

Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and all amendments to those reports are available free of charge though our website (http://www.naturalshrimp.com) as soon as practicable after such material is electronically filed with, or furnished to, the Securities and Exchange Commission (the “SEC”). Except as otherwise stated in these documents, the information contained on our website or available by hyperlink from our website is not incorporated by reference into this report or any other documents we file, with or furnish to, the SEC.

Human Capital Management

Employees

As of the date of the filing we had a very limited number of full-time employees due to the cessation of our current business operations. In addition to our very limited number of full-time employees, we retain the services of outside consultants for various functions including legal and accounting services.

ITEM 1A. RISK FACTORS

As a smaller reporting company, we are not required to provide the information required by this item.

ITEM 1B. UNRESOLVED STAFF COMMENTS

Not Applicable.

ITEM 1C. CYBERSECURITY

Risk management and strategy

Management of material risks from cybersecurity threats is integrated into the Company’s overall risk management processes and is monitored as an enterprise risk. ToDue ~~that~~to ~~extent~~our limited operations, the Company ~~has~~does ~~engaged~~not ~~with~~currently aengage ~~third-party~~with ~~service~~any ~~provider~~assessors, ~~DATAECON~~consultants, ~~in order to help manage~~auditors ~~its~~or ~~ongoing~~other ~~cybersecurity~~third ~~risk.~~parties ~~This~~as ~~includes~~part ~~processes that are put in place to oversee and identify risks from cybersecurity threats associated with its use~~ of ~~any~~this ~~third-party service provider~~process.

During our fiscal year ended March 31, 2023 , the email of one of our former executive officers was hacked by an unknown third party. Utilizing ~~the~~ the hacked email of ~~our~~the former executive officer, the unknown third party requested a $100,000 payment from one of our investors. In response to the email, the investor wired the $100,000 payment to a bank account provided in the email. The investor funds were not recovered, ~~and~~ and the Company was required to make certain restitution to the investor (via the issuance of common shares). ~~As a result of the incident, the Company engaged with DATAECON in order to reduce the potential of such cybersecurity risks going forward.~~

Governance

While the board of directors does not have any formal oversight of risks from cybersecurity threats, it is important to note that ~~our~~Mr. ~~board~~Antelo ~~of directors~~ is ~~comprised~~currently ~~solely~~our ofsole ~~Messrs. Easterling~~director, ~~Delgado~~chief executive officer and ~~Untermeyer~~chief financial officer. As such, ~~pursuant~~Mr. toAntelo ~~the~~is ~~information~~responsible ~~provided~~for ~~below,~~monitoring ~~all~~and ~~risks~~addressing ~~from~~ cybersecurity ~~threats~~risks ~~our~~as ~~immediately~~they ~~shared~~become ~~with~~known to the ~~board of directors~~Company.

Our chief technology officer (the “CTO”), Tom Untermeyer, is responsible for managing the Company’s cybersecurity risk. Mr. Untermeyer has served as the Company’s CTO since 2015. His business experience includes systems engineering, program development and technical management. Further, Mr. Untermeyer holds a Bachelor of Science in Electrical Engineering from St. Mary’s University. As NaturalShrimp is a small company with a limited number of employees, any cybsecurity threat or incident is immediately brought to the attention of Mr. Untermeyer. Further, as noted above, Mr. Untermeyer will then immediately inform his fellow board members including Mr. Easterling and Mr. Delgado.

ITEM 2. PROPERTIES

Not applicable

ITEM 3. LEGAL PROCEEDINGS

~~Receivership~~Not applicable

On September 4, 2024, Streeterville Capital, LLC, a Utah limited liability company, and Bucktown Capital, LLC, a Utah limited liability company (collectively, “Lenders”), filed a Verified Emergency Motion for Appointment of Receiver (the “Motion”) under Civil Case No. 240907138, in the District Court of Salt Lake County, Utah, against NaturalShrimp, Inc. (“NaturalShrimp”).

The Motion alleges, among other things, that NaturalShrimp has defaulted under the terms of its loan agreements with the Lenders. The Motion sought the appointment of a Receiver to immediately take control of NaturalShrimp’s assets to preserve the same.

On November 20, 2024, the Lenders and NaturalShrimp filed a Verified Amended and Stipulated Emergency Motion for Immediate Appointment of a Receiver in the Receivership Case.

On February 11, 2025, the Receiver filed a Motion for Approval to Sell Substantially all of the Receivership Entities’ Assets to Streeterville Captial, LLC and Bucktown Captial, LLC (or Their Designees) or Any Other Party With a Higher and Better Offer Free and Clear of All Liens, Interests, Claims, and Encumbrances (the “Sale Motion”) in the Receivership Case. The Sale Motion seeks the Utah State Court’s approval for the Receiver to sell substantially all of the Receivership Entities’ assets free and clear of all liens, interests, claims, and encumbrances to Streeterville and Bucktown Capital, through their designated entities, NaturalShrimp Farms, Inc. (“NV Purchaser”), a Nevada corporation, Iowa Shrimp Holdings, LLC (“IA Purchaser”), an Iowa limited liability company, Texas Shrimp Holdings, LLC (“TX Purchaser” or together with NV Purchaser and IA Purchaser, the “Purchasers”), a Texas limited liability company, for a roughly $35,703,789.87 credit bid (based on a secured and administrative claim basis) and $100,000 cash, pursuant to the terms and conditions set forth in that certain Asset Purchase Agreement (“APA”) between Trustee and Purchasers. The order to sell the assets was approved on March 30, 2025 and the title to the assets was transferred to the lenders on May 14, 2025. As part of the sale, the Company transferred its ownership rights to its fixed assets, patents and license agreements in exchange for the extinguishment of its outstanding debt to both Streeterville and Buckstown Capital. As of the date of the ownership transfer, the Company ceased its current business operations.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

115

PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market Information

Our common stock was historically quoted on the OTC Markets Group quotation system under the symbol “SHMP.” Currently, our common stock is only eligible for unsolicited broker quotations and is now traded on the OTC Markets “Expert Market,” which is accessible solely to broker-dealers and professional investors. As a result, there is no established public trading market for our common stock and a range of high and low bid information is not available.

Transfer Agent

Our transfer agent is TranShare Corporation, 15500 Roosevelt Blvd, Suite 302, Clearwater, FL 33760. Their telephone number is (303) 662-1112.

Holders of Common Stock

As of ~~October~~July 65, ~~2025~~2026, there were approximately 520 shareholders of record of our common stock. As of such date, 1,277,546,746 shares were issued and outstanding.

Dividends

We have never declared or paid any cash dividends on our common stock, nor do we have any intention to do so in the future.

Securities Authorized for Issuance Under Equity Compensation Plans

There were no equity compensation plans formally approved by the shareholders of the Company as of March 31, ~~2025~~2026.

Recent Sales of Unregistered Securities

WeIn ~~have~~conjunction ~~previously~~with ~~disclosed~~the inIntellectual ~~our~~Property ~~quarterly~~agreement ~~reports~~entered oninto ~~Form~~by ~~10-Q~~the ~~and~~Company ~~current~~on ~~reports~~March on17, ~~Form~~2026 ~~8-K~~(and ~~filed~~consummated ~~since~~on ~~April~~June 125, 2026), ~~2023~~we issued 2,450,000 ~~all~~warrants ~~sales~~to former employees in consideration for advisory services to be provided by those individuals over ofa ~~securities~~three ~~without~~year ~~registration~~period. ~~under~~The ~~the~~warrants ~~Securities~~have ~~Act~~a term of ~~1933~~three years, asan ~~amended,~~exercise ~~during~~price ~~the~~of ~~fiscal~~$0.00125, ~~year~~and ~~ended~~are ~~March~~not ~~31,~~currently ~~2025~~exercisable.

Issuer Purchases of Equity Securities

During the fiscal year ended March 31, ~~2025~~2026, we did not repurchase any of our equity securities.

ITEM 6. [RESERVED]

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Cautionary Notice Regarding Forward Looking Statements

The information contained in Item 7 contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Actual results may materially differ from those projected in the forward-looking statements as a result of certain risks and uncertainties set forth in this report. Although management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable, there is no assurance that the underlying assumptions will, in fact, prove to be correct or that actual results will not be different from expectations expressed in this report.

We desire to take advantage of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. This report contains a number of forward-looking statements that reflect management’s current views and expectations with respect to our business, strategies, products, future results and events, and financial performance. All statements made in this report other than statements of historical fact, including statements addressing operating performance, clinical developments which management expects or anticipates will or may occur in the future, including statements related to our technology, market expectations, future revenues, financing alternatives, statements expressing general optimism about future operating results, and non-historical information, are forward looking statements. In particular, the words “believe,” “expect,” “intend,” “anticipate,” “estimate,” “may,” variations of such words, and similar expressions identify forward-looking statements, but are not the exclusive means of identifying such statements, and their absence does not mean that the statement is not forward-looking. These forward-looking statements are subject to certain risks and uncertainties, including those discussed below. Our actual results, performance or achievements could differ materially from historical results as well as those expressed in, anticipated, or implied by these forward-looking statements. We do not undertake any obligation to revise these forward-looking statements to reflect any future events or circumstances.

126

Readers should not place undue reliance on these forward-looking statements, which are based on management’s current expectations and projections about future events, are not guarantees of future performance, are subject to risks, uncertainties and assumptions (including those described below), and apply only as of the date of this report. Our actual results, performance or achievements could differ materially from the results expressed in, or implied by, these forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, risks discussed in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. For additional information regarding forward-looking statements, see “Forward-Looking Statements” at the beginning of this report.

~~Use~~Corporate ~~of Generally Accepted Accounting Principles (“GAAP”) Financial Measures~~History

WeThe ~~use~~Company ~~United~~was ~~States~~incorporated ~~GAAP~~in ~~financial~~the ~~measures,~~State ~~unless~~of ~~otherwise~~Nevada ~~noted.~~on ~~All~~July of3, 2008 under the ~~GAAP~~name ~~financial~~“Multiplayer ~~measures~~Online ~~used~~Dragon, byInc.” usOn inJanuary 30, ~~this~~2015, ~~report~~we ~~relate to~~acquired ~~the~~substantially ~~inclusion~~all of ~~financial~~the ~~information.~~assets ~~This~~of ~~discussion~~NaturalShrimp ~~and~~Holdings, ~~analysis~~Inc. ~~should~~(“NSH”), bewhich ~~read~~had indeveloped ~~conjunction~~proprietary technology ~~with~~to ~~our~~grow ~~financial~~and ~~statements~~sell ~~and the~~shrimp. ~~notes~~As ~~thereto~~a ~~included~~result ~~elsewhere~~of inthe ~~this~~transaction, ~~annual~~we ~~report.~~changed ~~All~~our ~~references~~principal business to ~~dollar~~a ~~amounts~~global inshrimp ~~this~~farming ~~section~~company and ~~are~~changed inour ~~United~~name ~~States~~to ~~dollars, unless~~“NaturalShrimp ~~expressly~~Incorporated” ~~stated~~in ~~otherwise~~2015.

~~This discussion and analysis should be read in conjunction with our financial statements and the notes thereto included elsewhere in this annual report.~~Receivership

~~Overview~~On September 4, 2024, Streeterville Capital, LLC, a Utah limited liability company, and Buckstown Capital, LLC, a Utah limited liability company (collectively, “Lenders”), filed a Verified Emergency Motion for Appointment of Receiver (the “Motion”) under Civil Case No. 240907138, in the District Court of Salt Lake County, Utah, against NaturalShrimp, Inc. (“NaturalShrimp”).

WeThe ~~were~~Motion analleged, ~~aquaculture~~among ~~technology~~other ~~company~~things, that ~~developed~~NaturalShrimp ~~proprietary,~~had ~~patented~~defaulted ~~platform~~under ~~technologies to allow for~~ the ~~production~~terms of ~~aquatic species~~its inloan anagreements ~~ecologically~~with ~~controlled,~~the ~~high-density,~~Lenders. ~~low-cost~~The ~~environment,~~Motion sought ~~and~~the inappointment ~~fully~~of ~~contained~~a ~~and~~Receiver ~~independent~~to ~~production~~immediately ~~facilities without~~take ~~the~~control ~~use~~ of ~~antibiotics~~NaturalShrimp’s orassets ~~toxic~~to ~~chemicals~~preserve the same.

WeAn ~~were~~order ~~incorporated~~was inentered ~~July~~ex ~~2008~~parte ~~and~~by ~~acquired~~the ~~substantially~~Utah ~~all~~State ofCourt in the ~~assets~~Receivership ofCase ~~NSH,~~on ~~the~~September ~~company~~9, ~~that~~2024 ~~developed~~granting the ~~proprietary~~relief ~~technology to~~requested ~~grow~~by ~~and~~Lenders. The ~~sell~~Utah ~~shrimp~~State ~~potentially~~Court ~~anywhere~~duly inappointed ~~the~~Amplēo ~~world~~Turnaround ~~that~~and isRestructuring, ~~now~~LLC (the ~~basis~~“Receiver”) ofas ~~our~~the ~~business.~~receiver Inover NaturalShrimp’s ~~2015 NSH acquired 88~~assets.~~62%~~ ofThe ~~the~~Utah ~~issued and~~State ~~outstanding~~Court’s ~~shares~~order offurther ~~NaturalShrimp~~scheduled ~~Common~~a ~~Stock,~~hearing ~~NSC~~to ~~and~~be NSheld ~~Global~~on ~~became~~September ~~our~~17, ~~wholly-owned subsidiaries~~2024, ~~and~~on wea ~~changed our principal~~preliminary ~~business~~injunction to aaddress ~~global~~issues ~~shrimp~~raised ~~farming~~in ~~company~~the Motion.

On ~~October~~November 520, ~~2015~~2024, wethe ~~formed~~Lenders ~~NAS~~and ~~with~~NaturalShrimp ~~F&T,~~filed ~~the~~a ~~purpose~~Verified ofAmended ~~which~~and ~~was~~Stipulated toEmergency ~~jointly~~Motion ~~develop~~for ~~with~~Immediate ~~F&T~~Appointment of ~~certain~~a ~~water~~Receiver ~~technologies~~in the Receivership Case.

On ~~December~~November 1722, ~~2020~~2024, wethe ~~acquired~~Utah ~~for~~State ~~$10.0~~Court ~~million~~entered ~~certain~~an ~~assets~~order ~~from~~granting ~~VeroBlue~~the ~~Farms~~Stipulated ~~USA,~~Motion ~~Inc~~and appointed Receiver as the receiver over the assets of NaturalShrimp. ~~and~~Under ~~its~~the ~~subsidiaries~~Amended Receivership Order, ~~which~~the ~~assets~~Receiver ~~included our~~is ~~three~~the ~~current~~receiver ~~facilities~~over ~~located~~the inReceivership ~~Iowa~~Entities’ assets.

On ~~May~~February 2511, ~~2021~~2025, wethe ~~purchased~~Receiver ~~certain~~filed ~~parent~~a Motion for Approval to Sell Substantially all of the Receivership Entities’ Assets to Streeterville Captial, LLC and ~~intellectual~~Bucktown ~~property~~Captial, ~~rights~~LLC ~~from~~(or ~~F&T~~Their Designees) or Any Other Party With a Higher and ~~acquired~~Better ~~all~~Offer Free and Clear of ~~its~~All ~~outstanding~~Liens, ~~shares~~Interests, Claims, and Encumbrances (the “Sale Motion”) in the Receivership Case. The Sale Motion ~~NAS,~~sought ~~thereby~~the ~~making~~Utah ~~NAS~~State ~~our~~Court’s ~~wholly-owned~~approval ~~subsidiary~~for the Receiver to sell substantially all of the Receivership Entities’ assets free and clear of all liens, interests, claims, and encumbrances to Streeterville and Bucktown Capital for a roughly $335,703,789.087 ~~million~~credit bid in(based on a secured and administrative claim basis) and $100,000 cash, pursuant to the terms and 13conditions set forth in that certain Asset Purchase Agreement (“APA”) between Trustee and Purchasers. The order to sell the assets was approved on March 30,~~861~~ 2025 and the title to the assets was transferred to the lenders on May 14,~~386~~ ~~shares~~2025. As part of ~~NaturalShrimp~~the ~~Common~~sale, ~~Stock~~the Company transferred its ownership rights to its fixed assets, patents and license agreements in exchange for the extinguishment of its outstanding debt to both Streeterville and Buckstown Capital. As of the date of the ownership transfer, the Company ceased all of its business operations.

OnPerpetual ~~August~~License ~~25, 2021, through NAS, we entered into an Equipment Rights Agreements with Hydrenesis-Delta Systems, LLC and a Technology Rights~~ Agreement with Hydrenesis Aquaculture LLC. The Equipment Rights Agreement relates to specialized and proprietary equipment used to produce and control, dose, and infuse Hydrogas® and RLS® into both water and other chemical species, while the Technology Rights Agreement provides us with a sublicense to the rights to Hydrogas® and RLS®.

~~The~~During ~~Company~~March ~~has~~of ~~three~~2026, ~~wholly-owned~~NaturalShrimp ~~subsidiaries:~~Incorporated ~~NSC,~~entered NSinto ~~Global,~~an ~~and~~Intellectual ~~NAS,~~Property and ~~owns~~Management ~~51%~~Transition ofAgreement ~~NaturalShrimp/~~(the “Agreement”) with Hydrenesis, ~~LLC~~Inc., a ~~Texas~~Florida ~~limited~~corporation ~~liability company~~(“Hydrenesis”), and David Antelo. Pursuant to the agreement:

~~During September~~● of 2024, Ampleo Turnaround and Restructuring, LLC was placed as the receiver over the Company’s. Further, during February of 2025, the receiver submitted a motion to sell substantially all of the Company’s assets to Streeterville and Bucktown Capital for an approximate credit bid of $35.7 million and $100,000 in cash. The ~~motion to sell was approved by the court on March 30, 2025. The~~ Company ~~believes~~will ~~that~~transition it continued to function as a going concern until the date of the approved sale. As such, the Company has presented going concern financial statements as of March 30, 2025 and for the period from April 1, 2024 through March 30, 2025. Furthermore, in accordance with ASC 205-30, Liquidation Basis of Accounting, the Company has presented its ~~financial~~operations ~~statements~~toward ~~(using a convenience date) as of March 31, 2025 under~~ the ~~liquidation~~commercialization ~~basis~~ of ~~accounting.~~aquaculture As such, the financial statements included in the filing also include a Statement of Net Liabilities in liquidation as of March 31, 2025. As there was only a one-day period between the time liquidation became imminent and ~~the~~ ~~end~~water oftreatment ~~the~~technologies; ~~reporting period, a Statement of Changes in Net Assets (liabilities) in liquidation has not been provided.~~and

~~Results~~ ● Governance and control of ~~Operations~~the Company transferred (as of the agreement date) in accordance with the Agreement.

As● ~~discussed~~Hydrenesis ~~above,~~will grant the Company ~~ceased being~~ a ~~going~~perpetual ~~concern~~license onto ~~March~~certain ~~30,~~intellectual ~~2025 and~~property, ~~subsequent~~technology ~~to that date~~rights, ~~began applying the liquidation basis of accounting. As such~~know-how, ~~the~~and ~~Company~~related ~~believes~~commercialization ~~that a discussion of its results of operations~~rights, ~~whether~~subject ~~that includes i) comparing the liquidation basis period~~ to the ~~going~~terms ~~concern~~and ~~period~~conditions orof ~~ii) comparing~~ the ~~going concern period ended March 30, 2025 to the prior year period ended March 31, 2024 would not be informative.~~agreement

13● The Company’s outstanding obligation to Hydrenesis in the amount of approximately $1,034,112 will be converted into equity;

●

The Company approved and executed Certificates of Designation for Series P, Series P-2, and Series L Preferred Stock, which are expected to be filed with the Nevada Secretary of State;

●

Liquidity and Capital Resources

AtThe ~~March~~Company ~~31,~~is ~~2025,~~currently weworking ~~had~~on ~~cash~~a plan with its existing creditors on ~~hand~~how ofto ~~$101~~settle its remaining outstanding balances,~~969.~~ Aswhich ~~discussed~~were inprimarily comprised ~~the~~of ~~filing,~~i) ~~the~~payables ~~Company~~to ~~has~~finance ~~liquidated~~and ~~its~~legal ~~primary~~service ~~operating~~providers ~~assets in~~ii) ~~order~~accrued compensation to ~~settle~~former ~~its~~employees ~~outstanding~~and ~~debt~~ii) ~~with~~related ~~Streeterville~~party and third ~~Buckstown~~party ~~Capital.~~loans At(including the ~~time~~corresponding ofaccrued ~~this~~interest). ~~filing,~~As ~~the~~discussed ~~Company~~in ~~does~~our ~~not~~Form ~~have~~8-K filed with the Securities and Exchange aCommission ~~finalized~~on ~~plan~~March ~~regarding~~30, 2026, the ~~settlement~~Company ofintends ~~its~~to ~~remaining~~seek ~~outstanding~~the ~~liabilities~~exchange orof ancertain ~~exact~~existing ~~timeline~~liabilities ~~regarding~~and ~~its~~obligations ~~liquidation~~into ~~process~~newly authorized preferred shares.

Results of Operations

During the year ended March 31, 2026, the Company settled its outstanding liabilities to both Streeterville and Buckstown (approximately $36 million as of March 31, 2025) through the transfer of ownership rights to its fixed assets and intangible assets. As of the date of the transfer, i) the outstanding debt to those entities was considered extinguished and ii) the fixed assets and intangible assets were derecognized. The Company had limited other activity during the period, as reflected in the Statement of Change in Net Assets.

Critical Accounting Estimates

Fair Value Measurement

The fair value measurement guidance clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in the valuation of an asset or liability. It establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under the fair value measurement guidance are described below:

Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities;

Level 2 - Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability; or

Level 3 - Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

The derivative and warrant liabilities are Level 3 fair value measurements.

Liquidation Basis of Accounting

In accordance with ASC 205-30, Liquidation Basis of Accounting, the Company ~~will~~prepares ~~prepare~~ its financial statements using the liquidation basis of accounting when liquidation is imminent. Liquidation is considered imminent when either of the following occurs-i) A plan for liquidation has been approved by the person or persons with the authority to make such a plan effective, and the likelihood is remote that either execution of the plan will be blocked by other parties or the entity will return from liquidation and ii) A plan for liquidation is imposed by other forces, and the likelihood is remote that the entity will return from liquidation.

When using the liquidation basis of accounting, the Company will i) recognize other items that is previously had not recognized but it expects to sell in liquidation or use to settle liabilities ii) accrue costs and income that it expects to incur or earn through the end of its liquidation if and when it has a reasonable basis for estimation iii) measure its assets to reflect the estimated amount of cash or other consideration that it expects to collect in settling or disposing of those assets in carrying out its plan for liquidation and iv) measure its liabilities in accordance with the measurement provision of other topics that it would otherwise apply to those liabilities.

Recently Issued Accounting Standards

As the Company is currently reporting under the liquidation basis of accounting, it does not believe that there are any recently issued accounting standards that would be material to its financial statements.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not Applicable.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

The information called for by Item 8 is included following the “Index to Financial Statements” on page F-1 contained in this annual report on Form 10-K.

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosures. In designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance of achieving the desired control objectives.

Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based upon that evaluation and subject to the foregoing, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective due to the material weaknesses in internal control over financial reporting described below.

Management’s Annual Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) and Rule 15d-15(f) under the Exchange Act). Our internal control over financial reporting is a process designed by, or under the supervision of, our principal executive and principal financial officers and effected by our Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our consolidated financial statements for external reporting purposes in accordance with U.S. generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. In addition, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.

158

Material Weakness in Internal Control over Financial Reporting

Management assessed the effectiveness of the Company’s internal control over financial reporting as of March 31, ~~2025~~2026 based on the criteria for effective internal control over financial reporting established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission and SEC guidance on conducting such assessments. Based on this assessment, management has determined that the Company’s internal control over financial reporting as of March 31, ~~2025~~2026 was not effective. Management realized that there were deficiencies in the design or operation of our internal control over financial reporting that adversely affected it and that management considers to be material weaknesses. Such material weaknesses in our internal control over financial reporting have not been remedied.

The ineffectiveness of our internal control over financial reporting was due to the following material weaknesses, which are indicative of many small companies with small number of staff:

●	Inadequate segregation of duties consistent with control objectives;
●	Lack of independent board of directors (as of the balance sheet date) and absence of an audit committee to exercise oversight responsibility related to financial reporting and internal control;
●	Lack of risk assessment procedures on internal controls to detect financial reporting risks in a timely manner; and
●	Lack of documentation on policies and procedures that are critical to the accomplishment of financial reporting objectives.

Management continues to implement measures designed to ensure that control deficiencies contributing to the material weakness are remediated, such that these controls are designed, implemented, and operating effectively.

The remediation actions planned include:

● Identify gaps in our skills base and the expertise of our staff required to meet the financial reporting requirements of a public company; ● Establish an independent board of directors and an audit committee (which the company intends to ~~implement~~evaluate atas the ~~time~~transition ofplan, ~~the~~financing ~~completion~~needs, ofand ~~the~~operating ~~Business~~activities ~~Combination~~develop) to provide oversight for remediation efforts and ongoing guidance regarding accounting, financial reporting, overall risks and the internal control environment; ● Retain additional accounting personnel with public company financial reporting, technical accounting, SEC compliance, and strategic financial advisory experience to achieve adequate segregation of duties; and ● Continue to develop formal policies and procedures on accounting and internal control over financial reporting and monitor the effectiveness of operations on existing controls and procedures.

Our management will continue to monitor and evaluate the relevance of our risk-based approach and the effectiveness of our internal controls and procedures over financial reporting on an ongoing basis and is committed to taking further action and implementing additional enhancements or improvements, as necessary and as funds allow.

This annual report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to rules of the SEC that permit us to provide only management’s report in this annual report, which may increase the risk that weaknesses or deficiencies in our internal control over financial reporting go undetected.

Changes in Internal Control over Financial Reporting

There ~~have been~~ were no changes in our internal control over financial reporting during the fiscal quarter ended March 31, ~~2025~~2026 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.

ITEM 9B. OTHER INFORMATION

None.

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.

Not applicable.

169

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

~~Set~~As ~~forth below are the present directors and executive officers~~ of ~~the~~March ~~Company. Except as set forth below~~31, ~~there are no other persons who have been nominated or chosen to become directors~~2026, ~~nor~~David ~~are~~Antelo ~~there~~was ~~any~~the ~~other~~Company’s ~~persons~~i) ~~who~~chief ~~have been chosen to become~~ executive ~~officers. Other~~officer ~~than~~ii) aschief ~~set~~financial ~~forth~~officer ~~below, there are no arrangements or understandings between any of the directors, officers~~ and ~~other~~iii) ~~persons~~sole ~~pursuant to which such person was selected as a director or an officer~~Director.

Name	Age	Position	Since
Gerald Easterling	77	Chief Executive Officer, President and Director	2015
William Delgado	66	Treasurer, Chief Financial Officer and Director	2014
Tom Untermeyer	66	Chief Operating Officer, Chief Technology Officer and Director	2019
William Steven Walker	74	General Counsel and Secretary	2022

Biographies

~~The~~David ~~Board~~Antelo of– ~~Directors~~Chief isExecutive ~~comprised of only one class. All of the directors serve for a term of one year and until their successors are elected at the Company’s annual shareholders meeting and are qualified~~Officer, ~~subject~~Chief toFinancial ~~removal~~Officer ~~by the Company’s shareholders. Each executive officer serves, at the pleasure of the Board of Directors, for a term of one year~~ and ~~until~~Sole ~~his successor is elected at a meeting of the Board of Directors and is qualified.~~Director

~~Our~~David ~~Board~~Antelo ofhas ~~Directors~~served ~~believes~~as ~~that all members of the Board and all executive officers encompass~~ a ~~range of talent~~founder, ~~skill~~executive, and ~~experience sufficient~~operator toin ~~provide~~the ~~sound~~water technology and ~~prudent~~aquaculture ~~guidance~~sectors ~~with~~for ~~respect~~over toa ~~our~~decade. ~~operations~~From ~~and~~2018 through ~~interests.~~the ~~The~~present, ~~information~~he ~~below~~has ~~with~~been ~~respect~~actively ~~to our~~leading ~~directors~~ and ~~executive~~developing ~~officers includes each individual’s experience~~Hydrenesis, ~~qualifications,~~a ~~attributes,~~company ~~and~~focused ~~skills~~on ~~that~~advancing ~~led~~proprietary ~~our~~technologies ~~Board~~for ofwater ~~Directors~~treatment, toaquaculture ~~the~~systems, ~~conclusion that he or she should serve as a director~~ and~~/or~~ ~~executive~~environmental ~~officer~~remediation.

~~Biographies~~During ofthe ~~Executive~~past ~~Officers~~five years, Mr. Antelo has been responsible for structuring and ~~Directors~~executing the commercialization strategy for Hydrenesis technologies, including electrocoagulation-based treatment systems and hydrogen-based water treatment applications. His role has included negotiating and structuring licensing agreements, overseeing intellectual property positioning, and identifying market applications across aquaculture, agriculture, and industrial wastewater sectors.

~~Set~~Mr. ~~forth~~Antelo ~~below~~is ~~are~~also ~~brief~~the ~~accounts~~founder of ~~the~~HydrEvolve ~~business~~Inc., ~~experience~~a ~~during~~U.S.-based atcompany ~~least~~focused on the ~~past~~development ~~five~~of ~~years~~decentralized ofwater ~~each~~purification ~~director~~systems for disaster relief, off-grid communities, and ~~executive~~industrial ~~officer~~applications. His responsibilities include product strategy, commercialization planning, and coordination of engineering and prototype development. HydrEvolve Inc. is not a parent or subsidiary of the ~~Company~~registrant but is an affiliated entity under common control.

~~Gerald~~Mr. ~~Easterling~~Antelo –has ~~Chief~~also ~~Executive~~led ~~Officer~~capital formation efforts, ~~President~~strategic partnerships, and ~~Director~~product development initiatives tied to these technologies. His work has included coordinating engineering development, guiding prototype deployment, and aligning technical capabilities with commercial opportunities.

~~Mr.~~In ~~Easterling~~addition, has served as President and a director of the Company since January 2015 and as its Chief Executive Officer since August 2019. He also co-founded and has served as President and a director of NSH since its inception in 2001. Mr. ~~Easterling~~Antelo ~~has~~spent ~~over~~approximately 4017 years~~’ experience~~ inas ~~the~~an ~~food~~investment ~~business and related industries. From 1995 to 2001~~advisor, ~~Mr.~~where ~~Easterling~~he was ~~Chief~~responsible ~~Executive~~for ~~Officer~~advising ~~and~~clients ~~Chairman~~on ofcapital ~~the Board of Excel Vending Companies~~allocation, ~~headquartered~~financial ~~in Austin~~planning, ~~Texas,~~and ~~which~~investment ~~utilized the Café Quick patented customer automated fast food vending equipment~~strategies. HeThis ~~was~~experience ~~co-founder~~provides ~~and served as President and~~ a ~~Director~~foundation ofin ~~Cafe~~capital ~~Quick Enterprises~~markets, ~~Inc.,~~investor ~~a Dallas-headquartered~~relations, ~~company~~and ~~that~~financial ~~designed~~structuring, ~~developed,~~which ~~and~~is ~~patented~~directly ~~both~~applicable ~~packaging~~to ~~and~~ the ~~Café~~management ~~Quick automated fast food vending equipment. Café Quick licensed the patented technology manufacturing rights both domestically~~ and ~~internationally,~~oversight ~~from~~of ~~1988 to 2008. Mr. Easterling has also served as~~ a ~~member~~publicly oftraded ~~the board of directors of NSC and NS Global since 2001~~company.

Our Board of Directors believes that Mr. Easterling is qualified to serve as a director because of his business experience, including his experience as a director of companies in industries similar to those as the Company, as described above.

William J. Delgado – Treasurer, Chief Financial Officer and Director

Mr. Delgado has served as Chief Financial Officer and Treasurer of the Company since July 2015 and as a Director since May 2014. He also served as President of the Company from May 2014 through January 2015. Mr. Delgado has served as a Director of Global Digital Solutions, Inc. (“GDSI”), a publicly traded company that provides cyber arms technology and complementary security and technology solutions, since 2005 and as its Chief Executive Officer and Chairman of the Board since May 2016. He also previously served as GDSI’s President and Chief Executive Officer and Chief Financial Officer from August 2004 to August 2013 and as its Executive Vice President in charge of business development from August 2013 to May 2016. He has also served as the President, Chief Executive Officer, and Chief Financial Officer of Eco-Growth Strategies, Inc., a nutraceutical company developing a range of CBD-based products, since May 2007.

Mr. Delgado began his career with Pacific Telephone in the Outside Plant Construction. He later transferred to their network engineering group and concluded his career at Pacific Bell as the Chief Budget Analyst for the Northern California region. Prior to that, in 1991 Mr. Delgado founded and served as President of All Star Telecom, specializing in Open Settlement Protocol construction and engineering and systems cabling. All Star Telecom was sold to International FiberCom, which provided a wide variety of services and equipment to the telecommunications, cable television and other related industries, in 1999 and Mr. Delgado served as Executive Vice President of International FiberCom until 2002. Thereafter, Mr. Delgado served as President and Chief Executive Officer of Pacific Comtel in San Diego, California, a provider of structured cabling design, installation, and maintenance for companies, governments, and educational institutions, that was acquired by GDSI in 2004. Mr. Delgado holds a BS with honors in Applied Economics from the University of San Francisco and Graduate studies in Telecommunications Management at Southern Methodist University.

Our Board of Directors believes that Mr. Delgado is qualified to serve on our board because of his business experience, including his experience in management and as a director of public companies including GDSI and International FiberCom, as described above.

Thomas Untermeyer – Chief Operating Officer, Chief Technology Officer and Director

Mr. Untermeyer co-founded NSH and invented the initial technology behind its computer-controlled shrimp-raising system acquired by the Company in 2015 and that forms the core of its business. He has served as a director of the Company since September 2020, as its Chief Operating Officer since September 2019, its Chief Technology Officer since January 2015, and as its Secretary from September 2020 through February 2021. Prior to the Company’s acquisition of NSH in 2015 he had been an engineering consultant to NSH since 2001. From 1981 to 2017 Mr. Untermeyer served as a Senior Program Manager with Southwest Research Institute, an independent and nonprofit applied research and development organization in San Antonio, Texas. His business experience includes systems engineering, program development, and technical management. Mr. Untermeyer has spent his entire career in the process of defining, designing, and developing electronic products and systems for both commercial and government clients. This has included small design programs to large multi-million dollar programs involving large multidisciplinary teams composed of software, electrical, and mechanical engineers. Mr. Untermeyer holds a Bachelor of Science in Electrical Engineering from St. Mary’s University.

Our Board of Directors believes that Mr. Untermeyer is qualified to serve on the board because of his technical expertise and historical knowledge of our business.

William Steven Walker – General Counsel and Secretary

Mr. Walker was licensed in the State of Texas in November 1976 and has been engaged in the private practice of law since March 1983. Since 1983, Mr. Walker has been a solo practitioner specializing in corporate law, oil and gas transactions and litigation. Mr. Walker has served as the Company’s General Counsel since July 2022 and Secretary since February 2021. He served as the original General Counsel of NSH from 2001 to 2015 and on its board of directors from 2001 to 2015. Mr. Walker brings a wide range of experience to the Company and also has historical knowledge of the Company’s history. Mr. Walker is a graduate of the University of Texas and received his law degree from Saint Mary University School of Law.

Family Relationships

~~There~~Not ~~are no family relationships between or among any of our directors and executive officers.~~applicable

Involvement in Certain Legal Proceedings

NoNot ~~director, executive officer, significant employee or control person of the Company has been involved in any legal proceeding listed in Item 401(f) of Regulation S-K in the past 10 years.~~applicable

Meetings of the Board; Committees

We do not currently have a standing audit, nominating or compensation committee of the Board of Directors, or any committee performing similar functions. Our ~~Board~~sole ofdirector ~~Directors~~ performs the functions of audit, nominating and compensation committees.

Audit Committee

Our Board of Directors has not established a separate audit committee within the meaning of Section 3(a)(58)(A) of the Exchange Act. Instead, ~~the~~our ~~entire~~sole ~~Board~~director ~~of Directors~~ acts as the audit committee within the meaning of Section 3(a)(58)(B) of the Exchange Act and will continue to do so until such time as a separate audit committee has been established.

Audit Committee Financial Expert

We currently have not designated anyone as an “audit committee financial expert,” as defined in Item 407(d)(5) of Regulation S-K, as we have not yet created an audit committee of the Board of Directors.

Nominations to the Board of Directors

~~Our~~The ~~directors~~Company ~~play~~currently aonly ~~critical~~has ~~role~~a insingle ~~guiding~~director ~~our strategic direction~~ and ~~oversee~~may evaluate the ~~management~~addition of ~~the~~qualified ~~Company.~~directors ~~Board candidates are considered based upon various criteria, such~~ as ~~their~~its ~~broad-based~~transition ~~business and professional skills and experiences~~plan, afinancing ~~global business and social perspective~~needs, ~~concern for the long-term interests of the stockholders, diversity,~~ and ~~personal~~operating ~~integrity~~activities ~~and judgment~~develop.

In addition, directors must have time available to devote to Board activities and to enhance their knowledge in the growing business. Accordingly, we seek to attract and retain highly qualified directors who have sufficient time to attend to their substantial duties and responsibilities to the Company.

In carrying out its responsibilities, the Board will consider candidates suggested by stockholders. If a stockholder wishes to formally place a candidate’s name in nomination, however, he or she must do so in accordance with the provisions of the Company’s Bylaws. Suggestions for candidates to be evaluated by the proposed directors must be sent to the Board of Directors, c/o NaturalShrimp Incorporated, 13601 Preston Road, Suite E1092, Dallas, Texas 75240.

Director Nominations

As of March 31, ~~2025~~2026, we did not effect any material changes to the procedures by which our shareholders may recommend nominees to our Board of Directors.

Board Leadership Structure and Role on Risk Oversight

~~Gerald~~David ~~Easterling~~Antelo currently serves as our ~~Principal~~Chief Executive Officer, ~~and~~Chief ~~President~~Financial Officer and ~~CEO~~sole director. We have determined that our leadership ~~structure~~ structure was appropriate for the Company due to our small size and limited operations and resources. ~~The~~Mr. ~~Board~~Antelo ~~of Directors~~ will continue to evaluate the Company’s leadership structure and modify as appropriate based on the size, resources and operations of the Company. It is anticipated that the Board of Directors will establish procedures to determine an appropriate role for the Board of Directors in our risk oversight function.

1910

Compensation Committee Interlocks and Insider Participation

No interlocking relationship exists between our board of directors and the board of directors or compensation committee of any other company, nor has any interlocking relationship existed in the past.

Code of Ethics

We have adopted a written code of ethics that applies to our chief executive officer and chief financial officer. A copy of such code of ethics is available upon written request to the Company.

ITEM 11. EXECUTIVE COMPENSATION

General Philosophy

Our Board of Directors is responsible for establishing and administering the Company’s executive and director compensation.

The following summary compensation table indicates the cash and non-cash compensation earned from the Company during the fiscal years ended March 31, ~~2025~~2026 and March 31, ~~2024~~2025 by our current principal executive officer and each of the other two highest paid executives whose total compensation exceeded $100,000 during those years.

Summary Compensation Table

Name and Principal Position	Year	Salary		Bonus		Stock Awards		All Other ~~Compen- sation~~Compensation		Total
Gerald Easterling,	~~2025~~2026	$	~~180,000~~-	$	-	$	-	$	~~14,385~~-	$	~~194,385~~-
Chairman of the Board, President and CEO (1)	~~2024~~2025	$	180,000		-		-	$	14,385	$	194,385
William Delgado,	~~2025~~2026	$	~~160,000~~-	$	-	$	-	$	~~9,132~~-	$	~~169,132~~-
CFO (2)	~~2024~~2025	$	160,000	$	-	$	-	$	9,132	$	169,132
Tom Untermeyer,	~~2025~~2026	$	~~160,000~~-	$	-	$	-	$	~~8,910~~-	$	~~168,910~~-
COO, CTO (3)	~~2024~~2025	$	160,000	$	-	$		$	8,910	$	168,910
David Antelo,	2026	$	-	$	-	$	-	$	-	$	-
CEO, CFO and Director(4)

(1) Mr. Easterling is entitled to receive medical insurance reimbursement, of which $0 was paid during the fiscal years ended March 31, 2025 and March 31, 2024, respectively, and $16,770 was accrued at March 31, 2025. Mr. Easterling is also entitled to an automobile allowance of $500 per month, of which $0 was paid during the fiscal year ended March 31, 2025 and 2024 and $14,000 was accrued for as of March 31, 2025. As of March 31, 2025, Mr. Easterling was owed $412,500 for accrued and unpaid wages. The accrued amount represents his entire salary for fiscal years 2025 and 2024.

⁽¹⁾	Mr. Easterling resigned from his roles as Chief Executive Officer and Director effective March 17, 2026. The Company still owes Mr. Easterling accrued compensation the amount of which is currently under discussion with the former employee.

⁽²⁾	Mr. Delgado resigned from his role as Chief Financial Officer effective March 17, 2026. The Company still owed Mr. Delgado accrued compensation the amount of which is currently under discussion with the former employee.

⁽³⁾	Mr. Untermeyer resigned from his roles as Chief Operating Officer and Chief Technology Officer effective March 17, 2026. The Company still owed Mr. Delgado accrued compensation the amount of which is currently under discussion with the former employee.

⁽⁴⁾	Mr. Antelo joined the Company on March 17 2026 and did not receive any compensation for his services provided during the fiscal year ended March 31, 2026.

2011

(2)

As of March 31, 2025, Mr. Delgado was owed $266,667 for accrued and unpaid wages. The accrued amount represents his entire salary for fiscal years 2025 and 2024. Mr. Delagado is also eligible to receive healthcare reimbursement, of which $0 was paid during our fiscal year ended March 31, 2025.

(3)

As of March 31, 2025 and March 31, 2024, Mr. Untermeyer was owed $430,667 for accrued and unpaid salary. The accrued amount represents his entire salary for fiscal years 2025 and 2024. Mr. Untermeyer is entitled to receive medical insurance reimbursement, of which $0 was paid during the fiscal years ending March 31, 2025 and 2024. Mr. Untermeyer is also entitled to an automobile allowance of $500 per month, of which $0 was paid during the fiscal years 2025 and 2024 and $14,000 was accrued and unpaid.

Employment Agreements

Gerald Easterling

As of April 1, 2015, the Company entered into an employment agreement with Gerald Easterling as the Company’s President, as amended pursuant to an amendment thereto dated as of May 21, 2021. The agreement as amended provides for an annual base salary of $180,000 and that Mr. Easterling may also receive one or more bonuses at such times and in such amounts as determined in the sole discretion of the Company’s Board of Directors. Mr. Easterling is also entitled to certain benefits including health insurance, reimbursement of cell phone costs, and a monthly $500 car allowance. As noted in the table above, Mr. Easterling resigned from the Company effective March 17, 2026.

Mr. Easterling’s employment agreement terminates automatically upon his death. In addition, the Company may terminate the agreement because of Mr. Easterling’s Total Disability or for certain events constituting Cause, in each case as defined in the agreement, or without Cause. Mr. Easterling may terminate his employment agreement for certain events constituting Good Reason, as defined in the agreement, or without Good Reason.

The agreement provides that in the event that Mr. Easterling is terminated without Cause or resigns for Good Reason, he will receive, as severance, his base salary for a period of 60 months following the date of termination. In the event of a Change of Control (as defined in the agreement) of the Company, Mr. Easterling may elect to terminate the agreement within 30 days thereafter and upon such termination would be entitled to receive a lump sum payment equal to 500% of his annual base salary.

The agreement contains certain restrictive covenants relating to non-competition, non-solicitation of customers and non-solicitation of employees for a period of one year following termination of the agreement, as well as confidentiality provisions.

Tom Untermeyer

As of November 1, 2017, the Company entered into an employment agreement with Tom Untermeyer as its Chief Technology Officer, as amended pursuant to an amendment thereto dated as of May 21, 2021. The agreement as amended provides for an annual base salary of $160,000 and that Mr. Untermeyer may also receive one or more bonuses at such times and in such amounts as determined in the sole discretion of the Company’s Board of Directors. As noted in the table above, Mr. Untermyer resigned from the Company effective March 17, 2026.

Mr. Untermeyer’s employment agreement terminates automatically upon his death. In addition, NaturalShrimp may terminate the agreement because of Mr. Untermeyer’s Total Disability or for certain events constituting Cause, in each case as defined in the agreement, or without Cause. Mr. Untermeyer may terminate his employment agreement for certain events constituting Good Reason, as defined in the agreement, or without Good Reason.

The agreement provides that in the event that Mr. Untermeyer is terminated without Cause he will receive, as severance, his base salary for a period of six months following the date of termination. The agreement also provides, however, that in the event of a Change of Control (as defined in the agreement) of the Company, Mr. Untermeyer may elect to terminate the agreement within 30 days thereafter and upon such termination would be entitled to receive a lump sum payment equal to 50% of his annual base salary.

The agreement contains certain restrictive covenants relating to non-competition, non-solicitation of customers and non-solicitation of employees for a period of two years following termination of the agreement, as well as confidentiality provisions.

William Delgado

As of May 1, 2021, the Company entered into an employment agreement with William Delgado as its Chief Financial Officer. The agreement provides for an annual base salary of $160,000 and that Mr. Delgado may also receive one or more bonuses at such times and in such amounts as determined in the sole discretion of our Board of Directors. As noted in the table above, Mr. Delgado resigned from the Company effective March 17, 2026.

~~Mr.~~David Delgado’s employment agreement terminates automatically upon his death. In addition, the Company may terminate the agreement because of Mr. Delgado’s Total Disability or for certain events constituting Cause, in each case as defined in the agreement, or without Cause. Mr. Delgado may terminate his employment agreement for certain events constituting Good Reason, as defined in the agreement, or without Good Reason.Antelo

~~The~~As ~~agreement~~of ~~provides~~May ~~that~~20, in2026, the ~~event~~Company ~~that~~entered ~~Mr.~~into ~~Delgado~~a isconsulting ~~terminated~~agreement ~~without~~with ~~Cause~~Mr. orAntelo ~~resigns~~to ~~for~~provide ~~Good~~services ~~Reason~~as heits ~~will~~Chief ~~receive,~~Executive ~~as severance~~Officer, ~~his~~Chief ~~base~~Financial ~~salary~~Officer ~~for~~and asole ~~period of 60 months following the date of termination~~director. InThe ~~the~~agreement ~~event~~provides offor a ~~Change~~bi-weekly ofconsulting ~~Control~~fee ~~(as defined in the agreement)~~ of ~~the Company~~$5,000 ~~Mr. Delgado may elect to terminate the agreement within 30 days thereafter~~ and ~~upon~~does ~~such~~not ~~termination~~currently ~~would be entitled~~include toany ~~receive~~additional aemployee ~~lump sum payment equal to 50% of his annual base salary~~benefits.

Potential Payments Upon Termination or Change-in-Control

SEC regulations state that we must disclose information regarding agreements, plans or arrangements that provide for payments or benefits to our executive officers in connection with any termination of employment or change in control of the Company. ~~Such payments are set forth above in the section entitled “Employment Agreements.”~~

Except as described above, none of our executive officers or directors received, nor do we have any arrangements to pay out, any bonus, stock awards, option awards, non-equity incentive plan compensation, or non-qualified deferred compensation.

Compensation of Directors

We do not compensate our directors for their service on the Board of Directors. However, we intend to review and consider future proposals regarding board compensation. All travel and lodging expenses associated with corporate matters are reimbursed by us, if and when incurred.

Stock Option Plans - Outstanding Equity Awards at Fiscal Year End

None of NaturalShrimp’s executive officers held any unexercised options to purchase stock of NaturalShrimp, unvested shares of NaturalShrimp common or preferred stock, or outstanding equity incentive plan awards at March 31, ~~2025~~2026.

Compensation Committee

The Company does not have a separate Compensation Committee. Instead, the Company’s Board of Directors reviews and approves executive compensation policies and practices, reviews salaries and bonuses for other officers, administers the Company’s stock option plans and other benefit plans, if any, and considers other matters.

Risk Management Considerations

We believe that our compensation policies and practices for our employees, including our executive officers, do not create risks that are reasonably likely to have a material adverse effect on the Company.

2212

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The following tables set forth certain information regarding our shares of common stock and our voting shares beneficially owned as of ~~November 2~~July 5, ~~2025~~2026 and is based on ~~(i)~~ 1,277,546,746 shares of common stock issued and outstanding, (ii) 5,000,000 shares of Series A Preferred Stock issued and outstanding all owned by Gerald Easterling (which equals 300 million votes and is convertible into the number of shares of common stock equal to the difference between our authorized and issued shares of common stock (122,453,254 shares), and (iii) 750,000 shares of Series F Preferred Stock issued and outstanding (which equals 750 million votes and is not currently convertible into shares of common stock) for ~~(A)~~ each stockholder known to be the beneficial owner of 5% or more of our outstanding shares of common stock and voting shares, ~~(B)~~and each named executive officer and director~~, and (C) all executive officers and directors as a group~~. A person is ~~considered~~ considered to beneficially own any shares (1) over which such person, directly or indirectly, exercises sole or shared voting or investment power, or (2) of which such person has the right to acquire beneficial ownership at any time within 60 days through an exercise of stock ~~options~~ options or warrants. Unless otherwise indicated, voting and investment power relating to the shares shown in the tables for our directors ~~and~~ and executive officers is exercised solely by the beneficial owner or shared by the owner and the owner’s spouse or children.

For purposes of these tables, a person or group of persons is deemed to have “beneficial ownership” of any shares of common stock that such person has the right to acquire within 60 days of ~~October~~July 85, ~~2025~~2026. For purposes of computing the percentage of outstanding ~~shares~~ shares of our common stock held by each person or group of persons, any shares that such person or persons has the right to acquire within 60 60 days of ~~October~~July 85, ~~2025~~2026 is deemed to be outstanding but is not deemed to be outstanding for the purpose of computing the percentage ~~ownership~~ ownership of any other person. The inclusion herein of any shares listed as beneficially owned does not constitute an admission of beneficial ownership. Except as otherwise indicated, the address of each of the shareholders listed below is: ~~P.O.~~1200 ~~Box~~N ~~1256~~Federal Highway, ~~Dallas~~Suite 200, ~~Texas~~Boca ~~75225~~Raton, FL, 33432.

Beneficial Owner	Common Stock Shares Beneficially Owned			% of Common Stock Shares Beneficially Owned			Voting Shares Beneficially Owned			% of Voting Shares Beneficially Owned (7)
Gerald Easterling		125,910,161	(1)		8.7	% (3)		553,456,907	(4)		23.73	%
William Delgado		5,715,719	(2)		*			255,715,719	(5)		10.96	%
Tom Untermeyer		5,140,666	(2)		*			255,140,666	(6)		10.94	%
Directors and Executive Officers as a Group (three persons)
Total		136,766,546			8.7	%		1,064,313,292			45.63	%

Security Ownership of Certain Beneficial Owners

*There ~~Less~~were no beneficial owners who owned more than 15% of our outstanding shares of common stock and voting shares.

(1)	Consists of (a) 3,456,907 shares of common stock and (b) 122,453,254 shares of common stock into which the 5 million shares of Series A Preferred Stock is convertible.
(2)	Consists solely of shares of common stock owned. Of the 5,715,719 shares owned, all but 500,000 are held by Dragon Acquisitions LLC, of which Mr. Delgado is the managing member.
(3)	Solely with regard to Mr. Easterling, the percentage is based on the 1,277,546,746 shares of common stock outstanding plus the 122,453,254 shares of common stock into which the 5 million shares of Series A Preferred Stock is convertible.
(4)	Consists of (a) 3,456,907 shares of common stock, (b) 300 million votes to which the 5 million shares of Series A Preferred Stock held by Mr. Easterling is entitled (60 votes per share), and (c) 250 million votes to which the 250,000 shares of Series F Preferred Stock held by Mr. Easterling is entitled (1,000 votes per share).
(5)	Consists of (a) 5,715,719 shares of common stock and (b) 250 million votes to which the 250,000 shares of Series F Preferred Stock held by Mr. Delgado is entitled (1,000 votes per share).
(6)	Consists of (a) 5,140,666 shares of common stock and (b) 250 million votes to which the 250,000 shares of Series F Preferred Stock held by Mr. Untermeyer is entitled (1,000 votes per share).
(7)	Each percentage in this column is based on (a) 1,277,546,746 shares of common stock outstanding, (b) 300 million votes to which the 5 million shares of Series A Preferred Stock outstanding is entitled (60 votes per share), (c) 5,143,000 votes to which the 1,571 shares of Series E Preferred Stock outstanding is entitled, and (c) 750 million votes to which the 750,000 shares of Series F Preferred Stock outstanding is entitled (1,000 votes per share).

Securities Ownership of Management

~~Securities~~As ~~Authorized~~of ~~for~~the ~~Issuance~~most ~~Under~~recent ~~Equity~~practicable ~~Compensation~~date, ~~Plans~~Mr. David Antelo was the sole executive officer and director of the Company. Mr. Antelo did not beneficially own any shares as of the date of this report, before giving effect to the proposed preferred share issuances described elsewhere herein.

~~None.~~Change in Control

~~Non~~On March 17, 2026, a change in control of the Company occurred as a result of the execution of the agreement outlined in our Form 8-~~Cumulative~~K filed ~~Voting~~with the Securities and Exchange Commission on March 30, 2026. The change in control was as a result of i) the execution of the agreement ii) the governance provisions contained therein granting contractual control over board composition and executive authority, and (iii) the appointment of David Antelo as Chief Executive Officer, Chief Financial Officer and sole director of the Company; however, the related preferred share issuances and legacy security restructurings was not consummated until June 25, 2026.

The holders of our shares of common stock do not have cumulative voting rights, which means that the holders of more than 50% of such outstanding shares, voting for the election of Directors, can elect all of the Directors to be elected, if they so choose. In such event, the holders of the remaining shares will not be able to elect any of our Directors.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

Transactions with Related Persons

During the year ended March 31, 2025, the Company received $40,000 in proceeds from the issuance of a promissory note with a ~~family members of~~ related ~~parties~~party. The notes bear interest at 10% and ~~have~~is ~~maturity~~currently ~~dates~~in ~~one year from the issuance date~~default.

~~During~~In ~~the year ended~~ March 312026, ~~2024,~~ the Company ~~received~~entered ~~$140,000~~into inthe ~~proceeds~~Intellectual ~~from~~Property ~~the~~and ~~issuance~~Management ofTransition ~~three~~Agreement ~~promissory~~with ~~notes~~Hydrenesis, ~~with~~Inc. ~~family~~and ~~members~~David Antelo, ofa related ~~parties.~~party, ~~The~~which ~~notes~~includes ~~bear~~a ~~interest~~proposed atperpetual ~~10%~~license and ~~have maturity dates one year from~~ the ~~issuance~~proposed ~~date.~~conversion ~~The promissory notes were in default as~~ of ~~the~~approximately ~~date~~$1,034,112 ofowed ~~the~~to ~~filing~~Hydrenesis into equity.

NaturalShrimp Holdings, Inc.

As discussed under “Item 1. Business,” on January 30, 2015, the Company acquired substantially all of the assets of NSH, which consisted primarily of all of the issued and outstanding shares of capital stock of its subsidiaries NSC and NS Global and certain real property located outside of San Antonio, Texas, in exchange for its issuance of 75,520,240 shares of NaturalShrimp Common Stock to NSC. As a result of the transaction, NSH acquired 88.62% of the issued and outstanding shares of the Company’s common stock, NSC and NS Global became wholly-owned subsidiaries of the Company, and the Company changed its principal business to a global shrimp farming company. It changed its name to “NaturalShrimp Incorporated” in 2015.

There were no material relationships between the Company and NSH or between the Company’s or NSH’s respective affiliates, directors, or officers or associates thereof, other than in respect of the asset acquisition and the related asset purchase agreement.

On January 1, 2016 the Company entered into a notes payable agreement with NaturalShrimp Holdings, Inc.(“NSH”), a shareholder. The note payable has no set monthly payment or maturity date with a stated interest rate of 2%. During the year ended March 31, 2022, the Company paid off $655,750 of the note payable. The outstanding balance was approximately $79,000 and $77,000 as of March 31, 2025 and March 31, 2024, respectively. As March 31, 2025 and March 31, 2024, accrued interest payable was approximately $93,000 and $74,000, respectively.

Director Independence

Our board of directors consists of Gerald Easterling, William Delgado and Tom Untermeyer. We evaluate independence by the standards for director independence established by applicable laws, rules, and listing standards including, without limitation, the standards for independent directors established by NYSE, Nasdaq, and the SEC.

Subject to some exceptions, these standards generally provide that a director will not be independent if: (i) the director is, or in the past three years has been, an employee of ours; (ii) a member of the director’s immediate family is, or in the past three years has been, an executive officer of ours; (iii) the director or a member of the director’s immediate family has received more than $120,000 per year in direct compensation from us other than for service as a director (or for a family member, as a non-executive employee); (iv) the director or a member of the director’s immediate family is, or in the past three years has been, employed in a professional capacity by our independent public accountants, or has worked for such firm in any capacity on our audit; (v) the director or a member of the director’s immediate family is, or in the past three years has been, employed as an executive officer of a company where one of our executive officers serves on the compensation committee; or (vi) the director or a member of the director’s immediate family is an executive officer of a company that makes payments to, or receives payments from, us in an amount which, in any twelve-month period during the past three years, exceeds the greater of $1,000,000 or two percent of that other company’s consolidated gross revenues. Based on these standards, we have determined that Messrs. Easterling, Untermeyer and Delgado are not independent directors.

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

Audit and Accounting Fees

The following tables set forth the fees billed to us for professional services ~~rendered by Turner, Stone & Company~~ for the years ended March 3031, ~~2025~~2026 and March 31, ~~2024~~2025:

Services	~~2025~~2026		~~2024~~2025
Audit fees	$	6651,000	$	8566,600
Audit related fees		-		~~12,600~~-
Tax fees		-		-
All other fees		-		~~31,935~~-
Total fees	$	6651,000	$	~~130~~66,~~135~~000

Audit Fees

The audit fees were paid for the audit services of our annual and quarterly reports and issuing consents for our registration statements.

Audit Related Fees

~~The audit related fees were paid for the services of issuing consents for our registration statements filed during 2024.~~n/a

Tax Fees

~~The taxes fees were paid for tax services provided during the years ended March 30, 2025 and March 31, 2024.~~n/a

All Other Fees

~~All other fees were for services provided related to the merger with Yotta Acquisition Corp during 2024.~~n/a

Pre-Approval Policies and Procedures

Our board of directors preapproves all services provided by our independent registered public accounting firm. All of the above services and fees were reviewed and approved by the board of directors before the respective services were rendered.

2513

PART IV

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

EXHIBIT INDEX

Exhibit		Incorporated by Reference
Number	Exhibit Description	Form	Exhibit	Filing Date
3.1	Articles of Incorporation of NaturalShrimp Incorporated, as amended	10-K	3.1	6/29/2022
3.2	Bylaws of NaturalShrimp Incorporated	S-1	3.2	6/11/2009
3.3	Certificate of Designation of Series A Preferred Stock	8-K	3.1	8/22/2018
3.4	Certificate of Designation of Series B Preferred Stock	10-Q	3.1	11/14/2019
3.5	Certificate of Designation of Series D Preferred Stock	8-K	3.1	12/22/2020
3.6	Certificate of Designation of Series E Preferred Stock	8-K	3.1	4/15/2021
3.7	Certificate of Designation of Series F Preferred Stock	8-K	3.1	3/1/2022
3.8	Certificate of Designation of Series G Preferred Stock	10-K	3.8	7/17/2024
4.1	Specimen Common Stock Certificate	S-1	4.1	6/11/2009
4.2	Description of Securities	10-K	4.2	6/29/2022
21.1*	Subsidiaries of the Registrant.	10-K	21.1	6/27/2023
10.1*	Amended Intellectual Property Transfer and Management Transition Agreement
31.1*	Rule 13a-14(a) / 15d-14(a) Certification of Chief Executive Officer. and Chief Financial Officer
31.2*	Rule 13a-14(a) / 15d-14(a) Certification of Chief Financial Officer.
32.1**	Section 1350 Certification of Chief Executive Officer and Chief Financial Officer
32.1**	Section 1350 Certification of Chief Executive Officer.
32.2**	Section 1350 Certification of Chief Financial Officer.
101.INS*	Inline XBRL Instance Document
101.SCH*	Inline XBRL Taxonomy Extension Schema Document
101.CAL*	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (embedded within the Inline XBRL document

* Filed herewith.

** Furnished herewith.

+ Management compensatory plan or contract.

# Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company will furnish supplementally copies of omitted schedules and exhibits to the Securities and Exchange Commission or its staff upon its request.

ITEM 16. FORM 10-K SUMMARY

Not applicable.

2614

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NATURALSHRIMP INCORPORATED

By:	/s/ ~~Gerald~~David ~~Easterling~~Antelo
Gerald Easterling
David Antelo
Chief Executive Officer (Principal Executive Officer)
Chief Executive Officer and Chief Financial Officer
Date:	~~November~~July 522, ~~2025~~2026

By:	/s/ William Delgado
William Delgado
Chief Financial Officer and Treasurer (Principal Financial Officer and Principal Accounting Officer)
Date:	November 5, 2025

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signatures	Title(s)	Date
/s/ Gerald Easterling	Chief Executive Officer and Chairman of the Board	Date: November 5, 2025
/s/ David Antelo	Chief Executive Officer and Interim Chief Financial Officer	Date: July 22, 2026
Gerald Easterling	of Directors (Principal Executive Officer)
David Antelo
/s/ William Delgado	Chief Financial Officer, Treasurer and Director	Date: November 5, 2025
William Delgado	(Principal Financial Officer and Principal Accounting Officer)
/s/ Tom Untermeyer	Chief Operating Officer, Chief Technology Officer and Director	Date: November 5, 2025
Tom Untermeyer

2715

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

NATURALSHRIMP INCORPORATED

~~CONSOLIDATED~~ FINANCIAL STATEMENTS AS OF MARCH 31, ~~2025,~~2026 ~~MARCH 30, 2025~~ AND MARCH 31, ~~2024~~2025

TABLE OF CONTENTS

	Page
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB FIRM ID 76)	F-1
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB FIRM ID 7158)	F-1
CONSOLIDATED FINANCIAL STATEMENTS:
FINANCIAL STATEMENTS:
Consolidated Statement of Net Liabilities in Liquidation	F-2
Statement of Net Liabilities in Liquidation	F-2
Consolidated Balance Sheet	F-3
Statement of Changes of Net Liabilities in Liquidation	F-3
Consolidated Statement of Operations	F-4
Going Concern Statement of Operations	F-4
Consolidated Statement of Changes in Stockholders’ Deficit	F-5
Going Concern Statement of Changes in Stockholders’ Deficit	F-5
Consolidated Statement of Cash Flows	F-6
Going Concern Statement of Cash Flows	F-6
Notes to Consolidated Financial Statements	F-7
Notes to Liquidation Basis Financial Statements	F-7

2816

Report of Independent Registered Public Accounting Firm

To the Board of Directors

and Stockholders of NaturalShrimp Incorporated

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated ~~balance~~statements of ~~sheets~~net liabilities in liquidation of NaturalShrimp Incorporated. and subsidiary (collectively, the “Company”) as of March 31, 2026 and 2025, the related consolidated ~~statements~~statement of ~~operations,~~changes ~~stockholders’~~in ~~equity~~net ~~(deficit),~~liabilities ~~and~~in ~~cash~~liquidation ~~flows~~ for the year ~~then~~ ended March 31, ~~and~~2026, and the related notes (collectively referred to as the “liquidation basis financial statements”). InWe ~~our~~have ~~opinion,~~also audited the ~~financial~~accompanying ~~statements~~consolidated ~~present~~statement ~~fairly~~of operations, consolidated statement of changes in ~~all~~stockholders’ ~~material~~equity ~~respects~~(deficit), ~~the~~and consolidated ~~financial~~statement of ~~position~~cash flows of the Company asfor ofthe year ended March 3130, 2025, ~~and~~prepared on the ~~results~~ ofgoing ~~its~~concern ~~operations~~basis of accounting, and ~~its~~the ~~cash~~related ~~flows~~notes (collectively ~~for~~referred to as the ~~year~~“going ~~then~~concern ~~ended~~basis financial statements”, inand ~~conformity~~together with ~~accounting~~the ~~principles~~liquidation ~~generally~~basis ~~accepted in~~financial statements, the ~~United~~“financial ~~States~~statements”).

~~Going~~In our opinion, (i) the liquidation basis financial ~~Concern~~statements present fairly, in all material respects, the net liabilities in liquidation of the Company as of March 31, 2026 and ~~Liquidation~~2025, and ~~Basis~~the changes in its net liabilities in liquidation for the year ended March 31, 2026, on the basis of ~~Accounting~~accounting described in Note 3 to the financial statements; and (ii) the going concern basis financial statements present fairly, in all material respects, the results of the Company’s operations and its cash flows for the year ended March 30, 2025, in conformity with accounting principles generally accepted in the United States of America.

~~The accompanying~~Basis ~~consolidated financial statements as~~ of ~~March~~Presentation ~~30,~~– 2025 have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”), assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As such, the Company has presented going concern financial statements as of March 30, 2025 and for the period from April 1, 2024 through March 30, 2025. Furthermore, in accordance with ASC 205-30, Liquidation Basis ~~of Accounting, the~~ ~~Company has presented its financial statements (using a convenience date) as~~ of ~~March 31, 2025 under the liquidation basis of accounting.~~Accounting

As discussed in Note 3 to the financial statements, the Company believes it continued to function as a going concern until March 30, 2025, the date on which the court approved the receiver’s motion to sell substantially all of the Company’s assets, at which point liquidation became imminent. Accordingly, in accordance with ASC 205-30, Liquidation Basis of Accounting, the Company has presented its financial statements as of March 31, 2026 and 2025, and for the year ended March 31, 2026, under the liquidation basis of accounting. Because the going concern basis results of operations for the year ended March 31, 2025 are not comparable to amounts presented under the liquidation basis of accounting, and to comply with the financial statement requirements of Article 8 of Regulation S-X, the Company has separately presented its consolidated statement of operations, consolidated statement of changes in stockholders’ equity (deficit), and consolidated statement of cash flows for the year ended March 31, 2025 on the going concern basis of accounting. These going concern basis financial statements should not be read together with, or considered comparable to, the liquidation basis financial statements.

Basis for Opinion

These ~~consolidated~~ financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s ~~consolidated~~ financial statements based on our ~~audit~~ audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our ~~audit~~audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the ~~audit~~audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our ~~audit~~audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our ~~audit~~ audits included performing procedures to assess the risks of material misstatement of the ~~consolidated~~ financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the ~~consolidated~~ financial statements. Our ~~audit~~audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the ~~consolidated~~ financial statements. We believe that our ~~audit~~audits ~~provides~~provide a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matter communicated below is a matter arising from the current period audit of the ~~consolidated~~ financial statements that ~~were~~ was communicated or required to be communicated to the audit committee and that: (1) ~~relate~~relates to accounts or disclosures that are material to the ~~consolidated~~ financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit ~~matters~~matter does not alter in any way our opinion on the ~~consolidated~~ financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate ~~opinions~~ opinion on the critical audit matter or on the accounts or disclosures to which it relates.

~~● Going Concern –~~ As discussed in ~~Note~~Notes 3 to the ~~consolidated~~ financial statements, in ~~due~~March to2026 the Company’s ~~significant~~entered ~~amount~~into ofan ~~debt~~Intellectual ~~that~~Property ~~was~~and inManagement ~~default~~Transition asAgreement ofwith ~~September 30~~Hydrenesis, ~~2024,~~Inc. ~~Ampleo Turnaround~~ and ~~Restructuring,~~a ~~LLC (“the receiver”) was placed as the receiver over the Company’s assets. Further~~related party, ~~the~~which ~~receiver~~includes ~~filed~~ a ~~motion~~proposed toperpetual ~~sell~~license ~~substantially~~and ~~all of~~ the ~~Company’s~~proposed ~~assets~~conversion ~~to Streeterville and Bucktown Capital for an approximate credit bid~~ of ~~$35.7~~approximately ~~million and~~ $~~100~~1,~~000 in cash. The motion to sell the assets was approved by the court on March 30~~034,112 ~~2025~~owed ~~and title~~ to ~~the~~Hydrenesis ~~assets~~into ~~was transferred to Streeterville on May 14, 2025~~equity. As ~~The~~of ~~Company believes that it continued to function as a going concern until~~ the date ~~that the motion to sell its assets was approved by the court on March 30, 2025 at which point liquidation became imminent. As such, the Company has presented going concern financial statements as~~ of ~~March~~this 30report, ~~2025 and for~~ the ~~period~~related ~~from~~license ~~April 1~~rights, ~~2024~~preferred ~~through~~share ~~March 30~~issuances, ~~2025.~~creditor ~~Furthermore~~restructuring, inand ~~accordance~~other ~~with~~closing ~~ASC~~matters contemplated ~~205-30,~~by ~~Liquidation~~this ~~Basis~~agreement ofhad ~~Accounting,~~not ~~the~~yet ~~Company~~been ~~has~~fully ~~presented~~consummated. ~~its~~As ~~financial statements (using~~ a ~~convenience~~result, ~~date)~~significant asuncertainty ofexists ~~March~~regarding ~~31, 2025 under~~ the ~~liquidation~~manner ~~basis~~and amount ofby ~~accounting.~~which ~~As such,~~ the ~~financial~~Company ~~statements~~will ~~included~~ultimately insettle ~~the~~its ~~filing~~approximately ~~also~~$8.9 ~~include~~million ~~a Statement~~ of ~~Net~~remaining ~~Liabilities~~net liabilities in liquidation as of March 31, ~~2025. As there was only a one-day period between the time liquidation became imminent and the end of the reporting period~~2026, ~~a Statement~~ of ~~Changes~~which inapproximately ~~Net~~$3.0 ~~Assets~~million ~~(liabilities)~~is inowed ~~liquidation~~to ~~has~~related ~~not been presented~~parties.

/s/ BCRG Group (PCAOB ID 7158)

We have served as the Company’s auditor since 2025.

Irvine, CA

~~November~~July 420, ~~2025~~ 2026

F-1

NATURALSHRIMP INCORPORATED ~~AND SUBSIDIARIES~~

~~CONSOLIDATED~~ STATEMENT OF NET LIABILITIES IN LIQUIDATION

	As of
	As of March 31,
	March 31, 2025
	2026			2025
Cash	$	~~101~~9,~~969~~851		$	101,969
Current assets		~~193,865~~-			193,865
Fixed assets and intangibles		~~35,800,000~~-			35,800,000
Other assets		~~86,330~~-			86,330
Accounts payable and accrued expenses		(6,~~809~~888,~~772~~615	)		(6,809,772	)
Notes payable and lines of credit		(371,~~200~~179,~~851~~832	)		(37,200,851	)
Othe liabilities		(962,553	)
Other liabilities		(933,993	)		(962,553	)
Net liabilities in liquidation	$	(8,~~791~~992,~~012~~589	)	$	(8,791,012	)

The accompanying notes are an integral part of these consolidated financial statements.

F-2

NATURALSHRIMP INCORPORATED ~~AND SUBSIDIARIES~~

~~CONSOLIDATED~~STATEMENT ~~BALANCE~~OF ~~SHEET~~CHANGES OF NET LIABILITIES IN LIQUIDATION

	As of
	For the Year Ended
	March 30, 2025
	Ended March 31, 2026
ASSETS
Net liabilities in liquidation, March 31, 2025	$	(8,791,012	)
Current assets
Changes in assets and liabilities in liquidation:
Cash	$	~~101~~(92,~~969~~118	)
Accounts receivable		1,415
Write-off of assets		(280,195	)
Inventory		31,001
Transfer of fixed assets and intangibles to creditor		(35,800,000	)
Prepaid expenses		161,449
Increase to accounts payable and accrued expenses		(78,843	)
Total current assets		295,834
Extinguishment of notes payable and lines of credit		36,021,019
Fixed assets, net		11,418,724
Extinguishment of other liabilities		28,560
Other assets
Net changes in liabilities in liquidation		(201,577	)
Patents, net		5,488,500
Changes in net assets in liquidation resulting from settlement of assets and liabilities:
License Agreement, net		6,982,376
Net liabilities in liquidation, March 31, 2026	$	(8,992,589	)
Right of Use asset		65,830
Deposits		20,500
Total other assets		12,557,206
Total assets	$	24,271,764
LIABILITIES, MEZZANINE AND STOCKHOLDERS’ DEFICIT
Current liabilities
Accounts payable	$	2,861,065
Accrued interest		133,050
Accrued interest - related parties		296,589
Accrued interest		296,589
Other accrued expenses		1,745,237
Accrued expenses - related parties		1,773,831
Short-term Note and Lines of credit		2,681,013
Notes payable		460,622
Restructured Senior note payable		30,091,495
Restructured August note payable		3,047,309
Notes payable - related parties		920,412
Notes payable		920,412
Dividends payable		933,993
Warrant liability		-
Lease Liability, current		28,560
Total current liabilities		44,973,176
Lease Liability, non-current		19,342
Total liabilities		44,992,518
Commitments and contingencies (Note 11)		-
Series E Redeemable Convertible Preferred stock, $0.0001 par value, 10,000 shares authorized, 1,571 and 1,656 shares issued and outstanding at March 30, 2025 and March 31, 2024, respectively		1,886,225
Series F Redeemable Convertible Preferred stock, $0.0001 par value, 750,000 shares authorized, 750,000 shares issued and outstanding at March 30, 2025 and March 31, 2024, respectively		43,612,000
Series G Redeemable Convertible Preferred stock, $0.0001 par value, 10,000 shares authorized, 745 and 445 shares issued and outstanding at March 30, 2025 and March 31, 2024, respectively		861,792
Temporary equity, value		861,792
Stockholders’ deficit
Series A Convertible Preferred stock, $0.0001 par value, 5,000,000 shares authorized, 5,000,000 shares issued and outstanding at March 30, 2025 and March 31, 2024, respectively		500
Common stock, $0.0001 par value, 1,400,000,000 shares authorized, 1,277,546,746 and 1,116,482,063 shares issued and outstanding at March 30, 2025 and March 31, 2024, respectively		127,818
Additional paid in capital		127,504,311
Stock to be issued		390,024
Subscription receivable		(56,250	)
Accumulated deficit		(195,047,174	)
Total stockholders’ deficit		(67,080,771	)
Total liabilities, mezzanine and stockholders’ deficit	$	24,271,764

The accompanying notes are an integral part of these consolidated financial statements.

F-3

NATURALSHRIMP INCORPORATED ~~AND SUBSIDIARIES~~

CONSOLIDATED STATEMENT OF OPERATIONS

	March 30, 2025
	Period Ended
	March 30, 2025
Sales	$	202,817
Cost of sales		138,890
Net revenue		63,927
Operating expenses:
General and administrative		3,406,189
Facility operations		383,829
Depreciation		1,725,480
Amortization		1,470,000
Total operating expenses		6,985,498
Net loss from operations		(6,921,571	)
Other income (expense):
Interest expense		(363,688	)
Interest expense - related parties		(41,996	)
Interest expense		(41,996	)
Amortization of debt discount		-
Change in fair value of warrant liability		24,000
Change in fair value of restructured notes payable		(3,463,804	)
Extension fee		-
Gain on termination of lease		-
Gain on sale of machinery and equipment		39,330
Total other income (expense), net		(3,806,158	)
Income (loss) before income taxes		(10,727,729	)
Provision for income taxes		-
Net loss		(10,727,729	)
Less net loss attributable to non-controlling interest		-
Net loss attributable to NaturalShrimp Inc.		(10,727,729	)
Accretion on Preferred shares		(180,884	)
Dividends		(300,388	)
Net loss available for common stockholders	$	(11,209,001	)
Loss per share (Basic and Diluted)	$	(0.01	)
WEIGHTED AVERAGE SHARES OUTSTANDING (Basic and Diluted)		1,236,795,030

(GOING CONCERN BASIS)

	Period Ended
	March 30, 2025

Sales	$	202,817
Cost of sales		138,890
Net revenue		63,927

Operating expenses:
General and administrative		3,406,189
Facility operations		383,829
Depreciation		1,725,480
Amortization		1,470,000

Total operating expenses		6,985,498

Net loss from operations		(6,921,571	)

Other income (expense):
Interest expense		(363,688	)
Interest expense - related parties		(41,996	)
Interest expense		(41,996	)
Amortization of debt discount		-
Change in fair value of warrant liability		24,000
Change in fair value of restructured notes payable		(3,463,804	)
Extension fee		-
Gain on termination of lease		-
Gain on sale of machinery and equipment		39,330

Total other income (expense), net		(3,806,158	)

Income (loss) before income taxes		(10,727,729	)

Provision for income taxes		-

Net loss		(10,727,729	)

Less net loss attributable to non-controlling interest		-

Net loss attributable to NaturalShrimp Inc.		(10,727,729	)

Accretion on Preferred shares		(180,884	)
Dividends		(300,388	)

Net loss available for common stockholders	$	(11,209,001	)

Loss per share (Basic and Diluted)	$	(0.01	)

WEIGHTED AVERAGE SHARES OUTSTANDING (Basic and Diluted)		1,236,795,030

The accompanying notes are an integral part of these consolidated financial statements.

F-4

NATURALSHRIMP INCORPORATED ~~AND SUBSIDIARIES~~

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ DEFICIT

	Shares		Amount		Shares		Amount		Capital		issued		receivable			deficit			deficit
	Series A Preferred stock				Common stock				Additional paid in		Stock to be		Subscription			Accumulated			Total stockholders’
	Shares		Amount		Shares		Amount		Capital		issued		receivable			deficit			deficit
Balance March 31, 2024		5,000,000	$	500		1,116,482,063	$	111,712	$	126,468,749	$	390,024	$	(56,250	)	$	(183,791,156	)		(56,876,421	)
Balance		5,000,000	$	500		1,116,482,063	$	111,712	$	126,468,749	$	390,024	$	(56,250	)	$	(183,791,156	)		(56,876,421	)
Issuance of common shares under financing agreement						141,064,683		14,106		847,562		-		-			-			861,668
Shares issued upon exchange of Partitioned Note						20,000,000		2,000		188,000		-		-			-			190,000
Accretion of Series E Preferred Shares						-		-		-		-		-			(58,300	)		(58,300	)
Accretion on Series G Preferred shares						-		-		-		-		-			(171,584	)		(171,584	)
Dividends payable on Preferred Shares						-		-		-		-		-			(298,405	)		(298,405	)
Net loss				-				-		-		-		-			(10,727,729	)		(10,727,729	)
Balance March 30, 2025		5,000,000	$	500		1,277,546,746	$	127,818	$	127,504,311	$	390,024	$	(56,250	)	$	(195,047,174	)		(67,080,771	)
Balance		5,000,000	$	500		1,277,546,746	$	127,818	$	127,504,311	$	390,024	$	(56,250	)	$	(195,047,174	)		(67,080,771	)

(GOING CONCERN BASIS)

	Shares		Amount		Shares		Amount		Capital		issued		receivable			deficit			deficit
	Series A Preferred stock				Common stock				Additional paid in		Stock to be		Subscription			Accumulated			Total stockholders’
	Shares		Amount		Shares		Amount		Capital		issued		receivable			deficit			deficit

Balance March 31, 2024		5,000,000	$	500		1,116,482,063	$	111,712	$	126,468,749	$	390,024	$	(56,250	)	$	(183,791,156	)		(56,876,421	)

Issuance of common shares under financing agreement						141,064,683		14,106		847,562		-		-			-			861,668
Shares issued upon exchange of Partitioned Note						20,000,000		2,000		188,000		-		-			-			190,000
Accretion of Series E Preferred Shares						-		-		-		-		-			(58,300	)		(58,300	)
Accretion on Series G Preferred shares						-		-		-		-		-			(171,584	)		(171,584	)
Dividends payable on Preferred Shares						-		-		-		-		-			(298,405	)		(298,405	)
Net loss		-		-													(10,727,729	)		(10,727,729	)

Balance March 30, 2025		5,000,000	$	500		1,277,546,746	$	127,818	$	127,504,311	$	390,024	$	(56,250	)	$	(195,047,174	)		(67,080,771	)

The accompanying notes are an integral part of these consolidated financial statements.

F-5

NATURALSHRIMP INCORPORATED ~~AND SUBSIDIARIES~~

CONSOLIDATED STATEMENT OF CASH FLOWS

	March 30, 2025
	Period Ended
	March 30, 2025
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(10,727,729	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense		1,725,480
Amortization expense		1,470,000
Amortization of debt discount		-
Change in fair value of warrant liability		(24,000	)
Change in fair value of restructured notes payable		3,463,804
Extension fee		-
Financing costs		7,300
Gain on sale of machinery and equipment		39,330
Shares issued for services		-
Amortization of operating lease right-of-use assets		68,690
Gain on termination of lease		-
Issuance of Series G Preferred Stock for services		-
Changes in operating assets and liabilities:
Accounts receivable		26,035
Inventory		37,509
Prepaid expenses and other current assets		8,199
Deferred offering costs		-
Accounts payable		(603,879	)
Other accrued expenses		1,438
Accrued expenses - related parties		657,724
Accrued interest		-
Accrued interest - related parties		41,996
Operating lease liabilities		(85,054	)
Cash used in operating activities		(3,893,157	)
CASH FLOWS FROM INVESTING ACTIVITIES
Cash paid for fixed assets		-
Cash received for sale of machinery and equipment		117,712
Cash used in investing activities		117,712
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from short-term promissory note and lines of credit		2,661,196
Proceeds from sale of stock		760,693
Proceeds from promissory note, related parties		40,000
Proceeds from sale of Series E Preferred Shares		-
Proceeds from sale of Series G Preferred Shares		300,000
Cash provided by financing activities		3,761,889
NET CHANGE IN CASH		(13,556	)
CASH AT BEGINNING OF PERIOD		115,525
CASH AT END OF PERIOD	$	101,969
INTEREST PAID	$	616
Supplemental Disclosure of Non-Cash Investing and Financing Activities:
Construction in process transferred to fixed assets	$	-
Shares issued upon conversion of Preferred stock	$	-
Shares issued upon exchange of Partitioned Note	$	90,000
Dividends on Series E Preferred stock	$	-
Dividends in kind issued	$	300,388
Shares issued/to be issued, for legal settlement	$	-

(GOING CONCERN BASIS)

	Period Ended
	March 30, 2025
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(10,727,729	)

Adjustments to reconcile net loss to net cash used in operating activities

Depreciation expense		1,725,480
Amortization expense		1,470,000
Amortization of debt discount		-
Change in fair value of warrant liability		(24,000	)
Change in fair value of restructured notes payable		3,463,804
Extension fee		-
Financing costs		7,300
Gain on sale of machinery and equipment		39,330
Shares issued for services		-
Amortization of operating lease right-of-use assets		68,690
Gain on termination of lease		-
Issuance of Series G Preferred Stock for services		-

Changes in operating assets and liabilities:
Accounts receivable		26,035
Inventory		37,509
Prepaid expenses and other current assets		8,199
Deferred offering costs		-
Accounts payable		(603,879	)
Other accrued expenses		1,438
Accrued expenses - related parties		657,724
Accrued interest		-
Accrued interest - related parties		41,996
Operating lease liabilities		(85,054	)

Cash used in operating activities		(3,893,157	)

CASH FLOWS FROM INVESTING ACTIVITIES

Cash paid for fixed assets		-
Cash received for sale of machinery and equipment		117,712

Cash used in investing activities		117,712

CASH FLOWS FROM FINANCING ACTIVITIES

Proceeds from short-term promissory note and lines of credit		2,661,196
Proceeds from sale of stock		760,693
Proceeds from promissory note, related parties		40,000
Proceeds from sale of Series E Preferred Shares		-
Proceeds from sale of Series G Preferred Shares		300,000

Cash provided by financing activities		3,761,889

NET CHANGE IN CASH		(13,556	)

CASH AT BEGINNING OF PERIOD		115,525

CASH AT END OF PERIOD	$	101,969

INTEREST PAID	$	616

Supplemental Disclosure of Non-Cash Investing and Financing Activities:
Construction in process transferred to fixed assets	$	-
Shares issued upon conversion of Preferred stock	$	-
Shares issued upon exchange of Partitioned Note	$	90,000
Dividends on Series E Preferred stock	$	-
Dividends in kind issued	$	300,388
Shares issued/to be issued, for legal settlement	$	-

The accompanying notes are an integral part of these consolidated financial statements.

F-6

NATURALSHRIMP INCORPORATED ~~AND SUBSIDIARIES~~

NOTES TO ~~CONSOLIDATED~~ FINANCIAL STATEMENTS

NOTE 1 – NATURE OF THE ORGANIZATION AND BUSINESS

Nature of the Historical Business

NaturalShrimp Incorporated (“NaturalShrimp” or the “Company”), a Nevada corporation, iswas a biotechnology company ~~and~~that ~~has~~ developed a proprietary technology that ~~allows~~allowed it to grow Pacific White shrimp (Litopenaeus vannamei, formerly Penaeus vannamei) in an ecologically controlled, high-density, low-cost environment, and in fully contained and independent production facilities. The Company’s system uses technology which allows it to produce a naturally-grown shrimp “crop” weekly and accomplishes this without the use of antibiotics or toxic chemicals. The Company has developed several proprietary technology assets, including a knowledge base that allows it to produce commercial quantities of shrimp in a closed system with a computer monitoring system that automates, monitors and maintains proper levels of oxygen, salinity and temperature for optimal shrimp production.

The Company has three wholly-owned subsidiaries including NaturalShrimp USA Corporation (“NSC”) and NaturalShrimp Global, Inc. (“NS Global”) and Natural Aquatic Systems, Inc. (“NAS”), and owns 51% of NaturalShrimp/Hydrenesis LLC, a Texas limited liability company.

Receivership and Liquidation

On September 4, 2024, Streeterville Capital, LLC, a Utah limited liability company, and Bucktown Capital, LLC, a Utah limited liability company (collectively, “Lenders”), filed a Verified Emergency Motion for Appointment of Receiver (the “Motion”) under Civil Case No. 240907138, in the District Court of Salt Lake County, Utah, against NaturalShrimp, Inc. (“NaturalShrimp”).

On November 20, 2024, the Lenders and NaturalShrimp filed a Verified Amended and Stipulated Emergency Motion for Immediate Appointment of a Receiver in the Receivership Case.

Pending Intellectual Property Agreement

During March of 2026, NaturalShrimp Incorporated entered into an Intellectual Property Acquisition and Management Transition Agreement (the “Agreement”) with Hydrenesis, Inc., a Florida corporation (“Hydrenesis”), and David Antelo. Pursuant to the agreement:

● The Company will transition its operations toward the commercialization of aquaculture and water treatment technologies; and

● Certain governance and control rights were transferred pursuant to the Agreement

● Hydrenesis will grant the Company a perpetual license to certain intellectual property, technology rights, know-how, and related commercialization rights, subject to the terms and conditions of the agreement

● The Company’s outstanding obligation to Hydrenesis in the amount of approximately $1,034,112 will be converted into equity at Closing;

● The Company approved and executed Certificates of Designation for Series P, Series P-2, and Series L Preferred Stock, which are expected to be filed with the Nevada Secretary of State;

● Existing liabilities, obligations, and legacy securities, including Series A Preferred Stock and Series F Preferred Stock, will be restructured, amended, cancelled, or exchanged into Series L Preferred Stock;

The Hydrenesis transaction was consummated on June 25, 2026; however, the related preferred share issuances, creditor restructuring, and accounting recognition of the license rights remained subject to completion as of the date of this filing.

F-7

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“US GAAP”). ~~The~~As the Company’s ~~has~~liquidation ~~presented~~became ~~going~~imminent ~~concern financial statements~~ as of March 30, 2025, ~~and~~the ~~for~~Company ~~the~~has ~~period~~presented ~~from~~its ~~April~~financial statements 1under the liquidation basis of accounting as of both March 31, ~~2024~~2026 ~~through~~and March 3031, 2025. ~~The~~To ~~comparative~~comply ~~period~~with ~~has~~ASC ~~not~~205-30, ~~been~~Liquidation ~~presented~~Basis of asAccounting, the Company ~~does~~has ~~not~~presented ~~believe~~a itconsolidated ~~would~~statement beof ~~required~~net ~~based~~liabilities onin ~~the guidance~~liquidation ~~outlined~~as inof ~~ASC~~March ~~205-30~~31, ~~Liquidation~~2026 ~~Basis~~and ofMarch 31, ~~Accounting.~~2025 Asand ofa ~~March~~consolidated ~~31,~~statement ~~2025,~~of ~~which~~changes isof ~~the~~net ~~(convenience)~~liabilities ~~date that~~in liquidation for the ~~Company’s~~year ~~liquidation~~ended ~~became~~March ~~imminent~~31, ~~the~~2026. ~~Company~~In ~~has~~addition, ~~presented~~to comply ~~its~~with the financial ~~statements~~statement ~~under~~requirements ~~the~~of ~~liquidation~~Article ~~basis~~ 8 of ~~accounting.~~Regulation ~~As such~~S-X, the Company has also presented a consolidated statement of ~~net~~operations, ~~liabilities~~a consolidated statement of changes in ~~liquidation~~shareholders asequity and a consolidated statement of cash flows for the year ended March 31, 2025. ~~As there~~under ~~was~~the ~~only~~going aconcern ~~single~~basis ~~day~~of ~~between~~accounting. ~~the~~The ~~time~~going ~~that~~concern ~~liquidation~~financial ~~became~~statements ~~imminent~~have ~~and~~been presented separately from the ~~end~~liquidation ofbasis ~~the~~financial ~~reporting~~statements ~~period,~~as nothe ~~consolidated~~results ~~statement of~~should ~~changes~~not inbe ~~net~~considered ~~liabilities~~comparable inunder ~~liquidation~~the ~~has~~two ~~been~~presentation ~~presented~~methods.

Consolidation

The consolidated financial statements include the accounts of NaturalShrimp Incorporated and its wholly-owned subsidiaries, NaturalShrimp USA Corporation, NaturalShrimp Global and NAS, and the 51% ownership of NaturalShrimp/Hydrenesis LLC. All significant intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

Preparing financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Liquidation Basis of Accounting

When using the liquidation basis of accounting, the Company will i) recognize other items that it previously had not recognized but it expects to sell in liquidation or use to settle liabilities ii) accrue costs and income that it expects to incur or earn through the end of its liquidation if and when it has a reasonable basis for estimation iii) measure its assets to reflect the estimated amount of cash or other consideration that it expects to collect in settling or disposing of those assets in carrying out its plan for liquidation and iv) measure its liabilities in accordance with the measurement provision of other topics that it would otherwise apply to those liabilities.

Basic and Diluted Earnings/Loss per Common Share

Basic and diluted earnings or loss per share (“EPS”) amounts in the consolidated financial statements are computed in accordance with Accounting Standards Codification (“ASC”) 260 – 10 “Earnings per Share”, which establishes the requirements for presenting EPS. Basic EPS is based on the weighted average number of shares of common stock outstanding. Diluted EPS is based on the weighted average number of shares of common stock outstanding and dilutive common stock equivalents. Basic EPS is computed by dividing net income or loss available to common stockholders (numerator) by the weighted average number of shares of common stock outstanding (denominator) during the period. Diluted EPS is not presented in periods where the Company recognizes a net loss as it would be considered anti-dilutive. Further, preferred dividends are subtracted from net income (loss) in the period in arriving at net income (loss) available to common stockholders.

Fair Value Measurements

ASC Topic 820, “Fair Value Measurement”, requires that certain financial instruments be recognized at their fair values at our balance sheet dates. However, other financial instruments, such as debt obligations, are not required to be recognized at their fair values, but GAAP provides an option to elect fair value accounting for these instruments. GAAP requires the disclosure of the fair values of all financial instruments, regardless of whether they are recognized at their fair values or carrying amounts in our balance sheets. For financial instruments recognized at fair value, GAAP requires the disclosure of their fair values by type of instrument, along with other information, including changes in the fair values of certain financial instruments recognized in income or other comprehensive income. For financial instruments not recognized at fair value, the disclosure of their fair values is provided below under Financial Instruments.

Nonfinancial assets, such as property, plant and equipment, and nonfinancial liabilities are recognized at their carrying amounts in the Company’s balance sheets. GAAP does not permit nonfinancial assets and liabilities to be remeasured at their fair values. However, GAAP requires the remeasurement of such assets and liabilities to their fair values upon the occurrence of certain events, such as the impairment of property, plant and equipment. In addition, if such an event occurs, GAAP requires the disclosure of the fair value of the asset or liability along with other information, including the gain or loss recognized in income in the period the remeasurement occurred.

F-8

The Company did not have any Level 1 or Level 2 assets and liabilities as of March 30, 2025 and March 31, 2024.

The warrant liabilities and Restructured notes are considered Level 3 fair value measurements.

The following is a summary of activity of Level 3 liabilities during the periods ended March 30, 2025 and March 31, 2024:

Warrant liability

SUMMARY OF ACTIVITY OF DERIVATIVES AT FAIR VALUE

	March 30, 2025
Warrant liability balance at beginning of year	$	24,000
Change in fair value		(24,000	)
Balance at end of year	$	-

During the period ended March 30, 2025, the Company’s shares ceased being quoted on the Over the Counter (“OTC”) market and technically had a fair value of $0. As such, the warrants were written down to $0.

Restructured August and Senior Notes Payable

SCHEDULE OF RESTRUCTURED AUGUST AND SENIOR NOTES PAYABLE AT FAIR VALUE

	March 30, 2025
Restructured notes payable fair value at beginning of year	$	29,760,000
Fair value of Promissory Notes upon Restructuring Agreement		-
Reclass of accrued interest		-
Note partition		(85,000	)
Change in fair value		3,463,804
Restructured Notes Payable fair value at end of year	$	33,138,804

F-9

On November 4, 2022, when the Company entered into a Restructuring Agreement for an Amended and Restated Secured Promissory Note for two of their outstanding debentures, which were accounted for as debt extinguishment, the Company elected to recognize the new debt under ASC 825 fair value option. The fair value is based on the maturity dates, the interest of 12%, the 15% exit fee, the 2% appreciation fee for an estimated period, and a 45% present value factor as of March 30, 2025. In accordance with ASC 825, the Company chose to present the component for the accrued interest in the same line item on the accompanying consolidated balance sheet with the fair value option, and as of April 1, 2023, reclassed the accrued interest to not be presented as a separate line item. The notes were extinguished subsequent to the balance sheet date as part of the liquidation process.

Financial Instruments

The Company’s financial instruments include cash and cash equivalents, receivables, payables, and debt and are accounted for under the provisions of ASC Topic 825, “Financial Instruments”. The carrying amount of these financial instruments, with the exception of the restructured debt, as reflected in the consolidated balance sheets approximates fair value.

Cash and Cash Equivalents

For the purpose of the consolidated statements of cash flows, the Company considers all highly liquid instruments purchased with a maturity of three months or less to be cash equivalents. There were no cash equivalents as of March 31, ~~2025~~2026.

Concentration of Credit Risk

The Company maintains cash balances at two financial institutions. Accounts at this institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. As of March 31, 2025, the Company’s cash balance did not exceed FDIC coverage. The Company has not experienced any losses in such accounts and periodically evaluates the credit worthiness of the financial institutions and has determined the credit exposure to be negligible.

Fixed Assets

Equipment is carried at historical value or cost and is depreciated using the straight-line method over the estimated useful lives of the related assets. Estimated useful lives are as follows:

SCHEDULE OF ESTIMATED USEFUL LIVES

Buildings			39 years
Machinery and Equipment			7 – 10 years
Vehicles			10 years
Furniture and Fixtures			3 – 10 years

Maintenance and repairs are charged to expense as incurred. At the time of retirement or other disposition of equipment, the cost and accumulated depreciation will be removed from the accounts and the resulting gain or loss, if any, will be reflected in operations.

Income Taxes

Deferred income tax assets and liabilities are computed for differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities.

In addition, the Company’s management performs an evaluation of all uncertain income tax positions taken or expected to be taken in the course of preparing the Company’s income tax returns to determine whether the income tax positions meet a “more likely than not” standard of being sustained under examination by the applicable taxing authorities. This evaluation is required to be performed for all open tax years, as defined by the various statutes of limitations, for federal and state purposes.

F-10

Stock-Based Compensation

The Company accounts for stock-based compensation to employees and non-employees in accordance with ASC 718. “Stock-based Compensation to Employees” is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite employee service period. The Company estimates the fair value of stock-based payments using the Black-Scholes option-pricing model for common stock options and warrants and the closing price of the Company’s common stock for common share issuances. Once the stock is issued the appropriate expense account is charged.

Intangible Assets

The Company has intangible assets, which were acquired in a patent acquisition, and license rights agreements. The Company’s patents represent definite lived intangible assets and will be amortized over the twenty-year20 duration of the patent, unless at some point the useful life is determined to be less than the protected life of the patent. The Company’s license rights will be amortized on a straight-line basis over the expected term of the agreements of ten years.

On May 19, 2021, the Company entered into a Patents Purchase Agreement (the “Patents Agreement”) with F&T Water Solutions, LLC (“F&T”). The Company and F&T had previously jointly developed and patented a water treatment technology used or useful in growing aquatic species in re-circulating and enclosed environments (the “Patent”) with each party owning a fifty percent (50%) interest. Upon the closing of the Patents Agreement, the Company purchased F&T’s interest in the Patent, F&T’s 100% interest in a second patent associated with the first Patent issued to F&T in March 2018, and all other intellectual property rights owned by F&T for a purchase price of $2,000,000 in cash and issue 9,900,990 shares of the Company’s common stock with a market value of $0.505 per share for a total fair value of $5,000,000, for a total acquisition price of $7,000,000. Amortization expense was $390,000 for the period ended March 30, 2025.

On August 25, 2021, the Company, through its 100% owned subsidiary NAS, entered into an Equipment Rights Agreements with Hydrenesis-Delta Systems, LLC (“Hydrenesis-Delta”) and a Technology Rights Agreement (“Rights”), in a sub-license agreement with Hydrenesis Aquaculture LLC (“Hydrenesis-Aqua”). Both Rights agreements are for a 10-year term, which shall automatically renew for ten-year successive terms. The agreements accord the exclusive rights to purchase or distribute the technology, or buy or rent the equipment, which is the primary business and revenue stream generated from indoor aquaculture farming of any species in the territory, which will be named the NSI Technologies and Equipment (“NSI Technologies”).

The terms of the Agreements set forth that NAS will pay Hydrenesis 12.5% royalty fees. The royalties are calculated per all customer or sub-license revenue generated by NAS, NSI or any affiliate, from the sale or rental of either the Technologies or Hydrenesis Equipment, based on gross revenue less returns, rebates and sales taxes. There are sales milestones for exclusivity, whereby if NAS fails to achieve a sales milestone starting in Year 3, the exclusivity rights in both of the Rights agreements shall revert to non-exclusive rights. To maintain the exclusivity for the subsequent year, the Company may pay the amount of the royalty fees that would have been due if the Sales Milestones had been met in the current year.

The Sales Milestones are:

SCHEDULE OF SALES MILESTONE

Year 4	$	375,000 Royalty
Year 5	$	625,000 Royalty
Year 6	$	875,000 Royalty
All subsequent years	$	1,000,000 Royalty

For the period ended March 30, 2025, the amortization of the Rights was $1,080,000.

Impairment of Long-lived Assets

The Company will periodically evaluate the carrying value of long-lived assets to be held and used when events and circumstances warrant such a review and at least annually. The carrying value of a long-lived asset is considered impaired when the anticipated undiscounted cash flow from such asset is separately identifiable and is less than its carrying value. In that event, a loss is recognized based on the amount by which the carrying value exceeds the fair value of the long-lived asset. Fair value is determined primarily using the anticipated cash flows discounted at a rate commensurate with the risk involved. Losses on long-lived assets to be disposed of are determined in a similar manner, except that fair values are reduced for the cost to dispose.

Commitments and Contingencies

Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management and its legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s consolidated financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed.

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed.

Revenue Recognition

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers, as such, the Company records revenue when its customers obtain control of the promised goods or services in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. The Company will sell primarily to food service distributors, as well as to wholesalers, retail establishments and seafood distributors.

F-11

To determine revenue recognition for the arrangements that the Company determines are within the scope of Topic 606, the Company performs the following five steps: (1) identify the contract(s) with a customer by receipt of purchase orders and confirmations sent by the Company which includes a required line of credit approval process, (2) identify the performance obligations in the contract which includes shipment of goods to the customer FOB shipping point or destination, (3) determine the transaction price which initiates with the purchase order received from the customer and confirmation sent by the Company and will include discounts and allowances by customer if any, (4) allocate the transaction price to the performance obligations in the contract which is the shipment of the goods to the customer and transaction price determined in step 3 above and (5) recognize revenue when (or as) the entity satisfies a performance obligation which is when the Company transfers control of the goods to the customers by shipment or delivery of the products.

SCHEDULE OF REVENUE RECOGNITION

	March 30, 2025
	Period ended
	March 30, 2025
Shrimp sales	$	202,817
Technology and equipment services		-
Total revenues	$	202,817

Recently Issued Accounting Standards

F-128

NOTE 3 – LIQUIDATION BASIS OF ACCOUNTING

During September of 2024, Ampleo Turnaround and Restructuring, LLC was placed as the receiver over the Company’s assets due to its significant outstanding debt. Subsequently, during February of 2025, the receiver filed a motion to sell all of the Company’s assets to Streeterville and Bucktown Capital for an approximate credit bid of $35.7 million and $~~100,000~~0.1 million in cash. The motion was approved by the court (overseeing the motion) on March 30, 2025 with title to the assets being ~~transferred~~ transferred to the creditor on May 14, 2025. The Company believes that it continued to function as a going concern until the date the motion to sell its assets was approved by the court at which time its liquidation became imminent. ~~As such~~Further, inwhile ~~accordance with ASC 205-30,~~ the Company entered ~~has~~into ~~presented~~an ~~going~~intellectual ~~concern~~property ~~financial~~and ~~statements~~management asagreement ofduring March 30of 2026, ~~2025 and for~~ the ~~period~~related ~~from~~license ~~April 1~~rights, ~~2024~~preferred share ~~through~~issuances, ~~March~~creditor 30restructuring, ~~2025.~~and ~~Comparative~~other ~~periods~~closing ~~have~~matters had not yet been ~~provided~~consummated as of the ~~Company~~balance ~~does~~sheet ~~not believe they would be required under ASC 205-30~~date. ~~Furthermore~~As such, in accordance with ~~the~~ ASC ~~subtopic~~205-30, the Company has ~~also~~ presented i) a consolidated statement of net liabilities in liquidation ~~using~~as aof ~~convenience~~both ~~date~~March 31, of2026 and March 31, 2025. ~~The~~and ii) a consolidated statement of changes in net liabilities in liquidation ~~has~~for ~~been~~the ~~prepared~~year ~~using~~ended ~~the~~March ~~liquidation~~31, ~~basis of accounting~~2026. AsThe ~~there~~consolidated ~~was~~statements ~~only~~of ~~one~~net ~~day~~liabilities ~~from~~in ~~the time that our~~ liquidation ~~became imminent~~ and ~~the end of the reporting period, no consolidated~~ statement of changes inof net liabilities in liquidation have ~~has~~ been ~~presented~~prepared using the liquidation basis of accounting.

As part of the liquidation, the Company ~~sold~~transferred ownership of its revenue generating fixed assets and intangible assets on May 14, 2025 to two of its creditors (Streeterville and Buckstown) in exchange for the extinguishment of i) the restructured August and Senior notes ~~($33.1 million)~~ and Buckstown line of credit ~~($2~~.7 ~~million).~~ As of the date of this filing, the Company had limited assets available and was therefore uncertain as to the manner by which it expects to settle ~~our~~its remaining outstanding liabilities. ~~Furthermore~~However, wein ~~are~~accordance ~~also~~with ~~uncertain~~the ~~about~~intellectual property agreement, the ~~expected date~~Company byhopes ~~which~~to wesettle ~~expect~~its toremaining ~~complete~~outstanding liabilities in exchange for the ~~liquidation~~issuance of newly authorized preferred shares.

Our consolidated statement of net liabilities in liquidation as of March 31, 2026 and March 31, 2025 reflects the following:

● No additional items were recognized, such as trademarks, that the Company might either sell in liquidation or use to settle its liabilities ● Liabilities have been recognized in accordance with the recognition provisions of other topics that otherwise would apply to those liabilities. As of March 31, 2026, our remaining liabilities were primarily comprised of i) accounts payable and accrued expenses to finance and legal service providers and former employees and ii) outstanding debt. Of the approximately $8.9 million in outstanding liabilities as of March 31, 2026 approximately $3.0 million was to related parties and was comprised of i) accrued salaries and ii) outstanding loans (including accrued interest). ● ~~The~~As of March 31, 2025, the intangible assets and fixed assets ~~have~~were ~~been~~ recognized based on a settlement amount equal to the credit bid of approximately $35,800,000. As of March 31, 2026, intangible assets and fixed assets were fully de-recognized due to ownership of the assets being transferred to our creditors as of May 14, 2025. ● No additional costs ~~or income~~ expected to be incurred ~~or earned~~ through the end of our liquidation ~~have~~were ~~been~~ accrued as of March 31, 2026 as there has been limited activity subsequent to the ~~Company~~balance ~~does~~sheet date. We do not ~~believe~~expect to earn any additional income through the ~~amounts~~end toof bethe ~~material~~liquidation period.

NOTE 4 –STOCK ~~FIXED~~BASED ~~ASSETS~~COMPENSATION

AOn ~~summary~~March of17, 2026 the ~~fixed~~Company ~~assets~~entered isinto advisory agreements with four former employees to provide consulting services to the Company over a three-year period. In consideration for the consulting services, the Company issued warrants to purchase 2,450,000 with a three-year exercise term and $0.00125 strike price. Due to certain restrictions, the warrants were not currently exercisable. Further, as ~~follows:~~the Company currently has approximately 1.3 billion common shares outstanding the fair value of the warrants was not material.

~~SCHEDULE~~NOTE OF5 ~~FIXED~~SUBSEQUENT ~~ASSETS~~ EVENTS

	March 30, 2025
Land	$	187,609
Buildings		6,624,549
Machinery and equipment		11,210,985
Autos and trucks		188,415
Fixed assets, gross		18,211,558
Accumulated depreciation		(6,792,833	)
Fixed assets, net	$	11,418,724

The Company has evaluated subsequent events through the date these financial statements were issued. As disclosed elsewhere in this report, the Hydrenesis transaction was consummated on June 25, 2026; however, the related preferred share issuances, creditor restructuring, and accounting recognition of the license rights remained subject to completion. Other than the foregoing, there were no additional material subsequent events requiring recognition or disclosure.

The consolidated statements of operations reflect depreciation expense of approximately $1,725,000 for the period ended March 30, 2025. Subsequent to year end, primarily all of the land, buildings and machinery and equipment were transferred to a lender as part of the liquidation process.F-9

F-13

NOTE 5 – SHORT-TERM NOTE AND LINES OF CREDIT

The Company has a working capital line of credit with Capital One Bank for $50,000. The line of credit bears an interest rate of prime plus 25.9 basis points, which totaled 34.4% as of March 31, 2025. The line of credit is unsecured. The balance of the line of credit was $9,580 at March 31, 2025.

The Company also has a working capital line of credit with Chase Bank for $25,000. The line of credit bears an interest rate of prime plus 10 basis points, which totaled 18.5% as of March 31, 2025. The line of credit is secured by assets of the Company’s subsidiaries. The balance of the line of credit is $10,237 as of March 31, 2025.

During August of 2024, the Company entered into a line of credit with Bucktown Capital, LLC. The line of credit bears interest at 12%. The balance of the line of credit was $2,661,196 as of March 31, 2025. Subsequent to the balance sheet date the outstanding balance was extinguished as part of the liquidation process.

NOTE 6 – PROMISSORY NOTE

January 2023 Note

On January 20, 2023, the Company entered into a secured promissory note (“January 2023 Note”) with an investor (the “Investor”). The January 2023 Note is in the aggregate principal amount of $631,968. The Note has an interest rate of 10% per annum, with a maturity date nine months from the issuance date of the Note. The Note carried an original issue discount totaling $56,868, whereby the purchase price is $575,100. All payments made by the Company under the terms in the note, including upon repayment of this Note at maturity, shall be subject to an exit fee of 15% of the portion of the Outstanding Balance being paid. The cash was not transferred to the Company’s bank account, but instead to the merger entity, Yotta Acquisition Corporation (Note 11), for a contribution to a required extension fee for the business combination. On November 17, 2023, the Company received an extension of the maturity date to June 30, 2024, for a $5,000 extension fee. The maturity date was further extended to August 15, 2024.

On November 8, 2023, the Company and the Investor entered into an Exchange Agreement on the January 2023 Note. In the Exchange Agreement the original note was partitioned into a $132,000 new promissory note, leaving the original January 2023 Note with an adjusted balance of $499,968. The partitioned note was exchanged for 10,000,000 shares of the Company’s common stock. The shares of common stock issued had a fair value of $160,000 based on the market price of the shares of $0.016 on the execution date, resulting in an excess of $28,000 to be recognized as a financing expense.

On January 17, 2024, the Company and the Investor entered into an Exchange Agreement on the January 2023 Note. In the Exchange Agreement the remaining January 2023 Note was partitioned into a $99,450 new promissory note, leaving the original January 2023 Note with an adjusted balance of $400,518. The partitioned note was exchanged for 10,000,000 shares of the Company’s common stock. The shares of common stock issued had a fair value of $110,000 based on the market price of the shares of $0.011 on the execution date, resulting in an excess of $10,550 to be recognized as a financing expense.

On February 22, 2024, the Company and the Investor entered into an Exchange Agreement on the January 2023 Note. In the Exchange Agreement the remaining January 2023 Note was partitioned into a $91,800 new promissory note, leaving the original January 2023 Note with an adjusted balance of $313,718. The partitioned note was exchanged for 10,000,000 shares of the Company’s common stock. The shares of common stock issued had a fair value of $190,000 based on the market price of the shares of $0.019 on the execution date, resulting in an excess of $98,200 to be recognized as a financing expense.

On April 3, 2024, the Company and the Investor entered into an Exchange Agreement on the January 2023 Note. In the Exchange Agreement the remaining January 2023 Note was partitioned into a $92,700 new promissory note, leaving the original January 2023 Note with an adjusted balance of $221,018. The partitioned note was exchanged for 10,000,000 shares of the Company’s common stock. The shares of common stock issued had a fair value of $100,000 based on the market price of the shares of $0.010 on the execution date, resulting in an excess of $7,300 to be recognized as a financing expense. The note is in default as of the date of this filing.

April 2023 Promissory Note

On April 21, 2023, the Company entered into a $60,000 promissory note with Yotta Investment LLC (“Yotta Investment”), with no interest to accrue on the principal balance. The promissory note was to be settled on the date of closing of the business combination contemplated by the Merger Agreement with Yotta Acquisition Corporation, (“Merger Agreement”). Upon the termination of the Merger Agreement, the unpaid principal balance of the note, and all other sums payable with regard to this note, became due and payable. The promissory note was still outstanding as of the date of the filing.

May 2023 Promissory Note

On May 17, 2023, the Company entered into an additional $60,000 promissory note with Yotta Investment, with no interest to accrue on the principal balance. The promissory note was to be settled on the date of closing of the business combination contemplated by the Merger Agreement with Yotta Acquisition Corporation. Upon the termination of the Merger Agreement, the unpaid principal balance of the note, and all other sums payable with regard to this note, became due and payable. The promissory note was still outstanding as of the date of the filing.

Ms. Williams Promissory Note

On July 15, 2020, the Company issued a promissory note to Ms. Williams in the amount of $383,604 to settle the amounts that had been recognized per the separation agreement with the late Mr. Bill Williams dated August 15, 2019, for his portion of the related party notes and related accrued interest discussed above, and accrued compensation and allowances. The note bears interest at one percent per annum and calls for monthly payments of $8,000 until the balance is paid in full. During the year ended March 31, 2025, the Company did not make any monthly payments. The balance as of March 31, 2025 was $119,604.

F-14

NOTE 7 – RESTRUCTURED NOTE PAYABLES

August Note Payable

The Company entered into a securities purchase agreement (the “SPA”) with an investor (the “Investor”) on August 17, 2022. Pursuant to the SPA, the Investor purchased a secured promissory note (the “Note”) in the aggregate principal amount totaling approximately $5,433,333. The Note has an interest rate of 12% per annum, with a maturity date nine months from the issuance date of the Note. The Note carried an original issue discount totaling $433,333 and a transaction expense amount of $10,000, both of which are included in the principal balance of the Note. On the closing date the Company received $1,100,000, with $3,900,000 put into escrow to be held until certain terms were to be met, which included $3,400,000 upon the completion of a successful uplist to NYSE or NASDAQ. The SPA includes a Security Agreement, whereby the note is secured by the collateral set forth in the agreement, covering all of the assets of the Company. All payments made by the Company under the terms in the note, including upon repayment of this Note at maturity, were subject to an exit fee of 15% of the portion of the outstanding balance being paid (the “Exit Fee”). As the Exit Fee is to be included in every settlement of the Note, an additional 15% of the principal balance, which totals $816,500, was recognized along with the principal balance, and offset by a contra account in a manner similar to a debt discount.

As soon as reasonably possible, the Company will cause the common stock to be listed for trading on either of (a) NYSE, or (b) NASDAQ (in either event, an “Uplist”). In the event the Company has not effectuated the Uplist by November 15, 2022, the then-current outstanding balance will be increased by 10%. Following the Uplist, while the Note is still outstanding, ten days after the Company may have a sale of any of its shares of common stock or preferred stock, there shall be a Mandatory Prepayment equal to the greater of $3,000,000 or thirty-three percent of the gross proceeds of the equity sale.

In conjunction with the Merger Agreement, entered into on October 24, 2022, with Yotta Acquisition Corporation (Note 13), on November 4, 2022, the Company entered into a Restructuring Agreement for an Amended and Restated Secured Promissory Note (the “August Note”), through which the August Note was amended and restated in its entirety. The Restructured August Note decreased the principal to $1,748,667, less an OID of $138,667, and the amount in escrow was returned to the investor, The Restructuring Agreement included key modifications, in which i) the Uplist terms were removed, ii) in the event that the closing of the Merger does not occur on or before December 31, 2022, the then-current Outstanding Balance will be increased by 2% and shall increase by 2% every 30 days thereafter until the closing or termination of the Merger Agreement, and iii) the outstanding balance of the Convertible Note may be increased by 5% to 15% upon the occurrence of an event of default or failure to obtain the Lender’s consent or notify the Lender for certain major equity related transactions (“Trigger Events”). The Merger had not yet closed, and therefore the 2% of the outstanding balance was increased as of June 30, 2023, in the amount of approximately $272,000. On July 20, 2023, the Company sent Yotta notice of the Company’s termination of the Merger Agreement. (See Note 13) On November 20, 2023, the maturity date was extended to June 30, 2024. The maturity date was further extended to August 15, 2024.

The Restructured August Note was analyzed under ASC 470-50 as to if the change in terms qualified as a modification or an extinguishment of the note . The changes in terms were considered an extinguishment as the present value of the cash flows under the terms of the new debt instrument was evaluated to be a substantial change, as over 10% difference from the present value of the remaining cash flows under the terms of the original instrument. As such, with the removal of the original note and its debt discount and accrued interest as compared to the restructured note with a fair value of approximately $1,933,000, there was a loss in extinguishment of approximately $157,000. As a result of the extinguishment and at the Company’s election of the fair value option under ASC 825, the August Note was accounted for at fair value until settlement. In accordance with ASC 815- 15-25-1(b) a hybrid instrument that is measured at fair value under ASC 825 fair value option each period with changes in fair value reported in earnings as they occur should not be evaluated for embedded derivatives. Therefore, the provisions in the August Note were not evaluated as to if they fell under the guidance of embedded derivatives and were required to be bifurcated. The August Note was revalued as of March 31, 2025 and March 30, 2025 at approximately $3,047,309, with a change in fair value of approximately $407,309 in the current year recognized in the accompanying Consolidated Statement of Operations. Subsequent to the balance sheet date the outstanding balance was extinguished as part of the liquidation process.

F-15

Senior Note Payable

The Company entered into a securities purchase agreement (the “SPA”) with an investor (the “Investor”) on December 15, 2021. Pursuant to the SPA, the Investor purchased a secured promissory note (the “Note”) in the aggregate principal amount totaling approximately $16,320,000 (the “Principal Amount”). The Note has an interest rate of 12% per annum, with a maturity date 24 months from the issuance date of the Note (the “Maturity Date”).

Beginning on the date that is 6 months from the issuance date of the Note, the Investor had the right to redeem up to $1,000,000 of the outstanding balance per month. Payments could have been made by the Company, at the Company’s option, (a) in cash, or (b) by paying the redemption amount in the form of shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), per the following formula: the number of redemption shares equals the portion of the applicable redemption amount divided by the Redemption Repayment Price. The “Redemption Repayment Price” equaled 90% multiplied by the average of the two lowest volume weighted average price per share of the Common Stock during the ten (10) trading days immediately preceding the date that the Investor delivers notice electing to redeem a portion of the Note. The redemption amount shall include an Exit Fee, consisting of a premium of 15% of the portion of the outstanding balance being paid. As the Exit Fee is to be included in every settlement of the Note, an additional 15% of the principal balance, which totals $2,448,000, was recognized along with the principal balance, and offset by a contra account in a manner similar to a debt discount. In addition to the Investor’s right of redemption, the Company has the option to prepay the Notes at any time prior to the Maturity Date by paying a premium of 15% plus the principal, interest, and fees owed as of the prepayment date.

On November 4, 2022, the Company entered into a Restructuring Agreement for an Amended and Restated Secured Promissory Note (the “Senior Note”) with the December 2021 Investor through which the December 2021 Note was amended and restated in its entirety. These amendments were made in conjunction with the Merger Agreement, entered into on October 24, 2022, with Yotta Acquisition Corporation (Note 13), The main modification of the terms of the Senior Note was that the conversion feature was eliminated. Second, a Mandatory Payment was added whereby within 3 trading days of the closing upon the Merger an amount equal to the lesser of (A) one-third of the amount retained in the Trust Account at the Effective Time or (B) $10,000,000, in order to repay a portion of the outstanding balance of the Senior Note; after which the remaining balance of the Senior Note is to be repaid in equal monthly installments over a 12-month period beginning on a date after the Merger Agreement closing date (“Closing Date”) or the termination of such agreement. All payments made shall be subject to an Exit Fee of 15% of the portion of the outstanding balance being paid. Additionally, if the Closing Date is after December 31, 2022, the outstanding balance of all indebtedness owed by the Company to December 2021 Investor will be increased automatically by 2% and will automatically increase by 2% every 30 days thereafter until the Closing, a termination, or substantially similar terms as approved by the Board of Directors of the Company. Additional key modifications include i) uplist terms in which the Company was to cause the common stock to be listed for trading on either of (a) NYSE, or (b) NASDAQ, were removed, ii) Maturity date was modified from December 15, 2023 to 12 months from the Closing or termination of the Merger Agreement, provided not to be later than September 30, 2024, and iii) the outstanding balance of the Senior Note may be increased by 5% to 15% upon the occurrence of an event of default or failure to obtain the Lender’s consent or notify the Lender for certain major equity related transactions (“Trigger Events”). As of June 30, 2023, the Merger has not yet closed, and therefore the 2% of the outstanding balance was increased as of June 30, 2023, in the amount of approximately $2,675,000. On July 20, 2023, the Company sent Yotta notice of the Company’s termination of the Merger Agreement (See Note 13). Based on the termination in July of 2023, the equal monthly payments were to begin on September 20, 2023. On July 3, 2024, the Investor issued a waiver to the Company on the equal monthly payments, which are not currently required to be paid, through August 15, 2024.

The Note also contains certain negative covenants and Events of Default, which in addition to common events of default, include the Company fails to maintain the share reserve, the occurrence of a Fundamental Transaction without the Lenders written consent, the Company effectuates a reverse split of its common stock without 20 trading days written notice to Lender, fails to observe or perform or breaches any covenant, and, the Company or any of its subsidiaries, breaches any covenant or other term or condition contained in any Other Agreements in any material. Upon an Event of a Default, at its option and sole discretion, the Investor may consider the Note immediately due and payable. Upon such an Event of Default, the interest rate increases to 18% per annum and the outstanding balance of the Note increases from 5% to 15%, depending upon the specific Event of Default.

F-16

The Restructured Senior Note was analyzed under ASC 470-50 as to if the change in terms qualified as a modification or an extinguishment of the note. The changes in terms were considered an extinguishment as the conversion feature has been eliminated and therefore the modified Senior Note is determined to be fundamentally different from the original convertible note. As such, with the removal of the original note and its debt discount and accrued interest as compared to the restructured note with a fair value of approximately $18,914,000, there was a gain in extinguishment of approximately $2,540,000. As of the restructuring date the derivative had a fair value of $12,290,000, based on assumptions used in a bi-nomial option pricing model, which resulted in a change in fair value of $17,738,000 as of the restructuring date, from its previous fair value of $30,028,000. The key valuation assumptions used consist, in part, of the price of the Company’s common stock of $0.16 at issuance date; a risk-free interest rate of 3.73% and expected volatility of the Company’s common stock, of 117.77%, and the strike price of $0.1017.

As a result of the extinguishment and at the Company’s election of the fair value option under ASC 825, the Company will account for the Restructured Senior Note at fair value every period end until it is settled. In accordance with ASC 815- 15-25-1(b) a hybrid instrument that is measured at fair value under ASC 825 fair value option each period with changes in fair value reported in earnings as they occur should not be evaluated for embedded derivatives. Therefore, the Company did not evaluate the provisions in the Restructured Senior Note as to whether they fell under the guidance of embedded derivatives and were required to be bifurcated. The Restructured Senior Note was revalued as of March 31, 2025 and March 30, 2025 at approximately $30,091,000, with a change in fair value of approximately $2,971,000 recognized in the Company’s accompanying Consolidated Statement of Operations. Subsequent to the balance sheet date the outstanding balance was extinguished as part of the liquidation process.

NOTE 8 – STOCKHOLDERS’ EQUITY

Preferred Stock

As of March 31, 2025, the Company had 200,000,000 shares of preferred stock authorized with a par value of $0.0001, respectively. Of this amount, 5,000,000 shares of Series A Preferred Stock are authorized and outstanding, 5,000 shares Series B Preferred Stock are authorized and no shares outstanding; 5,000 shares Series D Preferred Stock are authorized with none outstanding; 10,000 shares Series E Preferred Stock are authorized with 1,571 and 1,670 outstanding, respectively; 750,000 shares Series F Redeemable Convertible Preferred stock are authorized with 750,000 shares outstanding, and 10,000 shares of Series G preferred stock are authorized with 745 outstanding, respectively.

F-17

Series E Preferred Stock

On April 14, 2021, the Board authorized the issuance of 10,000 shares of the Company’s Series E Preferred Stock and has filed a Certificate of Designation (“COD”) of Preferences of the Series E Convertible Preferred Stock with the State of Nevada. The shares of Series E Preferred Stock have a stated value of $1,200 per share and are convertible into shares of common stock at the election of the holder of the Series E Preferred Stock at any time at a price of $0.35 per share, subject to adjustment (the “Conversion Price”). The Series E Preferred Stock is convertible into that number of shares of common stock determined by dividing the Series E Stated Value (plus any and all other amounts which may be owing in connection therewith) by the Conversion Price, subject to certain beneficial ownership limitations. Each holder of Series E Preferred Stock shall be entitled to receive, with respect to each share of Series E Preferred Stock then outstanding and held by such holder, dividends at the rate of twelve percent (12%) per annum, payable quarterly. Each share of Series E Preferred Stock shall be redeemed by the Company on the date that is no later than one calendar year from the date of its issuance. The Series E Preferred Stock are also redeemable at the Company’s option, at percentages ranging from 115% to 125% for the first 180 days, based on the passage of time. The holders of Series E Preferred Stock rank senior to the Common Stock and Common Stock Equivalents (as defined in the Series E Designation) with respect to payment of dividends and rights upon liquidation and will vote together with the holders of the Common Stock on an as-converted basis, subject to beneficial ownership limitations, on each matter submitted to a vote of holders of Common Stock (whether at a meeting of shareholders or by written consent). Based upon a subsequent financing, the holder has the option to exchange (in lieu of conversion), all or some of the shares of Series E Preferred Stock then held for any securities or units issued in a subsequent financing on a $1.00 for $1.00 basis. In the event of a Fundamental Transaction, the holder has the option to request that the Company or the successor entity shall purchase the Preferred Stock from the Holder on the date of such request by paying to the Holder cash in an amount equal to the Black Scholes value. Upon any triggering event as set forth in the COD, including a change in control or the Company shall fail to have available a sufficient number of authorized and unreserved shares of common stock to issue to such holder upon a conversion, each holder shall have the right, exercisable at the sole option of such holder, to require the Company to redeem all of the Series E Preferred Stock then held by such holder for a redemption price, in cash, equal to the Triggering Redemption Amount (150% of the Stated Value and all accrued but unpaid dividends and all liquidated damages, late fees and other costs), and increase the dividend rate on all of the outstanding Preferred Stock held by such Holder to 18% per annum thereafter. Upon any liquidation, dissolution or winding-up of the Company, the holders shall be entitled to receive out of the assets of the Company an amount equal to the stated value, plus any accrued and unpaid dividends and any other fees or liquidated damages then due and owing for each share of Preferred Stock, before any distribution or payment shall be made to the holders of any Junior Securities, and if the assets of the Corporation shall be insufficient to pay in full such amounts, then the entire assets to be distributed to the holders shall be ratably distributed among the holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.

On November 22, 2021, the Company entered into a securities purchase agreement (“SPA”) for 1,500 shares of the Company’s Series E Preferred Stock, at a price of $1,000 per share and (ii) a warrant to purchase up to 1,500,000 shares of the Company’s common stock, with an exercise price equal to $0.75, which expires in five years, for a purchase price of $1,500,000. The warrant had a fair value of $561,000, estimated using the Black Scholes Model, with the following inputs: the price of the Company’s common stock of $0.38; a risk-free interest rate of 1.33%, the expected volatility of the Company’s common stock of 209.9%; the estimated remaining term, a dividend rate of 0%. The Company also issued 267,429 warrants as placement agent fees, with a fair value of $101,000, estimated with the same assumptions. All of the warrants were classified as a liability, as it is not known if there will be sufficient authorized shares to be issued upon settlement. The Company accreted the carrying value, reflecting the discount of $300,000 between the stated value and purchase price and the fair value of the warrants issued of $662,000, of the Series E Preferred Stock in temporary equity up to the redemption value over the period until its redemption which was fully accreted as of March 31, 2023.

On April 14, 2021, the Company, entered into a share exchange agreement (the “Exchange Agreement”) with a holder of the Series D Preferred Stock, whereby, at the closing of the Offering, the Holder agreed to exchange an aggregate of 3,600 shares of the Company’s Series D Preferred Stock, par value $0.0001 per share into 3,739.63 shares of the Company’s Series E Convertible Preferred stock, par value $0.0001 (the “Series E Preferred Stock”). The exchange was completed on April 15, 2021.

On June 16, 2022, one of the holders of the Series E Convertible Preferred Stock chose to exercise their right, pursuant to the Certificate of Designation relating to the Series E Convertible Preferred Stock, to receive the rights extended to the convertible noteholder, of 90% multiplied by the average of the two lowest volume weighted average price per share of the Common Stock during the ten (10) trading days immediately preceding the date of conversion. As the exercise of the conversion price adjustment was similar to a down round, and the Company has not yet adopted ASU 2020-06, the accounting treatment of ASU 2017-11 was applied, whereby the adjustment was treated as a contingent beneficial conversion feature recognized as of the triggering date. As of June 16, 2022, this holder held 940 shares of the Series E preferred stock. The Company analyzed the conversion feature under ASC 470-20, “Debt with conversion and other options”, and based on the market price of the common stock of the Company as compared to the conversion price, determined there was a $99,000 beneficial conversion feature to recognize, which was fully amortized as there is no remaining redemption date to their Series E Preferred Stock. The additional rights of the convertible note which were applied include the 10% increase in the outstanding balance if an uplist to a national exchange was not consummated by the Company by March 1, 2022, for an increase of 130 Series E Preferred shares with a stated value of $156,000, as well as an exit fee of 15% to be recognized upon conversions of the Series E Preferred shares into shares of common stock. As of March 31, 2023, 170 shares of Series E Preferred Stock were outstanding to this holder.

F-18

During the year ended March 31, 2023, 1,300 shares of Series E Preferred Stock were converted into 14,458,127 shares of common stock. As of March 30, 2025 there were 1,571 shares of Series E Preferred Stock remaining outstanding.

On November 5, 2022, the Company entered a restructuring agreement with the Series E Preferred Stockholders, whereby the Series E Preferred Stock and the warrants outstanding as of the Closing date shall have their terms adjusted. The outstanding warrants shall be a) cancelled in exchange for a cash payment equal to the fair value of the warrants based on the Black Scholes model, with the exercise price to be adjusted to equal 80% of the average volume weighted average price of the Company common stock during the five trading day period immediately prior to the Closing Date (the “Adjusted Exercise Price”); or (b) as of the Effective Time, canceled and treated as if exercised for that number of shares of the Company’s common stock calculated using the Black Scholes model fair value, the number of Warrant Shares on the Closing Date and the Adjusted Exercise Price, with the shares of the Company’s common stock that would have been due to Holder as a result of such exercise of the Warrant treated as if issued to Holder and then converted into the right to receive (i) the Closing Per Share Merger Consideration (as defined in the Merger Agreement) plus (ii) the Additional Per Share Merger Consideration (as defined in the Merger Agreement), if any, at the time and subject to the contingencies set forth in the Merger Agreement. For the Series E Preferred Stock that shall be outstanding immediately prior to the Effective Time, they shall be canceled and treated as if converted into that number of shares of the Company’s common stock equal to (i) the stated value of $1,200 per share plus any unpaid dividends, multiplied by 1.25, divided by (ii) 80% of the average volume weighted average price of the Company’s common stock during the five trading day period immediately prior to the Closing Date. The shares of the Company’s common stock that would have been due to the holder as a result of the conversion of such shares of Series E Convertible Preferred Stock shall be treated as issued to holder and converted, as of the Effective Time, into the right to receive (y) the Closing Per Share Merger Consideration plus (z) the Additional Per Share Merger Consideration, if any, at the time and subject to the contingencies set forth in the Merger Agreement. Due to the termination of the Merger Agreement (Note 13) this restructuring agreement is no longer effective.

On July 24, 2023, the Company entered into a Securities Purchase Agreement for the additional sale of 156 shares of Series E Preferred Stock at a price of $1,000 per share of Preferred Stock, for a total of $156,000. The Series E Preferred Stock will earn a dividend of 12% per annum, for as long as the relevant Preferred Stock has not been redeemed or converted. Dividends are to be paid quarterly, and at the Company’s discretion, in cash or Preferred Stock calculated at the purchase price.

For the period ended March 30, 2025, the accretion for the Series E Preferred Stock was $58,300.

On May 1, 2023, one of the holders converted 600 Series E Preferred Stock into 23,989,570 shares of common stock. The conversion represented their remaining Series E Preferred Stock outstanding as of that date, including the 10% increase, accrued dividends in kind of $516,000 and the 15% Exit Fee of $108,000.

Series G Preferred Stock

On December 1, 2023, the Board authorized the issuance of 10,000 preferred shares to be designated as Series G Preferred Stock (“Series G Preferred Stock”). The Series G Preferred Stock has a par value of $0.0001, a stated value of $1,200 and bear dividends at the rate of 8% per annum, payable quarterly, to be paid in cash or in-kind, at the discretion of the Company. The Series G Preferred Stock will vote together with the common stock on an as-converted basis subject to the beneficial ownership limitations. The Series G Preferred Stock is required to be redeemed by the Company no later than one calendar year from the date of its issuance. The Series G Preferred Stock is also redeemable at the option of the Company at any time after the original issued date, upon 3 business days’ notice, at a premium rate which is (a) 1.15 if all of the Series G Preferred Stock is redeemed within 90 calendar days from the issuance date thereof; (b) 1.2 if all of the Series G Preferred Stock is redeemed after 90 calendar days and within 120 calendar days from the issuance date thereof; (c) 1.25 if all of the Series G PS is redeemed after 120 calendar days and within 180 calendar days from the issuance date thereof. The Company shall be permitted to redeem the Series G Preferred Stock at any time in cash upon 3 business days prior notice to the Holder or the Holder may convert the Series G Preferred Stock within 3 business days period prior to redemption. The Holder shall have the right to either redeem for cash or convert the Series G Preferred Stock into common stock within 3 business days following the consummation of a qualified offering. The conversion price is based on the discounted market price which is the lower of: (i) A fixed price equaling the closing bid price for the common stock on the trading day preceding the execution of the SPA ; or (ii) 100% of the lowest volume weighted average price (“VWAP)” for the common stock during 10 trading days preceding the conversion request, subject to adjustment.

F-19

As the redemption feature is mandatorily redeemable within one year of the issuance date, with a substantive conversion option, the Series G Preferred Stock would not fall under liability classification but is to be classified as mezzanine equity.

Series G Preferred Equity Offering

On December 14, 2023, the Company entered into a Securities Purchase Agreement for the sale of 110 shares of Series G Preferred Stock at a price of $1,000 per share of preferred stock, for a total of $110,000. The Purchaser also received an “Equity Incentive”, which was an additional 35 Series G Preferred Stock issued to the Purchaser at the initial closing and deemed to be earned at the time of its issuance. Following the initial closing, the Company and Purchaser shall mutually agree from time to time for the Company to sell and the Purchaser to purchase up to 400 shares of Series G Preferred Stock at a price of $1,000 per share in separate closings . The Series G Preferred Stock will earn a dividend of 8% per annum, for as long as the relevant Preferred Stock has not been redeemed or converted. Dividends are to be paid quarterly, and at the Company’s discretion, in cash or Preferred Stock calculated at the purchase price. On December 19, 2023, the Company received an initial tranche of $110,000 under the SPA, less $13,000 for legal and commission fees. The $77,000 discount was accreted up to the redemption price over the one-year period until redemption.

On January 24, 2024, the Company received a tranche of $100,000 under the SPA for 100 Series G Preferred Stock with a stated value of $120,000, less $3,000 for legal and commission fees. The $23,000 discount was accreted up to the redemption price over the one-year period until redemption.

On February 23, 2024, the Company entered into a consulting agreement in which it was required to issue the consultant a retainer fee to be either $180,000 in cash or $200,000 in shares of the Company’s preferred stock. The Company issued 200 of their Series G, with a stated value of $240,000. The $40,000 discount was accreted up to the redemption price over the one-year period until redemption.

On April 23, 2024, the Company received a tranche of $100,000 under the SPA for 100 Series G Preferred Stock with a stated value of $120,000. The $20,000 discount will be accreted up to the redemption price over the one-year period until redemption.

On June 12, 2024, the Company received a tranche of $100,000 under the SPA for 100 Series G Preferred Stock with a stated value of $120,000. The $20,000 discount will be accreted up to the redemption price over the one-year period until redemption.

On July 10, 2024, the Company received a tranche of $100,000 under the SPA for 100 Series G Preferred Stock with a stated value of $120,000. The $20,000 discount will be accreted up to the redemption price over the one-year period until redemption.

During the years ending March 30, 2025, the accretion for the Series G Preferred Stock was approximately $172,000.

Common Stock

On September 28, 2023, the Company increased their authorized common shares to 1,400,000,000.

GHS 2022 Purchase Agreement

On November 4, 2022, the Company entered into a purchase agreement (the “GHS Purchase Agreement”) with GHS Investments LLC (“GHS”), an accredited investor, pursuant to which, the Company may require GHS to purchase a maximum of up to 64,000,000 shares of the Company’s common stock (“GHS Purchase Shares”) based on a total aggregate purchase price of up to $5,000,000 over a one-year term that ends on November 4, 2023. Notwithstanding the foregoing dollar limitations, the Company and GHS may, from time to time, mutually agree in writing to waive the aforementioned limitations for a relevant Purchase Notice, which waiver, shall not exceed the 4.99% beneficial ownership limitation contained in the GHS 2022 Purchase Agreement. The Company is to control the timing and amount of any sales of GHS Purchase Shares to GHS. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.

The “Purchase Price” means, with respect to a purchase made pursuant to the GHS Purchase Agreement, 90% of the lowest VWAP during the 10 consecutive business days immediately preceding, but not including, the applicable purchase date. The Company shall deliver a number of GHS Purchase Shares equal to 112.5% of the aggregate purchase amount for such GHS Purchase divided by the Purchase Price per share for such GHS Purchase.

F-20

If there are any default events, as set forth in the GHS Purchase Agreement, has occurred and is continuing, the Company shall not deliver to GHS any Purchase Notice.

Further, pursuant to the terms of the GHS Purchase Agreement, from November 4, 2022 until the date that is the later of (i) the closing of the transactions whereby Yotta Merger Sub, Inc. will merge with and into the Company, with the Company as the surviving company (the “Merger”); and (ii) the 12 month anniversary of the first delivery of GHS Purchase Shares, upon any issuance by the Company or any of its subsidiaries of Common Stock or Common Stock equivalents for cash consideration, indebtedness or a combination of units thereof (a “Subsequent Financing”), GHS shall have the right to participate in any financing, up to an amount of the Subsequent Financing equal to 100% of the Subsequent Financing (the “Participation Maximum”) on the same terms, conditions and price provided for in the Subsequent Financing. Following the Merger, the Participation Maximum shall be 50% of the Subsequent Financing.

$10,000,000 Common Stock Equity Financing

On April 28, 2023, the Company entered into an Equity Financing Agreement (“Equity Financing Agreement”) and Registration Rights Agreement with GHS. Under the terms of the Equity Financing Agreement, GHS agreed to provide the Company with up to $10,000,000 upon effectiveness of a registration statement on Form S-1 (the “Registration Statement”) filed with the SEC. The Registration Statement was filed on July 20, 2023 and the SEC declared it effective on August 14, 2023.

With the effectiveness of the Registration Statement, the Company now has the discretion to deliver puts to GHS and GHS will be obligated to purchase shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) based on the investment amount specified in each put notice. The maximum amount that the Company shall be entitled to put to GHS in each put notice shall not exceed two hundred percent (200%) of the average daily trading dollar volume of the Company’s Common Stock during the ten (10) trading days preceding the put, so long as such amount does not equal less than ten thousand dollars ($10,000) or greater than one million dollars ($1,000,000). Pursuant to the Equity Financing Agreement, GHS and its affiliates will not be permitted to purchase and the Company may not put shares of the Company’s Common Stock to GHS that would result in GHS’s beneficial ownership equaling more than 4.99% of the Company’s outstanding Common Stock. The price of each put share shall be equal to eighty percent (80%) of the Market Price (as defined in the Equity Financing Agreement). Following an up-list to the NASDAQ or equivalent national exchange, the price of each put share shall be equal to ninety percent (90%) of the Market Price, subject to a floor price of $1.00 per share. Puts may be delivered by the Company to GHS until the earlier of twenty-four (24) months after the effectiveness of the Registration Statement or the date on which GHS has purchased an aggregate of $10,000,000 worth of Common Stock under the terms of the Equity Financing Agreement.

During the year ended March 30, 2025, the Company sold 141,064,683 shares of common stock at a gross amount of approximately $861,668, at share prices of $0.003 through $0.008, in relation to the Equity Financing Agreement.

F-21

GHS 2023 Purchase Agreement

On May 9, 2023, the Company entered into a purchase agreement (the “GHS 2023 Purchase Agreement”) with GHS pursuant which the Company may require GHS to purchase a maximum of up to 45,923,929 shares of the Company’s common stock (“GHS 2023 Purchase Shares”) based on a total aggregate purchase price of up to $6,000,000 over a one-year term that ends on May 9, 2024. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.

The GHS 2023 Purchase Agreement provides that, upon the terms and subject to the conditions and limitations set forth in the agreement, the Company has the right from time to time during the term of the agreement, in its sole discretion, to deliver to GHS a purchase notice (a “Purchase Notice”) directing GHS to purchase (each, a “GHS Purchase”) a specified number of GHS 2023 Purchase Shares. A GHS Purchase will be made in a minimum amount of $10,000 and up to a maximum of $1,500,000 and provided that, the purchase amount for any purchase will not exceed 200% of the average of the daily trading dollar volume of the Company’s common stock during the 10 business days preceding the purchase date. Notwithstanding the foregoing dollar limitations, the Company and GHS may, from time to time, mutually agree (in writing) to waive the aforementioned limitations for a relevant Purchase Notice, which waiver, for the avoidance of doubt, shall not exceed the 4.99% beneficial ownership limitation contained in the GHS Purchase Agreement. The “Purchase Price” means, with respect to a purchase made pursuant to the GHS Purchase Agreement, 90% of the lowest VWAP (as defined in the GHS 2023 Purchase Agreement) during the Valuation Period (the ten (10) consecutive business days immediately preceding, but not including, the applicable purchase date). The Company shall deliver a number of GHS 2023 Purchase Shares equal to 112.5% of the aggregate purchase amount for such GHS Purchase divided by the Purchase Price per share for such GHS Purchase, against payment by GHS to the Company of the purchase amount with respect to such Purchase (less documented deposit and clearing fees, if any), as full payment for such GHS Purchase Shares via wire transfer of immediately available funds.

If there are any default events, as set forth in the GHS Purchase Agreement, has occurred and is continuing, the Company shall not deliver to GHS any Purchase Notice.

Further, pursuant to the terms of the GHS 2023 Purchase Agreement, from May 9, 2023 until the date that is the later of (i) the closing of the transactions whereby Yotta Merger Sub, Inc. will merge with and into the Company, with the Company as the surviving company (the “Merger”); and (ii) the 12 month anniversary of the initial closing pursuant to the Section 2(a) of GHS Purchase Agreement, upon any issuance by the Company or any of its subsidiaries of Common Stock or Common Stock equivalents for cash consideration, indebtedness or a combination of units thereof (a “Subsequent Financing”), GHS shall have the right to participate in any financing, up to an amount of the Subsequent Financing equal to 100% of the Subsequent Financing (the “Participation Maximum”) on the same terms, conditions and price provided for in the Subsequent Financing. Following the Merger, the Participation Maximum shall be 50% of the Subsequent Financing.

In the three months ended June 30, 2023, the Company sold 28,205,605 shares of common stock at a net amount of approximately $923,000, at share prices ranging from $0.03 to $0.04 related to the GHS 2023 Purchase Agreement.

Common Shares Issued to Consultants

On December 4, 2023, 40,000,000 shares of common stock were issued to a consultant under an Independent Consulting Agreement. The shares are a non-refundable retainer on behalf of their consulting services for one year of services. The shares had a fair value of $600,000, based on the market price of $0.015 on the grant date, recognized as consulting services in the nine months ended December 31, 2023.

On June 19, 2023, 100,000 shares of common stock were issued to a consultant. The shares had a fair value of $4,700, based on the market price of $0.047 on the grant date.

F-22

Common Stock Issued in Relation to Business Agreement

As of June 22, 2022, 250,000 common shares were issued in relation to a trial distribution agreement entered into with a consultant who was to introduce the Company to customers. Additionally, the consultant was also to assist the Company in the set-up of ancillary materials used or useful in the delivery of live shrimp, including installation of necessary equipment and facilities, logistical support, training of staff and packaging necessary for shipment of live shrimp. After the result of the trial period, the parties could have, but decided not to, negotiate and execute a long-term distribution agreement. The shares will be paid for by the Company withholding sufficient profits from the sale of the live shrimp to the customers introduced by the consultant.

Common Shares Issued to Employees

In February and March 2024, the Company issued 700,000 shares of common stock to four employees for a bonus compensation, with a total fair value of $8,100, based on the market price of $0.010 to $0.012 on the grant dates.

On October 10, 2023, a new employee was issued 50,000 shares of common stock as a signing bonus with a total fair value of $1,100, based on the market price of $0.02250 on the grant date.

NOTE 9 – OPTIONS AND WARRANTS

The Company has not granted any options since inception.

All of the warrants issued have been recognized as a liability, based on the fact it is not known if there will be sufficient authorized shares to be issued upon settlement. However, the 18,573,116 warrants outstanding as of March 31, 2025 had a fair value of $0 due to the underlying shares limited value.

NOTE 10 – RELATED PARTY TRANSACTIONS

Promissory Note

On July 10 through July 17, 2023, the Company received $140,000 in proceeds from the issuance of three promissory notes with family member related parties. The notes bear interest at 10% and have maturity dates one year from the issuance date. All of the notes were in default as of the date of the filing.

F-23

On August 10, 2022, the Company issued a loan agreement for $300,000, with employee and family member related parties, which is to be considered priority debt of the Company. As of this filing, five of the related parties have entered into promissory notes under the loan agreement for $50,000 each, for a total of cash received of $250,000. The notes bear interest at 10% per annum and are due in one year from the issuance date of the notes. The loans were in default as of the date of this filing.

For the year ended March 30, 2025, the interest expense for the related party promissory notes was approximately $42,000.

Bonus Compensation – Related Party

On May 11, 2021, the Company awarded the Chief Financial Officer (“CFO”) a bonus of $300,000. On August 10, 2021, the Board of Directors ratified the bonus payment to the CFO and awarded the President and the CTO compensation bonuses of $300,000 each. As of both March 30, 2025, there was $200,000 outstanding, which were presented in accrued expenses, related parties.

NaturalShrimp Holdings, Inc.

Shareholder Notes

The Company has entered into several working capital notes payable to multiple shareholders of NSH and Bill Williams, a former officer and director, and a shareholder of the Company, for a total of $486,500. The notes are unsecured and bear interest at 8%. These notes had stock issued in lieu of interest and have no set monthly payment or maturity date. The balance of these notes was $356,404 as of March 30, 2025, and is classified as a current liability on the consolidated balance sheets.

Shareholders

Beginning in 2010, the Company started entering into several working capital notes payable with various shareholders of NSH for a total of $290,000 and bearing interest at 8%. The balance of these notes as of March 30, 2025 was $54,647 and is classified as a current liability on the consolidated balance sheets.

NOTE 11 –INCOME TAXES

The Company accounts for income taxes under ASC 740-10, which provides for an asset and liability approach of accounting for income taxes. Under this approach, deferred tax assets and liabilities are recognized based on anticipated future tax consequences, using currently enacted tax laws, attributed to temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts calculated for income tax purposes.

The components of income tax expense for the year ended March 30, 2025 consisted of the following:

SCHEDULE OF INCOME TAX EXPENSE

	2025
Federal statutory rate		21.0	%
State taxes, net of federal benefit		-
Permanent differences		-
Valuation allowance		(21.0	)%
Effective rate		0.0	%

F-24

Significant components of the Company’s deferred tax assets as of March 30, 2025 is summarized below.

SCHEDULE OF DEFERRED TAX ASSET

	2025
Deferred tax assets:
Net operating loss carryforwards	$	19,852,823
Other		1,206,000
Total deferred tax asset		21,058,823
Valuation allowance		(21,058,823	)
Total	$	-

As of March 31, 2025, the Company had approximately $94,527,729 of federal net operating loss carry forwards. The carry forwards beginning in tax years 2018 are allowed to be carried forward indefinitely and are to be limited to 80% of the taxable income. Future utilization of the net operating loss carry forwards is subject to certain limitations under Section 382 of the Internal Revenue Code. The Company believes that the issuance of its common stock in exchange for Multiplayer Online Dragon, Inc. on January 30, 2015 resulted in an “ownership change” under the rules and regulations of Section 382. Accordingly, the Company’s ability to utilize their net operating losses generated prior to this date is limited to approximately $282,000 annually.

To the extent that the tax deduction is included in a net operating loss carry forward and is in excess of amounts recognized for book purposes, no benefit will be recognized until the loss carry forward is recognized. Upon utilization and realization of the carry forward, the corresponding change in the deferred asset and valuation allowance will be recorded as additional paid-in capital.

The Company provides for a valuation allowance when it is more likely than not that it will not realize a portion of the deferred tax assets. The Company has established a valuation allowance against the net deferred tax asset due to the uncertainty that enough taxable income will be generated in those taxing jurisdictions to utilize the assets. Therefore, the Company has not reflected any benefit of such deferred tax assets in the accompanying financial statements. The Company’s net deferred tax asset and valuation allowance increased by $2,252,823 in the year ended March 31, 2025.

The Company reviewed all income tax positions taken or that they expect to be taken for all open years and determined that the income tax positions are appropriately stated and supported for all open years. The Company is subject to U.S. federal income tax examinations by tax authorities for tax years after 2017 due to unexpired net operating loss carryforwards originating in and subsequent to that year. The Company may be subject to income tax examinations for the various taxing authorities which vary by jurisdiction.

NOTE 12 – LEASE

On May 26, 2021, the Company entered into a sublease for a new office space in Texas, on two floors. The lease commenced on August 1, 2021 for a monthly rent of $7,000, and will terminate on October 31, 2025, for one of the spaces, and commence in the second half of 2022 for monthly rent of $1,727, and terminate on October 31, 2025, for the second space. On June 2, 2021, the Company paid a deposit of $52,362 which shall be applied to the last six months of the sublease term, and $17,454 security deposit, which is included in Prepaid expenses on the accompanying consolidated balance sheet. The Company assessed its new office lease as an operating lease.

At inception, on August 1, 2021, the ROU and lease liability was calculated as approximately $316,000, based on the net present value of the future lease payments over the term of the lease. When available, the Company uses the rate implicit in the lease discount payments as the incremental borrowing rate to calculate the net present value; however, the rate implicit in the lease is not readily determinable for their corporate office lease. In this case, the Company estimated its incremental borrowing rate of 5.75% as the interest rate it could have incurred to borrow an amount equal to the lease payments in a similar economic environment on a collateralized basis over a term similar to the lease term . The Company estimated its rate based on observable risk-free interest rate and credit spreads for commercial debt of a similar duration as to what rate would have been effective for the Company.

F-25

On December 31, 2023, the Company moved to a new office space in Texas, and the sublease in effect was terminated.

On December 20, 2023, the Company entered into a sublease for a new office space in Texas, with a commencement date of January 1, 2024, which will terminate on March 31, 2027. The monthly rates are $2,063 for April 1, 2024 through March 31, 2025, $2,192 for the second year of April 1, 2025 through March 31, 2026 and $2,320 for the final year. On December 19, 2023, the Company paid a $2,063 security deposit, which is included in Prepaid expenses on the accompanying consolidated balance sheet. The Company assessed its new office lease as an operating lease.

At inception, as of January 1, 2024, the ROU and lease liability was calculated as approximately $61,000, based on the net present value of the future lease payments over the term of the lease. When available, the Company uses the rate implicit in the lease discount payments as the incremental borrowing rate to calculate the net present value; however, the rate implicit in the lease is not readily determinable for their corporate office lease. In this case, the Company estimated its incremental borrowing rate of 14.5% as the interest rate it could have incurred to borrow an amount equal to the lease payments in a similar economic environment on a collateralized basis over a term similar to the lease term. The Company estimated its rate based on observable risk-free interest rate and credit spreads for commercial debt of a similar duration as to what rate would have been effective for the Company.

On September 8, 2021, the Company entered into an equipment lease agreement for VOIP phone equipment. The lease term is for sixty months, with a monthly lease payment of approximately $300. The Company assessed the equipment lease as an operating lease. The Company determined the Right of Use asset and Lease liability values at inception as approximately $17,000 calculated at the present value of all future lease payments for the lease term, using an incremental borrowing rate of 5.75%.

All of the lease agreements were terminated subsequent to the balance sheet date.

NOTE 13 – COMMITMENTS AND CONTINGENCIES

Gary Shover

A shareholder of NaturalShrimp Holdings, Inc. (“NSH”), Gary Shover, filed suit against the Company on August 11, 2020 in the Northern District of Texas, Dallas Division, alleging breach of contract for the Company’s failure to exchange common shares of the Company for shares Mr. Shover owns in NSH. On November 15, 2021, a hearing was held before the US District Court for the Northern District of Texas, Dallas Division at which time Mr. Shover and the Company presented arguments as to why the Court should approve a joint motion for settlement. After considering the argument of counsel and taking questions from those NSH Shareholders who were present through video conferencing link, the Court approved the motion of the parties to allow Mr. Shover and all like and similarly situated NSH Shareholders to exchange each share of NSH held by a NSH Shareholder for a share of the Company. A final Order was signed on December 6, 2021 and the case was closed by an Order of the Court of the same date. The Company is to issue approximately 93 million shares in settlement, which as of December 6, 2021 was recognized as stock payable on the Company’s balance sheet, and its fair value of $29,388,000, based on the market value of the Company’s common shares of $0.316 on the date the case was closed, has been recognized in the Company’s statement of operations as legal settlement. As of March 31, 2022, 28,494,706 of the shares presented in Stock Payable have been issued, with the fair value of $9,415,950 reclassified out of Stock Payable. In the year ended March 31, 2023, an additional 61,558,203 of shares of common stock with a fair value of $19,445,284 were issued out of the Stock Payable. In the year ended March 31, 2024, an additional 863,110 of shares of common stock with a fair value of $272,743 were issued out of the Stock Payable.

Merger Agreement

On October 24, 2022, the Company entered into a Merger Agreement (as it may be amended, supplemented, or otherwise modified from time to time, the “Merger Agreement”), by and among the Company, Yotta Acquisition Corporation, a Delaware corporation (“Yotta”), and Yotta Merger Sub, Inc., a Nevada corporation and a wholly owned subsidiary of Yotta (“Merger Sub”). The Merger Agreement and the transactions contemplated thereby (the “Transactions”) were approved by the board of directors of each of the Company, Yotta, and Merger Sub.

The Merger Agreement provided, among other things, that Merger Sub will merge with and into the Company, with the Company as the surviving company (the “Surviving Company”) in the merger and, after giving effect to such merger, the Company shall be a wholly-owned subsidiary of Yotta (the “Merger”). In addition, Yotta would be renamed “NaturalShrimp, Incorporated” or such other name as shall be designated by the Company. Other capitalized terms used, but not defined, herein have the respective meanings given to such terms in the Merger Agreement.

On July 20, 2023, the Company sent Yotta notice of the Company’s termination of the Merger Agreement pursuant to Section 10.2(b) thereof based on breaches by Yotta of certain representations in the Merger Agreement that would render impossible the satisfaction of certain conditions to the Company’s obligations to consummate the transactions contemplated by the Merger Agreement. In particular, Yotta will not be able to comply with the provision of its Amended and Restated Certificate of Incorporation that prohibits Yotta from consummating an initial business combination unless it has net tangible assets of at least $5,000,001 upon consummation of such initial business combination. This conflicts with Yotta’s representation in the Merger Agreement that its consummation of the transactions contemplated by the Merger Agreement will not conflict with its organizational documents. The Company also cited delays in the SEC registration process that are attributable to Yotta, which breached its covenant pursuant to the Merger Agreement to use its reasonable best efforts to take all actions reasonably necessary or advisable to consummate the transactions contemplated by Merger Agreement as promptly as reasonably practicable. Per the Merger Agreement, if one of the parties validly terminates the Merger Agreement there will be a Breakup Fee of $3,000,000 to be paid to them by the other party. The Breakup Fee is not intended to be a penalty, but instead is liquidated damages to compensate the party which requests the termination, to not have any further liability with respect to the Merger Agreement. As of this filing date, Yotta has not responded to the Company’s notice of termination and the Company has not sought payment of the Breakup Fee beyond the July 20th notice.

F-26

As a result of the termination of the Merger Agreement the related Deferred offering costs in current assets of $1,394,366 was expensed in professional fees in the year ended March 31, 2024.

The Merger Agreement had provided for aggregate consideration to be issued to securityholders of the Company of 17,500,000 shares (the “Closing Merger Consideration Shares”) of Yotta’s common stock, par value $0.0001 per share (“Yotta Shares”), to be issued at the effective time of the Merger (the “Effective Time”), plus an additional (i) 5,000,000 Yotta Shares if the Surviving Corporation has at least $15,000,000 in revenue during the fiscal year ended March 31, 2024 and (ii) 5,000,000 Yotta Shares if the Surviving Corporation has at least $30,000,000 in revenue during the fiscal year ended March 31, 2025 (collectively, the “Contingent Merger Consideration Shares”).

In accordance with the terms and subject to the conditions of the Merger Agreement, at the Effective Time each share of Common Stock outstanding or deemed outstanding pursuant to the provisions discussed immediately below as of immediately prior to the Effective Time will be converted into the right to receive its allocable portion of the Closing Merger Consideration Shares and the Contingent Merger Consideration Shares (to the extent the required revenue thresholds are met).

Pursuant to the terms of the Merger Agreement and agreements that, pursuant to the Merger Agreement, the Company would have entered into with holders of such convertible securities, such convertible securities would have been canceled prior to the closing of the Merger in exchange (except for the Series A Convertible Preferred Stock of the Company, par value $0.0001 per share (the “Series A Preferred”) for a cash payment or Yotta Shares as follows: (i) at the option of the holder thereof, each outstanding warrant to purchase shares of Common Stock would have been e canceled in exchange for a cash payment based on the value thereof or treated as exercised for shares of Common Stock, in each case based on an adjusted exercise price and as otherwise set forth in the Merger Agreement and/or the individual agreements, and if treated as exercised, converted into the right to receive such deemed shares of Common Stock’s allocable portion of the Closing Merger Consideration Shares and the Contingent Merger Consideration Shares; (ii) each outstanding share of Series F Convertible Preferred Stock of the Company, par value $0.0001 per share, would have been canceled and treated as if converted into shares of Common Stock at an adjusted conversion rate as set forth in the Merger Agreement and/or such individual agreements, and converted into the right to receive such deemed shares of Common Stock’s allocable portion of the Closing Merger Consideration Shares and the Contingent Merger Consideration Shares; and (iii) each outstanding share of Series E Convertible Preferred Stock of the Company, par value $0.0001 per share (the “Series E Preferred”), would have been canceled and treated as if converted into shares of Common Stock at an adjusted conversion rate as set forth in the Merger Agreement and/or such individual agreements, and converted into the right to receive such deemed shares of Common Stock’s allocable portion of the Closing Merger Consideration Shares and the Contingent Merger Consideration Shares. In addition, each holder of Series E Preferred would have been entitled to receive at the Effective Time an additional number of Closing Merger Consideration Shares as are necessary to ensure that the per-share value of the Yotta Shares that such stockholder is entitled to receive is not less than the per-share value (based on the effective purchase price) of the aggregate Yotta Shares then held by any Yotta stockholder after taking into account any newly-issued Yotta Shares that such Yotta stockholder acquires directly from Yotta prior to the closing of the Merger (the “Closing”) (which will reduce the number of Closing Merger Consideration Shares that will be issued to the Company’s other securities holders). The Series A Preferred would have been e cancelled and retired without any conversion thereof and for no consideration.

NOTE 14 – SUBSEQUENT EVENTS

Liquidation Activities

During September of 2024, Ampleo Turnaround and Restructuring, LLC was placed as the receiver over the Company’s assets. Further, during February of 2025, the receiver filed a motion to sell all of the Company’s assets to Streeterville and Bucktown Capital for an approximate credit bid of $35.7 million and $100,000 in cash. The motion was approved on March 30, 2025 with title to the assets being transferred on May 14, 2025. In exchange for the transfer of the assets to certain creditors, which included the Company’s fixed assets and certain intangible assets, the restructured debt ($33.1 million as of March 31, 2025) and Buckstown line of credit ($2.7 million as of March 31, 2025) was extinguished.

F-27

Filing Compare · NaturalShrimp Inc